<!DOCTYPE HTML>
<html lang="en-uk">


<head>
    <meta charset="utf-8">
    <meta name="keywords" content="Immunity, Infection and Respiratory System, 天何言哉">
    <meta name="description" content="Consultation Skills
Gastrointestinal

Dyspepsia, GORD, constipation, diarrhoea, threadworm, IBS, haemorrhoids

Dyspepsia">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
    <meta name="renderer" content="webkit|ie-stand|ie-comp">
    <meta name="mobile-web-app-capable" content="yes">
    <meta name="format-detection" content="telephone=no">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
    <meta name="referrer" content="no-referrer-when-downgrade">
    <!-- Global site tag (gtag.js) - Google Analytics -->

<script async src="https://www.googletagmanager.com/gtag/js?id=G-CFBH42KL3R"></script>
<script>
    window.dataLayer = window.dataLayer || [];
    function gtag() {
        dataLayer.push(arguments);
    }

    gtag('js', new Date());
    gtag('config', 'G-CFBH42KL3R');
</script>


    <title>Immunity, Infection and Respiratory System | 天何言哉</title>
    <link rel="icon" type="image/png" href="/favicon.png">
    


    <!-- bg-cover style     -->



<link rel="stylesheet" type="text/css" href="/libs/awesome/css/all.min.css">
<link rel="stylesheet" type="text/css" href="/libs/materialize/materialize.min.css">
<link rel="stylesheet" type="text/css" href="/libs/aos/aos.css">
<link rel="stylesheet" type="text/css" href="/libs/animate/animate.min.css">
<link rel="stylesheet" type="text/css" href="/libs/lightGallery/css/lightgallery.min.css">
<link rel="stylesheet" type="text/css" href="/css/matery.css">
<link rel="stylesheet" type="text/css" href="/css/my.css">
<link rel="stylesheet" type="text/css" href="/css/dark.css" media="none" onload="if(media!='all')media='all'">




    <link rel="stylesheet" href="/libs/tocbot/tocbot.css">
    <link rel="stylesheet" href="/css/post.css">




    



    <script src="/libs/jquery/jquery-3.6.0.min.js"></script>

<meta name="generator" content="Hexo 6.3.0">
<style>.github-emoji { position: relative; display: inline-block; width: 1.2em; min-height: 1.2em; overflow: hidden; vertical-align: top; color: transparent; }  .github-emoji > span { position: relative; z-index: 10; }  .github-emoji img, .github-emoji .fancybox { margin: 0 !important; padding: 0 !important; border: none !important; outline: none !important; text-decoration: none !important; user-select: none !important; cursor: auto !important; }  .github-emoji img { height: 1.2em !important; width: 1.2em !important; position: absolute !important; left: 50% !important; top: 50% !important; transform: translate(-50%, -50%) !important; user-select: none !important; cursor: auto !important; } .github-emoji-fallback { color: inherit; } .github-emoji-fallback img { opacity: 0 !important; }</style>
<link rel="alternate" href="/atom.xml" title="天何言哉" type="application/atom+xml">
</head>


<body>
    <header class="navbar-fixed">
    <nav id="headNav" class="bg-color nav-transparent">
        <div id="navContainer" class="nav-wrapper container">
            <div class="brand-logo">
                <a href="/" class="waves-effect waves-light">
                    
                    <img src="/medias/logo.png" class="logo-img" alt="LOGO">
                    
                    <span class="logo-span">天何言哉</span>
                </a>
            </div>
            

<a href="#" data-target="mobile-nav" class="sidenav-trigger button-collapse"><i class="fas fa-bars"></i></a>
<ul class="right nav-menu">
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/" class="waves-effect waves-light">
      
      <i class="fas fa-home" style="zoom: 0.6;"></i>
      
      <span>Index</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/tags" class="waves-effect waves-light">
      
      <i class="fas fa-tags" style="zoom: 0.6;"></i>
      
      <span>Tags</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/categories" class="waves-effect waves-light">
      
      <i class="fas fa-bookmark" style="zoom: 0.6;"></i>
      
      <span>Categories</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/archives" class="waves-effect waves-light">
      
      <i class="fas fa-archive" style="zoom: 0.6;"></i>
      
      <span>Archives</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/about" class="waves-effect waves-light">
      
      <i class="fas fa-user-circle" style="zoom: 0.6;"></i>
      
      <span>About</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/contact" class="waves-effect waves-light">
      
      <i class="fas fa-comments" style="zoom: 0.6;"></i>
      
      <span>Contact</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/friends" class="waves-effect waves-light">
      
      <i class="fas fa-address-book" style="zoom: 0.6;"></i>
      
      <span>Friends</span>
    </a>
    
  </li>
  
  <li>
    <a href="#searchModal" class="modal-trigger waves-effect waves-light">
      <i id="searchIcon" class="fas fa-search" title="Search" style="zoom: 0.85;"></i>
    </a>
  </li>
  <li>
    <a href="javascript:;" class="waves-effect waves-light" onclick="switchNightMode()" title="深色/浅色模式" >
      <i id="sum-moon-icon" class="fas fa-sun" style="zoom: 0.85;"></i>
    </a>
  </li>
</ul>


<div id="mobile-nav" class="side-nav sidenav">

    <div class="mobile-head bg-color">
        
        <img src="/medias/logo.png" class="logo-img circle responsive-img">
        
        <div class="logo-name">天何言哉</div>
        <div class="logo-desc">
            
            鸿蒙初辟本无性，打破顽冥须悟空
            
        </div>
    </div>

    <ul class="menu-list mobile-menu-list">
        
        <li class="m-nav-item">
	  
		<a href="/" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-home"></i>
			
			Index
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/tags" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-tags"></i>
			
			Tags
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/categories" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-bookmark"></i>
			
			Categories
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/archives" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-archive"></i>
			
			Archives
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/about" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-user-circle"></i>
			
			About
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/contact" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-comments"></i>
			
			Contact
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/friends" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-address-book"></i>
			
			Friends
		</a>
          
        </li>
        
        
        <li><div class="divider"></div></li>
        <li>
            <a href="https://github.com/blinkfox/hexo-theme-matery" class="waves-effect waves-light" target="_blank">
                <i class="fab fa-github-square fa-fw"></i>Fork Me
            </a>
        </li>
        
    </ul>
</div>


        </div>

        
            <style>
    .nav-transparent .github-corner {
        display: none !important;
    }

    .github-corner {
        position: absolute;
        z-index: 10;
        top: 0;
        right: 0;
        border: 0;
        transform: scale(1.1);
    }

    .github-corner svg {
        color: #0f9d58;
        fill: #fff;
        height: 64px;
        width: 64px;
    }

    .github-corner:hover .octo-arm {
        animation: a 0.56s ease-in-out;
    }

    .github-corner .octo-arm {
        animation: none;
    }

    @keyframes a {
        0%,
        to {
            transform: rotate(0);
        }
        20%,
        60% {
            transform: rotate(-25deg);
        }
        40%,
        80% {
            transform: rotate(10deg);
        }
    }
</style>

<a href="https://github.com/blinkfox/hexo-theme-matery" class="github-corner tooltipped hide-on-med-and-down" target="_blank"
   data-tooltip="Fork Me" data-position="left" data-delay="50">
    <svg viewBox="0 0 250 250" aria-hidden="true">
        <path d="M0,0 L115,115 L130,115 L142,142 L250,250 L250,0 Z"></path>
        <path d="M128.3,109.0 C113.8,99.7 119.0,89.6 119.0,89.6 C122.0,82.7 120.5,78.6 120.5,78.6 C119.2,72.0 123.4,76.3 123.4,76.3 C127.3,80.9 125.5,87.3 125.5,87.3 C122.9,97.6 130.6,101.9 134.4,103.2"
              fill="currentColor" style="transform-origin: 130px 106px;" class="octo-arm"></path>
        <path d="M115.0,115.0 C114.9,115.1 118.7,116.5 119.8,115.4 L133.7,101.6 C136.9,99.2 139.9,98.4 142.2,98.6 C133.8,88.0 127.5,74.4 143.8,58.0 C148.5,53.4 154.0,51.2 159.7,51.0 C160.3,49.4 163.2,43.6 171.4,40.1 C171.4,40.1 176.1,42.5 178.8,56.2 C183.1,58.6 187.2,61.8 190.9,65.4 C194.5,69.0 197.7,73.2 200.1,77.6 C213.8,80.2 216.3,84.9 216.3,84.9 C212.7,93.1 206.9,96.0 205.4,96.6 C205.1,102.4 203.0,107.8 198.3,112.5 C181.9,128.9 168.3,122.5 157.7,114.1 C157.9,116.9 156.7,120.9 152.7,124.9 L141.0,136.5 C139.8,137.7 141.6,141.9 141.8,141.8 Z"
              fill="currentColor" class="octo-body"></path>
    </svg>
</a>
        
    </nav>

</header>

    
<script src="/libs/cryptojs/crypto-js.min.js"></script>
<script>
    (function() {
        let pwd = '';
        if (pwd && pwd.length > 0) {
            if (pwd !== CryptoJS.SHA256(prompt('请输入访问本文章的密码')).toString(CryptoJS.enc.Hex)) {
                alert('密码错误，将返回主页！');
                location.href = '/';
            }
        }
    })();
</script>




<div class="bg-cover pd-header post-cover" style="background-image: url('/medias/featureimages/13.jpg')">
    <div class="container" style="right: 0px;left: 0px;">
        <div class="row">
            <div class="col s12 m12 l12">
                <div class="brand">
                    <h1 class="description center-align post-title">Immunity, Infection and Respiratory System</h1>
                </div>
            </div>
        </div>
    </div>
</div>




<main class="post-container content">

    
    <div class="row">
    <div id="main-content" class="col s12 m12 l9">
        <!-- 文章内容详情 -->
<div id="artDetail">
    <div class="card">
        <div class="card-content article-info">
            <div class="row tag-cate">
                <div class="col s7">
                    
                    <div class="article-tag">
                        
                            <a href="/tags/Biology/">
                                <span class="chip bg-color">Biology</span>
                            </a>
                        
                    </div>
                    
                </div>
                <div class="col s5 right-align">
                    
                    <div class="post-cate">
                        <i class="fas fa-bookmark fa-fw icon-category"></i>
                        
                            <a href="/categories/Course-Notes/" class="post-category">
                                Course Notes
                            </a>
                        
                    </div>
                    
                </div>
            </div>

            <div class="post-info">
                
                <div class="post-date info-break-policy">
                    <i class="far fa-calendar-minus fa-fw"></i>Publish Date:&nbsp;&nbsp;
                    2025-11-29
                </div>
                

                
                <div class="post-date info-break-policy">
                    <i class="far fa-calendar-check fa-fw"></i>Update Date:&nbsp;&nbsp;
                    2025-12-07
                </div>
                

                
                <div class="info-break-policy">
                    <i class="far fa-file-word fa-fw"></i>Word Count:&nbsp;&nbsp;
                    26.5k
                </div>
                

                
                <div class="info-break-policy">
                    <i class="far fa-clock fa-fw"></i>Read Times:&nbsp;&nbsp;
                    156 Min
                </div>
                

                
            </div>
        </div>
        <hr class="clearfix">

        
        <!-- 是否加载使用自带的 prismjs. -->
        <link rel="stylesheet" href="/libs/prism/prism.min.css">
        

        

        <div class="card-content article-card-content">
            <div id="articleContent">
                <h2 id="Consultation-Skills">Consultation Skills</h2>
<h3 id="Gastrointestinal">Gastrointestinal</h3>
<blockquote>
<p>Dyspepsia, GORD, constipation, diarrhoea, threadworm, IBS, haemorrhoids</p>
</blockquote>
<h4 id="Dyspepsia-and-GORD">Dyspepsia and GORD</h4>
<blockquote>
<p>Which of the following symptoms are specific to GORD only?</p>
<ul>
<li>Upper abdomen pain, described as a dull ache or discomfort</li>
<li>Feeling bloated or heavy</li>
<li>Burning sensation in the sternum area</li>
<li>Acidic or sour taste in mouth</li>
</ul>
</blockquote>
<h5 id="Red-Flags">Red Flags</h5>
<ul>
<li>Blood in vomit or stools</li>
<li>Difficulty swallowing</li>
<li>Unexplained weight loss</li>
<li>Over 40 and first presentation</li>
<li>Pain radiating down arm/cardiac association (Dyspepsia only)</li>
</ul>
<p>Timescale for referral: 5-7 days</p>
<h5 id="Product-selection">Product selection</h5>
<ul>
<li>
<p>PPI – both conditions</p>
<ul>
<li>Reduce acid production</li>
<li>Long duration of action but also 2-3 day delay</li>
<li>Up to 14 days treatment, &gt;18</li>
<li><strong>Esomeprazole/omeprazole</strong></li>
</ul>
</li>
<li>
<p>Antacids – both conditions 抗酸剂</p>
<ul>
<li>Liquid or chewable tablets</li>
<li>Neutralise excess acid - Effect short lived but immediate</li>
<li>Liquids can be used in children</li>
<li><strong>Bisodol/Rennie/Mag trisilicate/Maalox</strong> etc</li>
</ul>
</li>
<li>
<p>Alginates – mostly GORD 藻酸盐</p>
<ul>
<li>Liquid or chewable tablets</li>
<li>Form a raft to protect the oesophagus and usually</li>
<li>mixed with an antacid</li>
<li>Effect short lived but immediate</li>
<li>Usually, &gt;12 years old</li>
<li><strong>Gaviscon</strong></li>
</ul>
</li>
</ul>
<h4 id="Constipation">Constipation</h4>
<h5 id="Red-flags">Red flags</h5>
<ul>
<li>Blood in stools</li>
<li>Nausea and vomiting</li>
<li>Abdominal pain</li>
<li>Change sin bowel habit &gt;2 weeks</li>
</ul>
<p>Referral time:</p>
<ul>
<li>2-3 days with OTC treatment</li>
<li>2 weeks with dietary advice</li>
</ul>
<h5 id="Product-selection-2">Product selection</h5>
<ul>
<li>Osmotic laxatives 渗透性泻药
<ul>
<li>Lactulose/Macrogol 乳果糖/聚乙二醇</li>
<li>Draws water into the bowel</li>
<li>Onset - 2-3 days</li>
</ul>
</li>
<li>Stimulant 兴奋剂
<ul>
<li>Senna/Bisacodyl/Sodium picosulphate/glycerol supps 番泻叶/比沙可啶/硫酸钠/甘油栓剂</li>
<li>Increase GIT motility (see MHRA guidance)
<ul>
<li>Should not be used unless other laxatives and dietary modification are ineffective</li>
<li>Stimulant laxatives should only ever be prescribed for children</li>
</ul>
</li>
<li>Onset – 8-12 hours</li>
<li>Glycerol supps – 15-30 mins!!</li>
</ul>
</li>
<li>Bulk forming
<ul>
<li>Ispaghula husk/methylcellulose 车前子壳/甲基纤维素</li>
<li>Increase faecal mass and fluid</li>
<li>Onset 12-36 hours</li>
</ul>
</li>
<li>Softening
<ul>
<li>Docusate 多库酯</li>
<li>Surfactant allows fluid to enter faeces + weak stimulant</li>
<li>Onset – depends on route of admin</li>
</ul>
</li>
</ul>
<h4 id="Diarrhoea">Diarrhoea</h4>
<h5 id="Red-flags-2">Red flags</h5>
<ul>
<li>Blood/mucus/white fat like liquid in stools</li>
<li>Change in bowel habit for more than 2 weeks</li>
<li>Severe abdominal pain</li>
</ul>
<p>Referral time:</p>
<ul>
<li>1 day in children under 1</li>
<li>2 days in children under 3</li>
<li>3 days in older children and adults</li>
</ul>
<h5 id="Product-selection-3">Product selection</h5>
<ul>
<li>Oral rehydration 口服补液盐
<ul>
<li>Dioralyte</li>
<li>Replaces fluid and electrolytes</li>
<li>Does not stop diarrhoea</li>
<li>Onset – immediately</li>
</ul>
</li>
<li>Loperamide 洛哌丁胺
<ul>
<li>Reduces GIT motility and stops diarrhoea</li>
<li>Onset – 2-4 hours but may need to take after each stool</li>
</ul>
</li>
</ul>
<h4 id="Threadworm">Threadworm</h4>
<h5 id="Red-flags-3">Red flags</h5>
<ul>
<li>Travel abroad</li>
<li>Persistent/heavy infection
<ul>
<li>Weight loss</li>
<li>Appetite loss</li>
<li>Insomnia</li>
</ul>
</li>
</ul>
<p>Referral time: Not resolved after 2nd dose</p>
<h5 id="Product-selection-4">Product selection</h5>
<ul>
<li>Mebendazole 甲苯咪唑
<ul>
<li>Ovex liquid/chewable tablets</li>
<li>Kills worms in the gut</li>
<li>Onset – 1-2 days</li>
<li>May need a 2nd dose in 2 weeks time</li>
</ul>
</li>
<li>Hygiene measures 卫生措施
<ul>
<li>Prevent re-infestation</li>
</ul>
</li>
</ul>
<h4 id="Irritable-bowel-syndrome-IBS">Irritable bowel syndrome (IBS)</h4>
<h5 id="Red-flags-4">Red flags</h5>
<ul>
<li>Blood in stools</li>
<li>White fat-like liquid in stools</li>
<li>Unexpected weight loss</li>
<li>Severe abdominal pain</li>
<li>Undiagnosed IBS</li>
</ul>
<p>Referral time: 1 week after OTC treatment if not resolved</p>
<p><strong>NEEDS INITIAL DIAGNOSIS BY GP</strong></p>
<h5 id="Product-selection-5">Product selection</h5>
<ul>
<li>Antispasmodic 解痉剂
<ul>
<li>Mebeverine/peppermint oil 美贝维林/薄荷油</li>
<li>Reduce cramping pain and spasms 减轻痉挛性疼痛和抽搐</li>
</ul>
</li>
<li>Hyoscine hydrobromide 氢溴酸东莨菪碱
<ul>
<li>Smooth muscle relaxant</li>
<li>Reduce cramping pain and spasms</li>
</ul>
</li>
<li>Laxatives 泻药
<ul>
<li>To relive constipation</li>
<li>Bulk forming/osmotic are the best for regular use</li>
</ul>
</li>
<li>Loperamide 洛哌丁胺
<ul>
<li>To relieve diarrhoea</li>
<li>Short term use only</li>
</ul>
</li>
</ul>
<h4 id="Haemorrhoids-Piles">Haemorrhoids (Piles)</h4>
<h5 id="Red-flags-5">Red flags</h5>
<ul>
<li>Blood in stools</li>
<li>Unexpected weight loss</li>
<li>Severe abdominal pain when emptying bowels</li>
</ul>
<p>Referral time: Up to 1 week</p>
<ul>
<li><strong>Should be diagnosed by GP initially</strong></li>
<li><strong>Need to keep bowel regular to prevent symptoms</strong></li>
</ul>
<h5 id="Product-selection-6">Product selection</h5>
<ul>
<li>Astringents 收敛剂
<ul>
<li>Zinc oxide/bismuth/allantoin 氧化锌/铋/尿囊素</li>
<li>Protective coat</li>
</ul>
</li>
<li>Anaesthetics 麻醉剂
<ul>
<li>Lidocaine/benzocaine 利多卡因/苯佐卡因</li>
<li>Temporary relief from pain/itching</li>
</ul>
</li>
<li>Corticosteroids
<ul>
<li>Hydrocortisone</li>
<li>Anti-inflammatory to reduce the size of the pile</li>
</ul>
</li>
<li>Antiseptics 抗菌剂
<ul>
<li>Prevent infection</li>
</ul>
</li>
<li>Protectorants 保护剂
<ul>
<li>Shark liver oil 鲨鱼肝油</li>
<li>Coating to prevent pain and itching</li>
</ul>
</li>
</ul>
<h3 id="Skin-conditions">Skin conditions</h3>
<blockquote>
<p>Eczema, contact dermatitis, acne vulgaris, burns and scalds, bites and stings</p>
</blockquote>
<h4 id="Eczema-and-Contact-dermatitis">Eczema and Contact dermatitis</h4>
<blockquote>
<p>Eczema is a type of dermatitis!!</p>
</blockquote>
<h5 id="Red-Flags-2">Red Flags</h5>
<ul>
<li>Signs of infection</li>
<li>Facial involvement</li>
<li>Widespread area</li>
</ul>
<p>Timescale for referral: 7 days if OTC product recommended</p>
<h5 id="Product-selection-7">Product selection</h5>
<ul>
<li>Emollients 润肤剂
<ul>
<li>Moisturisers 保湿霜/soap substitutes/Bath/shower additives</li>
<li>No active ingredient – paraffin based products 石蜡基产品</li>
<li>Patient preference – creams/ointments</li>
<li>Can be used by all (consider allergy e.g. lanolin 羊毛脂)</li>
</ul>
</li>
<li>Topical Corticosteroids
<ul>
<li>Treat inflammation</li>
<li>Hydrocortisone 1% cream (Hc45) 氢化可的松
<ul>
<li>10 years and over</li>
</ul>
</li>
<li>Clobetasone butyrate 0.05% cream (Eumovate) 丁酸氯倍他松
<ul>
<li>12 years and over</li>
</ul>
</li>
<li>Not licensed for use on:
<ul>
<li>broken skin</li>
<li>the face or ano-genital region</li>
</ul>
</li>
<li>Not to be used for more than 7 days</li>
</ul>
</li>
</ul>
<h4 id="Acne">Acne</h4>
<h5 id="Red-Flags-3">Red Flags</h5>
<ul>
<li>Moderate to severe acne (see Core Concept)</li>
</ul>
<p>Referral time: 6-8 weeks</p>
<h5 id="Product-selection-8">Product selection</h5>
<ul>
<li>Benzoyl peroxide 2.5%/5%/10% gel (Panoxyl Aquagel/Acnecide) 过氧化苯甲酰
<ul>
<li>Antibacterial, anticomedogenic 抗致粉刺性 and keratolytic 角质溶解 properties</li>
<li>Start with lowest strength and increase if necessary/tolerated</li>
<li>Skin reddening/irritation possible especially at the start of treatment</li>
<li>Can bleach clothes and bedding</li>
</ul>
</li>
<li>Nicotinamide 4% gel (Freederm) 烟酰胺: Mild anti-inflammatory action</li>
</ul>
<h5 id="Burns-and-scolds">Burns and scolds</h5>
<h5 id="Red-flags-6">Red flags</h5>
<ul>
<li>Greater than patient’s palm size 手掌大小</li>
<li>Burns on face or genitalia 生殖器</li>
<li>Extensive blistering 大面积水疱形成</li>
<li>Severe burn</li>
<li>Pale/charred burn 浅色/焦黑烧痕</li>
</ul>
<p>Referral time: Varies: 7-21 days/signs of infection</p>
<h5 id="Product-selection-9">Product selection</h5>
<ul>
<li>Keep cool: Burn gel/spray</li>
<li>Keep clean: Use antiseptic spray/liquid</li>
<li>Cover:
<ul>
<li>Cling film 保鲜膜</li>
<li>Low adherence dressing 低粘附性敷料</li>
<li>hydrogel plaster 水凝胶绷带</li>
</ul>
</li>
<li>Pain relief
<ul>
<li>Local aesthetic 局部麻醉剂</li>
<li>Oral pain relief (paracetamol/ibuprofen)</li>
</ul>
</li>
</ul>
<h4 id="Bites-and-Stings">Bites and Stings</h4>
<h5 id="Red-flags-7">Red flags</h5>
<ul>
<li>Signs of infection</li>
</ul>
<p>Referral time: 3-5 days</p>
<h5 id="Product-selection-10">Product selection</h5>
<ul>
<li>Antihistamines
<ul>
<li>Prevent itching</li>
<li>Mepyramine maleate cream (Anthisan) - &gt; 2 yrs 马来酸甲哌胺</li>
<li>Antihistamine tab/syrup: Chlorpheniramine (Piriton) - &gt; 1 yr 氯苯那敏</li>
</ul>
</li>
<li>Topical corticosteroids – see previous</li>
<li>Topical antiseptics 抗菌剂</li>
<li>Topical anaesthetics 麻醉剂
<ul>
<li>Benzocaine 苯佐卡因: Lanacane cream - &gt; 12 yrs</li>
</ul>
</li>
</ul>
<h3 id="Infectious-skin-conditions">Infectious skin conditions</h3>
<blockquote>
<p>Warts and verrucas, fungal skin infections, scabies, impetigo, herpes simplex/shingles</p>
</blockquote>
<h4 id="Warts-and-verrucae">Warts and verrucae</h4>
<blockquote>
<table>
<thead>
<tr>
<th>Warts</th>
<th>Verrucae</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human papilloma Virus</td>
<td>Human papilloma Virus</td>
</tr>
<tr>
<td>Cauliflower like appearance</td>
<td>On the soles of feet</td>
</tr>
<tr>
<td>Mainly on hands</td>
<td>Black capillaries visible</td>
</tr>
</tbody>
</table>
</blockquote>
<h5 id="Red-Flags-4">Red Flags</h5>
<ul>
<li>Diabetes</li>
<li>Change in size or colour</li>
<li>Itching</li>
<li>Bleeding</li>
<li>Warts specifically on face or ano-gential area</li>
<li>Multiple/widespread warts</li>
</ul>
<p>Timescale for referral: 3 months (ensure realistic expectations of timescale)</p>
<h5 id="Product-selection-11">Product selection</h5>
<ul>
<li>Salicylic Acid (Bazuka, Salactol, Salactac)
<ul>
<li>2 years and over</li>
<li>Protect the healthy surrounding skin (Vaseline) 凡士林</li>
</ul>
</li>
<li>Dimethyl Ether Propane (cryotherapy) 二甲醚丙烷（冷冻疗法）
<ul>
<li>Over 4 years</li>
<li>Requires precise application</li>
</ul>
</li>
</ul>
<h4 id="Fungal-Skin-Infections">Fungal Skin Infections</h4>
<h5 id="Red-Flags-5">Red Flags</h5>
<p>Athlete’s foot: (2 week referral)</p>
<ul>
<li>Signs of infection at wound site and systemic signs</li>
<li>Diabetics</li>
<li>Nail involvement 指甲受累</li>
</ul>
<p>Fungal nail: (9-12 months referral)</p>
<ul>
<li>Signs of infection at wound site and systemic signs</li>
<li>Diabetics</li>
<li>More than 2 toenails affected</li>
</ul>
<p>Ringworm: (4 weeks referral)</p>
<ul>
<li>Signs of infection at wound site and systemic signs</li>
</ul>
<p>Sweat rash: (7 day referral)</p>
<ul>
<li>Signs of infection at wound site and systemic signs</li>
</ul>
<h5 id="Product-Selection">Product Selection</h5>
<p>Creams</p>
<ul>
<li>Terbinafine 1% cream (Lamisil) 特比萘芬 – FIRST LINE!!!
<ul>
<li>Also available as a 1% cutaneous solution (Lamisil Once)</li>
<li>Athletes foot and Jock itch only 仅限脚癣和股癣</li>
</ul>
</li>
<li>Clotrimazole 1% cream (Canesten AF) 克霉唑</li>
<li>Ketoconazole 2% cream (Daktarin Gold) 酮康唑
<ul>
<li>Also available as a 2% powder (Daktarin Aktiv powder) and a 0.16% spray powder (Daktarin Aktiv spray powder)</li>
</ul>
</li>
<li>Miconazole 2% cream (Daktarin) 咪康唑
<ul>
<li>Available combined with hydrocortisone (Daktacort)</li>
</ul>
</li>
</ul>
<p>Powders</p>
<ul>
<li>Prevent reoccurrence – dust socks and shoes</li>
<li>Daktarin powder</li>
<li>Mycota powder</li>
</ul>
<p>Nail Paints – fungal nail only</p>
<ul>
<li>Curanail (amorolifine 5% nail lacquer) 阿莫罗芬
<ul>
<li>Over 18</li>
<li>Once weekly</li>
<li>6-12 months treatment time</li>
</ul>
</li>
</ul>
<h4 id="Scabies-疥疮">Scabies 疥疮</h4>
<h5 id="Red-flags-8">Red flags</h5>
<ul>
<li>Signs of infection due to intensive itching</li>
</ul>
<p>Timescale for referral: 2 weeks after first treatment</p>
<blockquote>
<p>TREAT WHOLE HOUSEHOLD! CHECK APPROPRIATE FOR EACH MEMBER OF THE HOUSEHOLD!!</p>
</blockquote>
<h5 id="Product-selection-12">Product selection</h5>
<ul>
<li>
<p>Permethrin 5% Dermal cream (Lyclear Dermal cream) 氯菊酯</p>
<ul>
<li>Scabies and Crab Lice</li>
</ul>
</li>
<li>
<p>Malathion 0.5% Liquid (Derbac-M) 马拉硫磷</p>
<ul>
<li>Head Lice, Scabies and Crab Lice 头虱、疥疮和阴虱</li>
<li>Aqueous – suitable for asthmatics</li>
</ul>
</li>
</ul>
<h4 id="Impetigo-脓疱疮">Impetigo 脓疱疮</h4>
<h5 id="Red-flags-9">Red flags</h5>
<ul>
<li>Eczema</li>
<li>Signs of infection</li>
</ul>
<h5 id="Product-selection-13">Product selection</h5>
<ul>
<li>Refer all cases – needs antibiotic treatment</li>
<li>Crystacide (hydrogen peroxide 1%) – no evidence to support its use</li>
</ul>
<h4 id="Herpes-Simplex-Shingles-单纯疱疹-带状疱疹">Herpes Simplex / Shingles 单纯疱疹 / 带状疱疹</h4>
<h5 id="Red-flags-10">Red flags</h5>
<p>Herpes simplex - (2 weeks)</p>
<ul>
<li>Signs of infection</li>
<li>Lesions elsewhere on face or body</li>
<li>Eyes affected</li>
<li>Painless sores 无痛溃疡</li>
</ul>
<p>Shingles – (4 weeks if only analgesia)</p>
<ul>
<li>Immunosuppression</li>
<li>Eyes affected</li>
</ul>
<h5 id="Product-selection-14">Product selection</h5>
<ul>
<li>Herpes
<ul>
<li>Acicolvir (Zovirax) 阿昔洛韦（Acicolvir? Aciclovir? Acyclovir?）
<ul>
<li>Adults and children</li>
<li>Face and lips</li>
<li>5 times a day for 4 days (up to 10 days)</li>
</ul>
</li>
</ul>
</li>
<li>Shingles
<ul>
<li>Refer</li>
<li>Consider analgesia 镇痛</li>
</ul>
</li>
</ul>
<h3 id="Respiratory">Respiratory</h3>
<blockquote>
<p>cough, cold, hay fever</p>
</blockquote>
<h4 id="Cough">Cough</h4>
<h5 id="Red-Flags-6">Red Flags</h5>
<ul>
<li>Chest pain</li>
<li>Pain on inspiration</li>
<li>Wheezing 喘息</li>
<li>Shortness of breath</li>
<li>Coughing up blood</li>
</ul>
<p>Check for sputum – differential diagnosis 检查痰液</p>
<p>Timescale for referral: More than 3 weeks duration see GP</p>
<h5 id="Product-selection-15">Product selection</h5>
<ul>
<li>
<p>Chesty/productive cough - Expectorants 有痰咳嗽 - 祛痰药</p>
<ul>
<li>Guaifenesin (Benylin chesty cough, Robitussin chesty cough) 愈创甘油醚</li>
</ul>
</li>
<li>
<p>Demulcents 润喉</p>
<ul>
<li>Simple linctus</li>
</ul>
</li>
<li>
<p>Dry/non productive cough</p>
<ul>
<li>Pholcodine (Galenphol, Covonia dry cough) 福尔可定</li>
<li>Dextromethorphan (Benylin dry cough, Covonia original, Robitussin dry cough) 右美沙芬</li>
<li>Codeine linctus – Adults - more historic (abuse potential) 可待因止咳糖浆</li>
<li>Sedative antihistamines - diphenhydramine 苯海拉明</li>
</ul>
</li>
</ul>
<h4 id="Colds">Colds</h4>
<h5 id="Red-Flags-7">Red Flags</h5>
<ul>
<li>Ear pain</li>
<li>Muscle ache/chills/fatigue/dry cough and vulnerable group</li>
<li>Pain on inspiration</li>
<li>Wheezing</li>
<li>Shortness of breath</li>
</ul>
<p>Timescale for referral: 2 weeks</p>
<h5 id="Product-selection-16">Product selection</h5>
<ul>
<li>
<p>Oral analgesics (+ caffeine/vit c)</p>
<ul>
<li>Paracetamol (Panadol, Calpol)</li>
<li>Aspirin (Disprin, Beechams powders)</li>
<li>NSAIDS i.e. Ibuprofen (Nurofen, Cuprofen)</li>
</ul>
</li>
<li>
<p>Used in combination with opioids:</p>
<ul>
<li>Potential for addiction – 3 days max</li>
<li>Codeine (co-codamol, Solpadeine Max) 可待因</li>
<li>Dihydrocodeine (Paramol) 双氢可待因</li>
</ul>
</li>
<li>
<p>Inhalations</p>
<ul>
<li>Eucalyptus oil/Vicks/Carvol/Olbas oil</li>
</ul>
</li>
<li>
<p>Decongestants (systemic Vs topical)</p>
<ul>
<li>Be aware of contra indications!!</li>
<li>Max 7 days treatment</li>
<li>Pseudoephedrine/Phenylephrine – systemic 伪麻黄碱/苯肾上腺素</li>
<li>Oxymetazoline/Xylometazoline - topical 羟甲唑啉/赛洛唑啉</li>
</ul>
</li>
<li>
<p>Combination products (analgesic/decongestant/cough)</p>
<ul>
<li>E.g. night nurse/day nurse/covonia cold and flu</li>
<li>These can be useful – but check:
<ul>
<li>That all ingredients are needed and appropriate</li>
<li>Drowsiness s/e’s with antihistamine</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="Hay-fever-seasonal-allergic-rhinitis">Hay fever (seasonal allergic rhinitis)</h4>
<h5 id="Red-Flags-8">Red Flags</h5>
<ul>
<li>Unilateral nasal blockage 单侧鼻塞</li>
<li>Muscle ache/chills/fatigue/dry cough and vulnerable group 肌肉酸痛/畏寒/疲劳/干咳以及易感人群</li>
</ul>
<p>Timescale for referral: 2 weeks</p>
<h5 id="Product-selection-17">Product selection</h5>
<ul>
<li>Oral antihistamines 口服抗组胺药
<ul>
<li>Non drowsy – adults and children
<ul>
<li>Loratadine tabs 6+/syrup 2+ 氯雷他定</li>
<li>Cetirizine tabs 12+/syrup 2+ 西替利嗪</li>
<li>Acrivastine capsules 12+ 阿克拉维斯汀</li>
</ul>
</li>
<li>Drowsy - adults and children
<ul>
<li>Chlorphenamine tabs 6+/syrup 1+ 氯苯那敏</li>
</ul>
</li>
</ul>
</li>
<li>Steroid Nasal sprays 类固醇鼻喷雾剂
<ul>
<li>Over 18’s only</li>
<li>Most effective for nasal symptoms, not immediate action</li>
<li>Beclometasone 倍氯米松</li>
<li>Fluticasone 氟替卡松</li>
<li>Budesonide 布地奈德</li>
<li>Mometasone 莫米松</li>
<li>Triamcinolone 曲安奈德</li>
</ul>
</li>
<li>Eye drops 眼药水
<ul>
<li>Sodium cromoglicate 6+ 色甘酸钠</li>
</ul>
</li>
<li>Decongestant tablets 减充血剂片剂
<ul>
<li>Pseudoephedrine tabs (Remember contra-indications!)</li>
</ul>
</li>
<li>Other nasal sprays
<ul>
<li>Decongestant nasal sprays 减充血剂鼻喷剂
<ul>
<li>Oxymetazoline/Xylometazoline Max 7 days – rebound congestion</li>
</ul>
</li>
<li>Protectants 鼻腔保护剂
<ul>
<li>Prevalin</li>
</ul>
</li>
<li>Saline 盐水</li>
</ul>
</li>
</ul>
<h2 id="Law">Law</h2>
<h2 id="Core-Concept-Immunity-and-Infection">Core Concept - Immunity and Infection</h2>
<h3 id="LECTURE7-01-Core-Concept-5-Interaction-of-pathogens">LECTURE7 01 Core Concept 5 Interaction of pathogens</h3>
<p>Lecturer: Gavin Humphreys</p>
<h4 id="1-Introduction-Key-Definitions">1. Introduction &amp; Key Definitions</h4>
<h5 id="Bacterial-Abundance">Bacterial Abundance</h5>
<ul>
<li><strong>Global Scale:</strong> There are estimated to be $10^{30}$ bacterial cells on Earth (more than stars in the observable universe).</li>
<li><strong>Human Scale:</strong> Bacterial cells in/on the human body outnumber eukaryotic cells by a ratio of approximately <strong>1.3 : 1</strong>.</li>
<li><strong>Location:</strong> The majority reside in the gut, but they also colonize the skin, nasal cavity, respiratory tract, etc.</li>
</ul>
<h5 id="Commensal-vs-Pathogen">Commensal vs. Pathogen</h5>
<ul>
<li><strong>Commensal Microbiota:</strong> Bacteria that normally live on/in a healthy host without causing harm.
<ul>
<li><strong>Functions/Benefits:</strong>
<ol>
<li><strong>Immune Development:</strong> Colonization from birth helps train the immune system.</li>
<li><strong>Colonisation Resistance:</strong> They occupy space and consume nutrients, preventing pathogens from establishing a stronghold.</li>
<li><strong>Metabolic Organ:</strong> They break down complex indigestible carbohydrates that humans cannot digest.</li>
</ol>
</li>
</ul>
</li>
<li><strong>Opportunistic Pathogen:</strong> Commensals that cause disease when the host’s immune system is compromised or when they enter a sterile site.</li>
<li><strong>Obligate Human Pathogen:</strong> Microorganisms that <em>must</em> cause disease to be transmitted and survive (e.g., <em>Neisseria gonorrhoeae</em>). They generally do not survive well outside the host.</li>
</ul>
<h5 id="Immunocompromised-States">Immunocompromised States</h5>
<p>Opportunistic infections occur when host defenses are breached:</p>
<ul>
<li><strong>Damage to Epithelia:</strong> Cuts, surgical wounds, eczema, burns.</li>
<li><strong>Disruption of Commensals:</strong> Overuse of antibiotics (e.g., leading to <em>C. difficile</em>).</li>
<li><strong>Immune Impairment:</strong> Flu/RSV infections, HIV/AIDS, chemotherapy.</li>
<li><strong>Foreign Devices:</strong> Catheters, prosthetic joints (no blood supply/immune presence, prone to <strong>biofilm</strong> formation).</li>
</ul>
<h4 id="2-Transmission-of-Infection-Epidemiology">2. Transmission of Infection (Epidemiology)</h4>
<p>Bacteria spread via various routes. These routes often overlap.</p>
<h5 id="Horizontal-Transmission-Person-to-Person-Environment-to-Person">Horizontal Transmission (Person-to-Person / Environment-to-Person)</h5>
<ol>
<li><strong>Aerosol/Airborne:</strong> Droplets from coughing/sneezing (e.g., Influenza, COVID-19).
<ul>
<li><em>Small droplets:</em> Stay suspended in air, travel through ventilation.</li>
<li><em>Large droplets:</em> Fall within ~2 meters, contaminating surfaces.</li>
</ul>
</li>
<li><strong>Direct Contact:</strong> Skin-to-skin contact (e.g., unwashed hands of healthcare workers).</li>
<li><strong>Fomite:</strong> Inanimate objects that transfer infection (e.g., mobile phones, keyboards, door handles).</li>
<li><strong>Vehicle:</strong> Contaminated food or water.</li>
<li><strong>Vector:</strong> Living organisms (arthropods) that transmit disease (e.g., mosquitoes).</li>
</ol>
<h5 id="Vertical-Transmission-Parent-to-Child">Vertical Transmission (Parent-to-Child)</h5>
<ul>
<li><strong>Via Placenta:</strong> During pregnancy.</li>
<li><strong>During Birth:</strong> Contact with vaginal canal (e.g., <em>Gonorrhea</em> conjunctivitis).</li>
<li><strong>Via Breast Milk.</strong></li>
</ul>
<h4 id="3-Virulence-Factors">3. Virulence Factors</h4>
<p>To cause disease, bacteria produce <strong>Virulence Factors</strong>. These are strategies to:</p>
<ol>
<li>Promote <strong>Colonisation &amp; Invasion</strong>.</li>
<li>Cause <strong>Host Damage</strong> (Toxicity).</li>
<li>Enable <strong>Immune Evasion</strong>.</li>
</ol>
<h5 id="A-Adhesion-Motility">A. Adhesion &amp; Motility</h5>
<p>The first step in infection is attaching to a surface to prevent being washed away.</p>
<ul>
<li><strong>Fimbriae</strong> / <strong>Pili:</strong>
<ul>
<li>Short, hair-like protein appendages anchored to the outer membrane.</li>
<li><strong>Function:</strong>
<ul>
<li><strong>Intimate Attachment:</strong> Adhesins at the tip bind specific host receptors.</li>
<li><strong>Twitching Motility:</strong> Extend, attach, and retract to drag the bacteria along a surface (“force-driven contraction”).</li>
<li><strong>Biofilm Formation:</strong> Aid in aggregation.</li>
</ul>
</li>
</ul>
</li>
<li><strong>Flagella:</strong>
<ul>
<li>Long, rigid, corkscrew-like structures.</li>
<li><strong>Function:</strong> Motility (movement). Powered by a proton motor to rotate.</li>
<li><strong>Microbial Taxis:</strong> Movement towards nutrients or away from danger (toxins/UV).</li>
</ul>
</li>
</ul>
<h5 id="B-Immune-Evasion-Capsules">B. Immune Evasion: Capsules</h5>
<ul>
<li><strong>Structure:</strong> A polysaccharide layer surrounding the bacterial cell.</li>
<li><strong>Importance:</strong> Critical for <strong>invasive infections</strong> (survival in the blood, e.g., meningitis, pneumonia). Without a capsule, these bacteria are easily cleared.</li>
<li><strong>Mechanisms of Evasion:</strong>
<ol>
<li><strong>Charge Effect:</strong> Capsules often have a high <strong>negative charge</strong>. Since phagocytes are also negatively charged, electrostatic repulsion prevents phagocytosis.</li>
<li><strong>Mimicry:</strong> The capsule composition mimics host tissue (e.g., Hyaluronic acid), masking the bacteria from the immune system. (It coats itself in what the immune system thinks is host tissue <strong>(connective tissue)</strong>, so it doesn’t recognize it as an invading pathogen)</li>
</ol>
</li>
</ul>
<h6 id="Case-Study-Neisseria-meningitidis-Meningitis">Case Study: <em>Neisseria meningitidis</em> (Meningitis)</h6>
<ul>
<li><strong>Virulence:</strong> The capsule is the critical factor allowing survival in the blood (septicaemia) and crossing the blood-brain barrier (meningitis).</li>
<li><strong>Capsule Serotype B:</strong> Mimics host tissue (NCAM). This made vaccine development difficult (took ~30 years) because the immune system does not recognize it as foreign.</li>
<li><strong>Clinical Sign:</strong> <strong>Non-blanching rash</strong> caused by bacteria damaging capillaries and leaking blood.</li>
</ul>
<h5 id="4-Bacterial-Toxins-Host-Damage">4. Bacterial Toxins (Host Damage)</h5>
<p>Bacteria damage the host to obtain nutrients or spread.</p>
<h6 id="1-Endotoxins-Lipopolysaccharide-LPS">1. Endotoxins (Lipopolysaccharide - LPS)</h6>
<ul>
<li><strong>Origin:</strong> Innate part of the <strong>Gram-negative</strong> bacterial outer membrane (specifically <strong>Lipid A</strong>, a part of Lipopolysaccharide (LPS)).</li>
<li><strong>Release:</strong> Released only when the bacterial cell dies or lyses.</li>
<li><strong>Mechanism:</strong> Not site-specific.</li>
<li><strong>Effect:</strong> Highly immunogenic. Triggers a massive, uncontrolled inflammatory response (Cytokine storm, Complement activation).</li>
<li><strong>Outcome:</strong> Can lead to Septicemia / Sepsis.</li>
</ul>
<h6 id="2-Exotoxins">2. Exotoxins</h6>
<ul>
<li><strong>Origin:</strong> Proteins specifically produced and <strong>secreted</strong> by living bacteria (both Gram+ and Gram-).</li>
<li><strong>Mechanism:</strong> Site-specific; they travel through the blood to target specific distal organs or cells.</li>
<li><strong>Examples:</strong>
<ul>
<li><strong>Scalded Skin Syndrome (Staphylococcus):</strong> Toxin produced in the umbilicus/nose enters blood, travels to skin, and cleaves <strong>desmoglein</strong> (skin glue), causing skin to peel off.</li>
</ul>
</li>
</ul>
<h6 id="Case-Study-Pneumolysin-Streptococcus-pneumoniae">Case Study: Pneumolysin (<em>Streptococcus pneumoniae</em>)</h6>
<p>A pore-forming exotoxin targeting <strong>cholesterol</strong> in host cell membranes.</p>
<ul>
<li><strong>Target:</strong> Respiratory tract (causes Pneumonia).</li>
<li><strong>Action 1: Immunosuppressive (Early stage/Low conc):</strong>
<ul>
<li>Attacks the cholesterol receptor, and it will open up a pore randomly in membrane. Inhibits the <strong>mucociliary escalator</strong> (stops cilia beating), preventing clearance of bacteria.</li>
<li>Causes <strong>apoptosis</strong> (cell death) of resident macrophages.</li>
</ul>
</li>
<li><strong>Action 2: Pro-inflammatory (Late stage/High conc):</strong>
<ul>
<li>Recruits <strong>Neutrophils</strong> to the lungs.</li>
<li>While this sounds like a defense, the neutrophils release enzymes that cause massive <strong>tissue damage</strong> (consolidation in lungs), allowing bacteria to proliferate further.</li>
</ul>
</li>
<li><strong>Symptoms:</strong> Fever, malaise, dyspnoea (breathlessness), productive cough, crackles.</li>
</ul>
<h4 id="Summary-Table-Endotoxin-vs-Exotoxin">Summary Table: Endotoxin vs. Exotoxin</h4>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Endotoxin</strong></th>
<th><strong>Exotoxin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source</strong></td>
<td>Gram-negative bacteria only</td>
<td>Gram-positive &amp; Gram-negative</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td>Part of cell wall (LPS / Lipid A)</td>
<td>Secreted from the cell</td>
</tr>
<tr>
<td><strong>Release</strong></td>
<td>Upon cell death/lysis</td>
<td>Produced by living cells</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>Non-specific (Systemic inflammation)</td>
<td>Highly specific targets (e.g., nerves, skin)</td>
</tr>
<tr>
<td><strong>Heat Stability</strong></td>
<td>Heat stable</td>
<td>Heat labile (usually proteins)</td>
</tr>
<tr>
<td><strong>Example</strong></td>
<td>Meningococcal Septicemia</td>
<td>Pneumolysin, Tetanus, Botulinum</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE9-01-Core-Concept-7-Overview-of-Immunity">LECTURE9 01 Core Concept 7 Overview of Immunity</h3>
<p>Lecturer: Dr. Costas Demonacos</p>
<h4 id="1-Introduction-to-the-Immune-System-免疫系统简介">1. Introduction to the Immune System (免疫系统简介)</h4>
<h5 id="Role-Function">Role &amp; Function</h5>
<p>The immune system’s primary role is to provide <strong>defense (防御)</strong> against various pathogens (bacteria, viruses, parasites, fungi).</p>
<ul>
<li><strong>Beneficial (有益):</strong>
<ul>
<li>Protection from Invaders (防御外来入侵).</li>
<li>Elimination of Altered Self (e.g., cancer cells) (清除自身变异细胞).</li>
</ul>
</li>
<li><strong>Detrimental (有害/副作用):</strong>
<ul>
<li>Discomfort (Inflammation) (不适/炎症).</li>
<li>Damage to self (Autoimmunity) (自身免疫损伤).</li>
</ul>
</li>
</ul>
<h5 id="Two-Major-Elements">Two Major Elements</h5>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Innate Immune System (先天性免疫系统)</strong></th>
<th><strong>Adaptive Immune System (适应性免疫系统)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response Time</strong></td>
<td>Rapidly evoked (First line of defense) (快速响应)</td>
<td>Slow activation (慢速激活)</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>Non-specific (非特异性)</td>
<td>Highly specific (高度特异性)</td>
</tr>
<tr>
<td><strong>Memory</strong></td>
<td>No memory (无记忆)</td>
<td>Immunological memory (免疫记忆)</td>
</tr>
<tr>
<td><strong>Development</strong></td>
<td>Present from birth (与生俱来)</td>
<td>Developed/Refined over time (后天获得)</td>
</tr>
</tbody>
</table>
<h4 id="2-Cells-of-the-Immune-System-免疫细胞">2. Cells of the Immune System (免疫细胞)</h4>
<p>Immune cells originate from <strong>Hematopoietic stem cells (造血干细胞)</strong> and differentiate into two main lineages: <strong>Myeloid (髓系)</strong> and <strong>Lymphoid (淋巴系)</strong>.</p>
<h5 id="A-Myeloid-Lineage-Innate-Immunity-mostly-髓系细胞-主要负责先天免疫">A. Myeloid Lineage (Innate Immunity mostly) (髓系细胞 - 主要负责先天免疫)</h5>
<ol>
<li><strong>Antigen Presenting Cells (APCs) (抗原提呈细胞):</strong>
<ul>
<li><em>Function:</em> Capture, process, and present antigens to adaptive immune cells (T cells). This bridges innate and adaptive immunity.</li>
<li><strong>Macrophages (巨噬细胞):</strong> Phagocytose (吞噬) pathogens, break them down, and present peptides.</li>
<li><strong>Dendritic Cells (DCs) (树突状细胞):</strong> “Professional” APCs. Located in tissues (skin, mucosa), capture antigens, and transport them to lymph nodes to activate T cells.</li>
<li>B cells as well that can be antigen presenting cells</li>
</ul>
</li>
<li><strong>Granulocytes (粒细胞):</strong>
<ul>
<li><strong>Neutrophils (中性粒细胞):</strong>
<ul>
<li>Main defense against <strong>rapidly dividing bacteria (快速分裂的细菌)</strong>.</li>
<li>First to migrate to infection sites (Chemotaxis).</li>
<li>Mechanism: Phagocytosis and destruction.</li>
</ul>
</li>
<li><strong>Basophils (嗜碱性粒细胞):</strong>
<ul>
<li>Produce different granules which contain several chemicals that attack foreign microorganisms, the contents of the granules are enzymes and proteins and so on which can then eliminate microorganisms.</li>
<li>Release <strong>Histamine (组胺)</strong>.</li>
<li>Active in <strong>allergic reactions (过敏反应)</strong>.</li>
</ul>
</li>
<li><strong>Eosinophils (嗜酸性粒细胞):</strong>
<ul>
<li>Similar to basopils</li>
<li>Release toxins to kill <strong>parasites (worms/protozoa) (寄生虫)</strong>.</li>
<li>Involved in allergic asthma.</li>
<li>Release <strong>Histamine</strong>.</li>
</ul>
</li>
<li><strong>Mast Cells (肥大细胞):</strong>
<ul>
<li>Concentrated under body surfaces (skin, mucosa).</li>
<li>Release factors causing <strong>vasodilation (血管扩张)</strong> and increased permeability (inflammation).</li>
</ul>
</li>
</ul>
</li>
<li><strong>Natural Killer (NK) Cells (自然杀伤细胞):</strong>
<ul>
<li><em>Note:</em> Part of the <strong>Innate</strong> system despite lymphoid origin.</li>
<li><em>Target:</em> <strong>Virus-infected cells (病毒感染细胞)</strong> and <strong>Cancer cells (癌细胞)</strong>.</li>
<li><em>Mechanism:</em> Recognize cells with low <strong>MHC Class I (主要组织相容性复合体 I类)</strong> expression. (Healthy cells inhibit NK cells via MHC I; infected/tumor cells often lose MHC I to hide, thus triggering NK killing).</li>
<li>the natural killer cells have two receptors, <strong>the activating receptor</strong> and <strong>the repressive receptor</strong>.</li>
</ul>
</li>
</ol>
<table>
<thead>
<tr>
<th><strong>Component of innate immunity</strong></th>
<th><strong>Main mechanisms of action</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cells (concentrated under the body  surfaces)</td>
<td>Release factors which increase blood  flow and vascular permeability bringing components of immunity to the site of  infection</td>
</tr>
<tr>
<td>Neutrophils and macrophages  (phagocytes)</td>
<td>Engulf (phagocytose) and destroy  micro-organisms</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Secrete factors which kill protozoa and  worms</td>
</tr>
<tr>
<td>Natural killer cells</td>
<td>Destroy virus infected cells</td>
</tr>
<tr>
<td>Cytokines - interferon</td>
<td>Toxic to viruses</td>
</tr>
</tbody>
</table>
<h5 id="B-Lymphoid-Lineage-Adaptive-Immunity-mostly-淋巴系细胞-主要负责适应性免疫">B. Lymphoid Lineage (Adaptive Immunity mostly) (淋巴系细胞 - 主要负责适应性免疫)</h5>
<ol>
<li><strong>T Lymphocytes (T Cells) (T 淋巴细胞):</strong>
<ul>
<li><strong>CD4+ T Helper Cells (</strong>$T_H$<strong>) (辅助性 T 细胞):</strong>
<ul>
<li>Recognize antigen on <strong>MHC Class II (MHC II类分子)</strong> (Macrophages, dendritic cells and B cells<br>
which are antigen presenting cells<br>
present antigen on <strong>MHC Class II</strong>).</li>
<li><strong>Th1:</strong> Stimulate Cell-Mediated Immunity (CMI) (细胞免疫).</li>
<li><strong>Th2:</strong> Stimulate B cells to produce antibodies (Humoral Immunity) (体液免疫).</li>
</ul>
</li>
<li><strong>CD8+ Cytotoxic T Cells (</strong>$T_C$<strong>) (细胞毒性 T 细胞):</strong>
<ul>
<li>Recognize antigen on <strong>MHC Class I (MHC I类分子)</strong> (present on all nucleated cells).</li>
<li>Directly kill infected/abnormal cells by producing enzymes and molecules, chemicals that are cytotoxic (Cytotoxicity).</li>
</ul>
</li>
</ul>
</li>
<li><strong>B Lymphocytes (B Cells) (B 淋巴细胞):</strong>
<ul>
<li>Differentiate into <strong>Plasma Cells (浆细胞)</strong>.</li>
<li>Produce <strong>Antibodies (Immunoglobulins, Ig) (抗体/免疫球蛋白)</strong>.</li>
</ul>
</li>
</ol>
<h4 id="3-Antibody-Structure-Function-抗体结构与功能">3. Antibody Structure &amp; Function (抗体结构与功能)</h4>
<ul>
<li><strong>Structure:</strong> Y-shaped.
<ul>
<li><strong>Fab region (Amino terminal):</strong> Recognizes and binds to specific <strong>Antigen (抗原)</strong>.</li>
<li><strong>Fc region (Carboxy terminal):</strong> Binds to receptors on immune cells (recruitment).</li>
<li>The <strong>amino terminal end</strong>, the top part of the antibody, recognizes the antigen whereas the bottom part, the <strong>carboxy terminal end</strong>, binds to receptors that exist on cells of the immune system.</li>
</ul>
</li>
<li><strong>Functions:</strong>
<ol>
<li><strong>Opsonisation (识别作用):</strong> Coating pathogens to make them “visible” and easier for phagocytes to eat.</li>
<li><strong>Neutralisation (中和作用):</strong> Binding to toxins or viruses to prevent them from entering/damaging cells.</li>
<li><strong>Complement Activation (补体激活):</strong> Triggering the complement cascade to form a “tube” (Membrane Attack Complex) that punches holes in bacteria.</li>
<li><strong>ADCC (Antibody-Dependent Cellular Cytotoxicity) (抗体依赖性细胞介导的细胞毒性):</strong> Recruiting cells (like NK cells) to kill targets bound by antibodies.</li>
</ol>
</li>
<li><strong>Classes of Immunoglobulins:</strong>
<ul>
<li><strong>IgM:</strong> First produced, produced from activated B lymphocytes.</li>
<li><strong>IgG:</strong> Main antibody in circulation; long-term immunity；  produced by B cells that are differentiated by the <strong>interferon gamma (γ干扰素)</strong>.</li>
<li><strong>IgA:</strong> Mucosal immunity; passed to infants via breast milk.</li>
<li><strong>IgE:</strong> Involved in <strong>Allergy (过敏)</strong> and parasitic infections.</li>
</ul>
</li>
</ul>
<h5 id="Immunological-Memory-免疫记忆">Immunological Memory (免疫记忆)</h5>
<ul>
<li><strong>Primary Response (初次应答):</strong> Slow (lag phase ~12 days), lower magnitude.</li>
<li><strong>Secondary Response (二次应答):</strong> Fast (lag phase ~4 days), much stronger (robust), due to Memory B/T cells.</li>
</ul>
<h4 id="4-Hypersensitivity-Allergy-超敏反应-过敏">4. Hypersensitivity (Allergy) (超敏反应/过敏)</h4>
<p>Hypersensitivity is an inappropriate immune response to benign antigens (allergens).</p>
<p><img src="https://raw.githubusercontent.com/thyzzs/Pic/main/image-20251202211255845.png" alt="image-20251202211255845"></p>
<h5 id="Type-I-Hypersensitivity-IgE-Mediated-I型超敏反应">Type I Hypersensitivity (IgE-Mediated) (I型超敏反应)</h5>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251202211628893.png" alt="image-20251202211628893"></p>
<ul>
<li><strong>Mechanism:</strong>
<ol>
<li>First exposure to allergen $\rightarrow$ Production of <strong>IgE</strong>.</li>
<li>IgE binds to <strong>Fc receptors</strong> on <strong>Mast Cells</strong> (Sensitization).</li>
<li>Subsequent exposure $\rightarrow$ Allergen cross-links IgE on mast cells.</li>
<li><strong>Degranulation (脱颗粒):</strong> Massive release of <strong>Histamine (组胺)</strong> and other vasoactive amines.</li>
</ol>
</li>
<li><strong>Symptoms:</strong> Vasodilation, itching, bronchoconstriction (Asthma), systemic anaphylaxis.</li>
<li>the production of IgE stimulates the mast cells to produce those allergens, which those vasoactive amines, which now cause all these undesirable effects on our body.</li>
<li><strong>allergies to pollen (花粉过敏)</strong></li>
</ul>
<h5 id="Treatment-Strategy">Treatment Strategy</h5>
<ul>
<li><strong>Antihistamines (抗组胺药):</strong> Block histamine receptors to prevent symptoms (do not stop the release, just the effect).</li>
</ul>
<h4 id="Summary-Table-Innate-vs-Adaptive-Cells">Summary Table: Innate vs. Adaptive Cells</h4>
<table>
<thead>
<tr>
<th><strong>Cell Type</strong></th>
<th><strong>Lineage</strong></th>
<th><strong>System</strong></th>
<th><strong>Main Function</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neutrophil</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Phagocytosis (Bacteria)</td>
</tr>
<tr>
<td><strong>Macrophage</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Phagocytosis + Antigen Presentation</td>
</tr>
<tr>
<td><strong>Dendritic Cell</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Professional Antigen Presentation</td>
</tr>
<tr>
<td><strong>NK Cell</strong></td>
<td>Lymphoid</td>
<td>Innate</td>
<td>Kill virus/cancer cells (low MHC I)</td>
</tr>
<tr>
<td><strong>B Cell</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Produce Antibodies (Humoral)</td>
</tr>
<tr>
<td><strong>T Helper (CD4)</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Coordinate response (Cytokines)</td>
</tr>
<tr>
<td><strong>Cytotoxic T (CD8)</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Kill infected cells (Cellular)</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE11-01-Core-Concept-9-Antimicrobial-Mechanisms">LECTURE11 01 Core Concept 9 Antimicrobial Mechanisms</h3>
<p>Lecturer: Richard Bryce</p>
<h4 id="1-Introduction-to-Microorganisms-Selective-Toxicity">1. Introduction to Microorganisms &amp; Selective Toxicity</h4>
<h5 id="Microbes-Microbiota">Microbes &amp; Microbiota</h5>
<ul>
<li><strong>Microbiota (微生物群):</strong> Microbes living in and around the body (e.g., intestines). 95% located in the GI tract.</li>
<li><strong>Microbiome (微生物组):</strong> The genetic material of all these micro-organisms.</li>
<li><strong>Pathogenic (致病的):</strong> Causing disease vs. Beneficial (Beneficial flora).</li>
</ul>
<h5 id="Selective-Inhibition-选择性抑制">Selective Inhibition (选择性抑制)</h5>
<p>To safely treat infections, drugs must target structures or processes unique to bacteria (prokaryotes) that are absent or different in humans (eukaryotes).</p>
<p><strong>Key Bacterial Targets:</strong></p>
<ol>
<li><strong>Outside:</strong>
<ul>
<li><strong>Cell Wall (细胞壁):</strong> Peptidoglycan (肽聚糖) structure.</li>
<li><strong>Cell Membrane (细胞膜):</strong> Plasma membrane.</li>
</ul>
</li>
<li><strong>Inside:</strong>
<ul>
<li><strong>Circular DNA (环状 DNA):</strong> And plasmids.</li>
<li><strong>Ribosomes (核糖体):</strong> 70S (50S + 30S), unlike human 80S.</li>
<li><strong>Metabolic Pathways (代谢途径):</strong> Unique enzymes (e.g., folate synthesis).</li>
</ul>
</li>
</ol>
<h5 id="Gram-positive-vs-Gram-negative-Bacteria">Gram-positive vs. Gram-negative Bacteria</h5>
<ul>
<li><strong>Gram-positive (革兰氏阳性菌):</strong> Thick peptidoglycan layer, no outer membrane.</li>
<li><strong>Gram-negative (革兰氏阴性菌):</strong> Thin peptidoglycan layer, has an <strong>Outer Membrane (外膜)</strong> containing Lipopolysaccharides (LPS).</li>
</ul>
<h4 id="2-Target-1-Bacterial-DNA-细菌-DNA">2. Target #1: Bacterial DNA (细菌 DNA)</h4>
<h5 id="The-Problem-DNA-Compaction">The Problem: DNA Compaction</h5>
<ul>
<li>Bacterial DNA is circular and very long (~1300 μm). It must fit into a tiny cell.</li>
<li><strong>Supercoiling (超螺旋):</strong> The DNA double helix is twisted into a superhelix to compact it.
<ul>
<li><strong>Negative Supercoiling (负超螺旋):</strong> Left-handed coiling. Loosens strands for replication/transcription. Most common.</li>
<li><strong>Positive Supercoiling (正超螺旋):</strong> Right-handed. Found in thermophiles to prevent denaturation.</li>
</ul>
</li>
</ul>
<h5 id="The-Enzymes-Topoisomerases-拓扑异构酶">The Enzymes: Topoisomerases (拓扑异构酶)</h5>
<ul>
<li><strong>DNA Gyrase (DNA 促旋酶):</strong> Introduces negative supercoils. Essential in <strong>Gram-negative</strong> bacteria.</li>
<li><strong>Topoisomerase IV (拓扑异构酶 IV):</strong> Essential in <strong>Gram-positive</strong> bacteria.</li>
<li><strong>Mechanism:</strong> Cuts one DNA region $\rightarrow$ Passes another region through the break $\rightarrow$ Reseals the break.</li>
</ul>
<h5 id="Drug-Class-1-Quinolones-喹诺酮类">Drug Class 1: Quinolones (喹诺酮类)</h5>
<p>These are <strong>DNA Gyrase Inhibitors</strong>.</p>
<ul>
<li><strong>1st Generation:</strong> <strong>Nalidixic acid (萘啶酸)</strong> (1962).
<ul>
<li>Mainly active against Gram-negative.</li>
<li>Used for UTIs (Urinary Tract Infections).</li>
<li><strong>Bacteriocidal (杀菌的):</strong> Irreversible inhibition.</li>
</ul>
</li>
<li><strong>2nd Generation (Fluoroquinolones):</strong> <strong>Ciprofloxacin (环丙沙星)</strong> (1980).
<ul>
<li>Fluorine atom added (Fluoro-).</li>
<li>Increased Gram-positive activity.</li>
</ul>
</li>
<li><strong>3rd Generation:</strong> <strong>Levofloxacin (左氧氟沙星)</strong> (1993).
<ul>
<li>Active against Streptococci (e.g., <em>S. pneumoniae</em>).</li>
<li><strong>Broad spectrum</strong> (广谱).</li>
</ul>
</li>
</ul>
<h5 id="Drug-Class-2-Nitroimidazoles-硝基咪唑类">Drug Class 2: Nitroimidazoles (硝基咪唑类)</h5>
<ul>
<li><strong>Example:</strong> <strong>Metronidazole (甲硝唑)</strong>.</li>
<li><strong>Mechanism (DNA Strand Breaking):</strong>
<ol>
<li>Requires <strong>Anaerobic environment (厌氧环境)</strong> to activate.</li>
<li>Nitro group ($-NO_2$) is reduced by bacterial electron transport to a <strong>Nitro radical anion</strong>.</li>
<li>Forms a toxic imidazole radical that extracts hydrogen from DNA, causing strand breaks (“<strong>Bactericidal</strong> Fireworks”).</li>
</ol>
</li>
<li><strong>Clinical Use:</strong> Anaerobic infections (e.g., <em>C. difficile</em>, Bacterial Vaginosis) and Protozoa.</li>
<li><strong>Side Effect:</strong> Alcohol intolerance (Disulfiram-like reaction).</li>
</ul>
<h4 id="3-Target-2-Protein-Synthesis-Ribosomes">3. Target #2: Protein Synthesis (Ribosomes)</h4>
<p><strong>Key Difference:</strong> Bacteria use <strong>70S Ribosomes</strong> (30S small subunit + 50S large subunit). Humans use 80S.</p>
<ul>
<li>Inhibition is usually <strong>Bacteriostatic (抑菌的)</strong> (stops growth, doesn’t kill).</li>
</ul>
<h5 id="The-Translation-Process-Drug-Targets">The Translation Process &amp; Drug Targets</h5>
<ol>
<li><strong>Initiation (起始):</strong> Subunits bind mRNA.
<ul>
<li>Subunits bind with mRNA “instructions” in middle (read from 5’ to 3’). <em>Inhibitor:</em> <strong>Oxazolidinones (e.g., Linezolid)</strong>. Binds 50S, prevents formation of the initiation complex (70S).</li>
</ul>
</li>
<li><strong>Elongation (延伸):</strong>
<ul>
<li>tRNA brings amino acid (encoded by codon) to A site. <em>Inhibitor:</em> <strong>Tetracyclines</strong>.</li>
<li>Peptide bond formation (Peptidyl transferase). Growing peptide chain at P site then added to tRNA in A site. <em>Inhibitor:</em> <strong>Chloramphenicol</strong>.</li>
<li>Deacylated tRNA exits from P site via E site</li>
<li>Peptidyl-tRNA moves from A to P site (translocation). <em>Inhibitor:</em> <strong>Macrolides</strong>.</li>
</ul>
</li>
<li><strong>Termination (终止).</strong>
<ul>
<li>Process terminates (stop codon) and subunits dissociate.</li>
</ul>
</li>
</ol>
<h5 id="Drug-Classes">Drug Classes</h5>
<p><img src="https://raw.githubusercontent.com/thyzzs/Pic/main/image-20251204143244494.png" alt="image-20251204143244494"></p>
<h6 id="A-Oxazolidinones-噁唑烷酮类">A. Oxazolidinones (噁唑烷酮类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Linezolid (利奈唑胺)</strong>.</li>
<li><strong>Action:</strong> Binds <strong>50S</strong> subunit. Blocks initiation.</li>
<li><strong>Use:</strong> “Reserve” antibiotic for multi-resistant Gram-positive bacteria (e.g., <strong>MRSA</strong>, VRE).</li>
</ul>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251204143401381.png" alt="image-20251204143401381"></p>
<h6 id="B-Tetracyclines-四环素类">B. Tetracyclines (四环素类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Tetracycline</strong>.</li>
<li><strong>Action:</strong> Binds <strong>30S</strong> subunit. Blocks aminoacyl-tRNA binding (A-site).</li>
<li><strong>Use:</strong> Acne, Lyme disease, Malaria.</li>
<li><strong>Contraindication:</strong> Children (Stains developing tooth enamel/bones).</li>
<li>Widespread resistance (vet use, feedstock additive)</li>
</ul>
<img src="https://raw.githubusercontent.com/thyzzs/Pic/main/image-20251204143531469.png" alt="image-20251204143531469" style="zoom:50%;">
<h6 id="C-Macrolides-大环内酯类">C. Macrolides (大环内酯类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Erythromycin (红霉素)</strong>.</li>
<li><strong>Action:</strong> Binds <strong>50S</strong> subunit near the exit tunnel (near peptidyl transferase centre). Blocks <strong>Translocation (易位)</strong> and peptide exit.</li>
<li><strong>Use:</strong> Gram-positive infections (Penicillin-allergic patients), Respiratory infections.</li>
</ul>
<img src="https://raw.githubusercontent.com/thyzzs/Pic/main/image-20251204143559171.png" alt="image-20251204143559171" style="zoom:50%;">
<h6 id="D-Chloramphenicol-氯霉素">D. Chloramphenicol (氯霉素)</h6>
<ul>
<li>
<p><strong>Action:</strong> Binds <strong>50S</strong> subunit. Also inhibits <strong>Peptidyl Transferase (肽基转移酶)</strong> (peptide bond formation).</p>
<ul>
<li><strong>Note:</strong> Competes with Macrolides (cannot use together).</li>
</ul>
</li>
<li>
<p><strong>Use:</strong> Eye/Ear infections (drops), Typhoid.</p>
</li>
<li>
<p><strong>Toxicity:</strong> Bone marrow toxicity (avoid in infants - “Grey baby syndrome”).</p>
</li>
</ul>
<h4 id="4-Target-3-Metabolism-Folate-Pathway">4. Target #3: Metabolism (Folate Pathway)</h4>
<p><strong>Why Folate?</strong> Folate (Vitamin B9) is essential for synthesizing DNA bases (thymidine).</p>
<ul>
<li><strong>Humans:</strong> Absorb folate from diet (cannot synthesize it).</li>
<li><strong>Bacteria:</strong> Must synthesize folate <em>de novo</em> (cannot absorb it). <strong>Selective Target!</strong></li>
<li>key enzyme = dihydrofolate reductase (DHFR)
<ul>
<li>common to humans and bacteria, but differences in amino acid sequence and structure</li>
<li>can be also used to target cancer (human DHFR), malaria (P. falciparum DHFR)</li>
</ul>
</li>
</ul>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251204152241310.png" alt="image-20251204152241310"></p>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251204152852670.png" alt="image-20251204152852670"></p>
<h5 id="The-Pathway-Inhibitors-Antimetabolites-抗代谢物">The Pathway &amp; Inhibitors (Antimetabolites - 抗代谢物)</h5>
<ol>
<li><strong>Step 1: PABA</strong> $\rightarrow$ <strong>Dihydropteroate</strong>
<ul>
<li><strong>Enzyme:</strong> <strong>DHPS</strong> (Dihydropteroate synthase). Unique to bacteria.</li>
<li><strong>Inhibitor:</strong> <strong>Sulfonamides (Sulfa drugs)</strong> e.g., <strong>Sulfamethoxazole</strong>.</li>
<li><strong>Mechanism:</strong> Mimics the substrate <strong>PABA</strong> (p-aminobenzoic acid). Competitive inhibition.</li>
<li><strong>SAR (Structure-Activity Relationship):</strong> Requires aromatic ring with para-amino group ($p-NH_2$). Secondary sulphonamide group ($pK_a$ 5-8) improves activity.</li>
</ul>
</li>
<li><strong>Step 2: Dihydrofolate</strong> $\rightarrow$ <strong>Tetrahydrofolate</strong>
<ul>
<li><strong>Enzyme:</strong> <strong>DHFR</strong> (Dihydrofolate reductase). Present in humans too, but bacterial enzyme is structurally different.</li>
<li><strong>Inhibitor:</strong> <strong>Trimethoprim (甲氧苄啶)</strong>.
<ul>
<li><strong>Mechanism:</strong> Mimics the <strong>Pteridine ring (蝶啶环)</strong> of folate. 100,000x more selective for bacterial DHFR. Used for UTIs in combination with other antibiotics e.g., SEPTRIN (see later).</li>
</ul>
</li>
<li><strong>Inhibitor:</strong> Methotrexate (MTX) (甲氨蝶呤).
<ul>
<li>Also targets human DHFR so mainly used against cancer and rheumatoid arthritis.</li>
</ul>
</li>
</ul>
</li>
</ol>
<h5 id="Combination-Therapy-Co-trimoxazole-复方新诺明-Septrim">Combination Therapy: Co-trimoxazole (复方新诺明/Septrim)</h5>
<ul>
<li><strong>Combination:</strong> <strong>Sulfamethoxazole + Trimethoprim</strong>.</li>
<li><strong>Concept:</strong> <strong>Sequential Blocking (序贯阻断)</strong>. Hits multiple enzymes in the same pathway.</li>
<li><strong>Benefit:</strong> Synergistic effect, lower doses required, reduces resistance.</li>
<li><strong>Use:</strong> UTIs, <em>Pneumocystis</em> pneumonia (in AIDS).</li>
</ul>
<h4 id="Summary-Table-Drug-Mechanisms">Summary Table: Drug Mechanisms</h4>
<table>
<thead>
<tr>
<th><strong>Drug Class</strong></th>
<th><strong>Target Site</strong></th>
<th><strong>Specific Mechanism</strong></th>
<th><strong>Effect</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quinolones</strong></td>
<td>DNA Gyrase / Topo IV</td>
<td>Prevents supercoiling (DNA replication)</td>
<td>Bacteriocidal</td>
</tr>
<tr>
<td><strong>Nitroimidazoles</strong></td>
<td>DNA Structure</td>
<td>Free radicals break DNA strands</td>
<td>Bacteriocidal</td>
</tr>
<tr>
<td><strong>Oxazolidinones</strong></td>
<td>50S Ribosome</td>
<td>Prevents Initiation complex</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Tetracyclines</strong></td>
<td>30S Ribosome</td>
<td>Blocks tRNA binding (A-site)</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Macrolides</strong></td>
<td>50S Ribosome</td>
<td>Blocks Translocation / Exit tunnel</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Chloramphenicol</strong></td>
<td>50S Ribosome</td>
<td>Inhibits Peptidyl transferase</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Sulfonamides</strong></td>
<td>DHPS Enzyme</td>
<td>Mimics PABA (Folate synthesis)</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Trimethoprim</strong></td>
<td>DHFR</td>
<td>Mimics the Pteridine ring of folate</td>
<td>Bacteriostatic</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE12-01-Core-Concept-10-Beta-Lactam-agents">LECTURE12 01 Core Concept 10 Beta-Lactam agents</h3>
<p>Lecturer: Richard Bryce</p>
<h4 id="1-Introduction-Targets-引言与靶点">1. Introduction &amp; Targets (引言与靶点)</h4>
<p>Following the previous lecture on intracellular targets (DNA, Ribosomes), this lecture focuses on external targets unique to bacteria:</p>
<ol>
<li><strong>Cell Wall (细胞壁)</strong>: Synthesis inhibition.</li>
<li><strong>Cell Membrane (细胞膜)</strong>: Disruption.</li>
</ol>
<h4 id="2-Target-4-Bacterial-Cell-Wall-Synthesis-细菌细胞壁合成">2. Target #4: Bacterial Cell Wall Synthesis (细菌细胞壁合成)</h4>
<h5 id="The-Target-Peptidoglycan-肽聚糖">The Target: Peptidoglycan (肽聚糖)</h5>
<ul>
<li><strong>Function:</strong> Provides mechanical strength to withstand high internal <strong>osmotic pressure (渗透压)</strong>. Without it, the cell absorbs water and bursts (<strong>lysis/溶菌</strong>).</li>
<li><strong>Structure:</strong> A polymer mesh (“chicken wire”).
<ol>
<li><strong>Glycan chains (聚糖链):</strong> Alternating sugars <strong>NAM</strong> (N-acetylmuramic acid) and <strong>NAG</strong> (N-acetylglucosamine).</li>
<li><strong>Peptide cross-links (肽交联):</strong> Short peptides linking the sugar chains.</li>
</ol>
</li>
</ul>
<h5 id="Gram-Positive-vs-Gram-Negative-革兰氏阳性-vs-阴性">Gram-Positive vs. Gram-Negative (革兰氏阳性 vs 阴性)</h5>
<ul>
<li><strong>Gram-Positive (+):</strong> Thick peptidoglycan layer on the outside. Retains purple stain.</li>
<li><strong>Gram-Negative (-):</strong> Thin peptidoglycan layer sandwiched between an <strong>Inner Membrane</strong> and an <strong>Outer Membrane (外膜)</strong>. Drugs must pass through <strong>Porins (孔蛋白)</strong> to reach the cell wall.</li>
</ul>
<h5 id="The-Enzyme-Transpeptidase-转肽酶">The Enzyme: Transpeptidase (转肽酶)</h5>
<ul>
<li>Also known as <strong>Penicillin Binding Protein (PBP)</strong>.</li>
<li><strong>Mechanism:</strong> It catalyzes the cross-linking of peptide chains.
<ul>
<li>It connects <strong>D-Alanine</strong> to <strong>DAP</strong> (Diaminopimelic acid).</li>
<li><strong>Active Site:</strong> Contains a <strong>Serine (丝氨酸)</strong> residue that attacks the peptide to form the bond.</li>
</ul>
</li>
</ul>
<h4 id="3-Beta-Lactam-Antibiotics-Penicillins-青霉素类">3. Beta-Lactam Antibiotics: Penicillins (青霉素类)</h4>
<h5 id="Structure">Structure</h5>
<ul>
<li><strong>Beta-Lactam Ring (</strong>$\beta$<strong>-内酰胺环):</strong> A 4-membered cyclic amide. Highly strained (90° bond angles) and reactive.</li>
<li><strong>Thiazolidine Ring (噻唑烷环):</strong> 5-membered sulfur-containing ring.</li>
<li><strong>Key Features:</strong> Cis-protons, carboxylic acid, amide side chain.</li>
</ul>
<h5 id="Mechanism-of-Action-作用机制">Mechanism of Action (作用机制)</h5>
<ul>
<li><strong>Irreversible Inhibition (不可逆抑制):</strong> The Beta-lactam ring mimics the D-Ala-D-Ala substrate.</li>
<li>The <strong>Transpeptidase</strong> attacks the beta-lactam ring instead of the cell wall peptide.</li>
<li>The ring opens and forms a stable <strong>covalent</strong> bond <strong>(共价键)</strong> with the enzyme’s Serine residue.</li>
<li>The enzyme is permanently disabled $\rightarrow$ No cross-linking $\rightarrow$ Cell wall weakens $\rightarrow$ Cell lysis (<strong>Bactericidal/杀菌</strong>).</li>
</ul>
<h5 id="Penicillin-G-The-Original">Penicillin G (The Original)</h5>
<ul>
<li><strong>Limitations:</strong>
<ol>
<li><strong>Acid Sensitivity (酸敏感性):</strong> Destroyed by stomach acid (cannot be taken orally).</li>
<li><strong>Beta-Lactamase Sensitivity (</strong>$\beta$<strong>-内酰胺酶敏感性):</strong> Bacteria produce enzymes (Beta-lactamases) that break the ring.</li>
<li><strong>Narrow Spectrum (窄谱):</strong> Active mainly against Gram +ve; ineffective against <em>Staphylococci</em>.</li>
</ol>
</li>
</ul>
<h5 id="Drug-Development-Solving-the-Problems">Drug Development (Solving the Problems)</h5>
<h6 id="1-Solving-Acid-Sensitivity-Oral-Administration">1. Solving Acid Sensitivity (Oral Administration)</h6>
<ul>
<li><strong>Problem:</strong> The side chain carbonyl attacks the beta-lactam ring in acid.</li>
<li><strong>Solution:</strong> Add an <strong>Electron-Withdrawing</strong> Group <strong>(吸电子基团)</strong> (e.g., $NH_2$) to the side chain.</li>
<li><strong>Drug:</strong> <strong>Ampicillin (氨苄西林)</strong> / <strong>Amoxicillin (阿莫西林)</strong>.
<ul>
<li>Acid stable (can be taken orally).</li>
</ul>
</li>
</ul>
<h6 id="2-Solving-Beta-Lactamase-Resistance-Enzyme-Resistance">2. Solving Beta-Lactamase Resistance (Enzyme Resistance)</h6>
<ul>
<li><strong>Problem:</strong> Bacteria break the drug before it works.</li>
<li><strong>Solution:</strong> Add a <strong>Bulky Side Chain (大体积侧链)</strong> (Steric Shield) to block the Beta-lactamase from binding.</li>
<li><strong>Drugs:</strong>
<ul>
<li><strong>Methicillin (甲氧西林):</strong> Acid sensitive (must be injected).</li>
<li><strong>Oxacillin (苯唑西林) / Flucloxacillin:</strong> Acid stable &amp; Beta-lactamase resistant.</li>
</ul>
</li>
<li><em>Note:</em> <strong>MRSA</strong> (Methicillin-Resistant <em>S. aureus</em>) has mutated transpeptidases that don’t bind these drugs.</li>
</ul>
<h6 id="3-Increasing-Spectrum-Broad-Spectrum">3. Increasing Spectrum (Broad Spectrum)</h6>
<ul>
<li><strong>Hydrophobic side chains:</strong> Good for Gram-positive.</li>
<li><strong>Hydrophilic side chains:</strong> Better for Gram-negative (pass through porins).</li>
<li><strong>Drug:</strong> <strong>Carbenicillin (羧苄西林)</strong>.
<ul>
<li>Has a hydrophilic carboxyl group. Active against both Gram +ve and Gram -ve (e.g., <em>Pseudomonas</em>).</li>
</ul>
</li>
</ul>
<h4 id="4-Other-Beta-Lactams-其他-beta-内酰胺类">4. Other Beta-Lactams (其他 $\beta$-内酰胺类)</h4>
<h5 id="Cephalosporins-头孢菌素">Cephalosporins (头孢菌素)</h5>
<ul>
<li><strong>Structure:</strong> 6-membered dihydrothiazine ring (instead of 5-membered thiazolidine).</li>
<li><strong>Generations (1st - 4th):</strong> Developed to improve stability and Gram-negative activity.</li>
</ul>
<h5 id="Beta-Lactamase-Inhibitors-酶抑制剂">Beta-Lactamase Inhibitors (酶抑制剂)</h5>
<ul>
<li><strong>Clavulanic Acid (克拉维酸):</strong>
<ul>
<li>Structure looks like penicillin but has no antibacterial activity itself.</li>
<li><strong>Mechanism:</strong> “Suicide inhibitor”. It permanently binds to and inactivates Beta-lactamases.</li>
<li><strong>Usage:</strong> Combined with Amoxicillin (e.g., <strong>Augmentin / Co-amoxiclav</strong>). The Clavulanic acid sacrifices itself so Amoxicillin can kill the bacteria.</li>
</ul>
</li>
</ul>
<h4 id="5-Non-Beta-Lactam-Cell-Wall-Inhibitors">5. Non-Beta-Lactam Cell Wall Inhibitors</h4>
<h5 id="Vancomycin-万古霉素">Vancomycin (万古霉素)</h5>
<ul>
<li><strong>Structure:</strong> Huge Glycopeptide (Sugar + Peptide).</li>
<li><strong>Mechanism:</strong>
<ul>
<li>Does <strong>NOT</strong> bind to the enzyme (transpeptidase).</li>
<li>Binds to the <strong>Substrate (底物)</strong> (the D-Ala-D-Ala tail of the cell wall peptide) via Hydrogen bonds.</li>
<li>Acts as a physical barrier (“Samson in the temple”), preventing cross-linking.</li>
</ul>
</li>
<li><strong>Use:</strong> Serious Gram-positive infections (e.g., MRSA, <em>C. difficile</em>). Too big to pass Gram-negative outer membrane.</li>
<li><strong>Resistance:</strong> <strong>VRE/VRSA</strong> (Bacteria change the peptide from D-Ala-D-Ala to D-Ala-D-Lactate, so Vancomycin can’t bind).</li>
</ul>
<h4 id="6-Target-5-Cell-Membrane-细胞膜">6. Target #5: Cell Membrane (细胞膜)</h4>
<h5 id="Gramicidin-A-短杆菌肽-A">Gramicidin A (短杆菌肽 A)</h5>
<ul>
<li><strong>Structure:</strong> Peptide that coils into a helix.</li>
<li><strong>Mechanism:</strong> Two molecules dimerize in the membrane to form an <strong>Ion</strong> Channel <strong>(离子通道)</strong>.</li>
<li><strong>Effect:</strong> Uncontrolled flow of ions (e.g., $K^+, Na^+$) destroys ion gradients $\rightarrow$ Cell death.</li>
<li><strong>Toxicity:</strong> Can affect human cells too. Used only <strong>Topically (局部使用)</strong> (e.g., eye drops, creams).</li>
</ul>
<h4 id="Summary-Table">Summary Table</h4>
<table>
<thead>
<tr>
<th><strong>Drug Class</strong></th>
<th><strong>Target</strong></th>
<th><strong>Mechanism</strong></th>
<th><strong>Effect</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Penicillins</strong></td>
<td>Transpeptidase</td>
<td>Covalent binding to enzyme</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Cephalosporins</strong></td>
<td>Transpeptidase</td>
<td>Covalent binding to enzyme</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Clavulanic Acid</strong></td>
<td>Beta-Lactamase</td>
<td>Inhibits the enzyme that breaks penicillins</td>
<td>Protective</td>
</tr>
<tr>
<td><strong>Vancomycin</strong></td>
<td>D-Ala-D-Ala (Substrate)</td>
<td>Physically blocks cross-linking</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Gramicidin A</strong></td>
<td>Cell Membrane</td>
<td>Forms ion pores</td>
<td>Bactericidal</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE19-01-Core-Concept-16-Antimicrobial-resistance">LECTURE19 01 Core Concept 16 Antimicrobial resistance</h3>
<p>Lecturer: Andrew McBain (Transcript indicates guest delivery or recording)</p>
<h4 id="1-Introduction-Historical-Context-引言与历史背景">1. Introduction &amp; Historical Context (引言与历史背景)</h4>
<h5 id="The-“Post-Antibiotic-Era”-后抗生素时代">The “Post-Antibiotic Era” (后抗生素时代)</h5>
<ul>
<li><strong>Pre-Antibiotic Era (1900):</strong> The leading causes of death were infectious diseases (e.g., influenza, pneumonia, tuberculosis, gastroenteritis). Life expectancy was lower.</li>
<li><strong>Antibiotic Era (Present/Recent):</strong> Major causes of death shifted to non-communicable diseases (e.g., heart disease, cancer, stroke).</li>
<li><strong>Current Threat:</strong> We are approaching a “post-antibiotic era” where common infections could kill again due to resistance. Patients are already dying from infections with no suitable antibiotic treatment options.</li>
</ul>
<h5 id="Defining-Resistance-耐药性的定义">Defining Resistance (耐药性的定义)</h5>
<ul>
<li><strong>Definition:</strong> The <strong>acquired ability (获得性能力)</strong> of a microorganism to resist the effects of a chemotherapeutic agent to which it is normally sensitive.</li>
<li><strong>Crucial Concept:</strong> It is the <strong>microbe (microorganism)</strong> that becomes resistant, <strong>NOT the patient</strong>.
<ul>
<li><em>Note:</em> Do not say “The patient became resistant to penicillin.” Say “The bacteria infecting the patient became resistant.”</li>
</ul>
</li>
</ul>
<h4 id="2-Classifications-of-Resistance-耐药性的分类">2. Classifications of Resistance (耐药性的分类)</h4>
<h5 id="1-Intrinsic-Natural-Resistance-固有-天然耐药">1. Intrinsic / Natural Resistance (固有/天然耐药)</h5>
<p>The organism is naturally resistant without needing genetic mutation.</p>
<ul>
<li><strong>Examples:</strong>
<ul>
<li>Lactobacilli in yoghurt are intrinsically resistant to Vancomycin (not clinically problematic).</li>
<li>Gram-negative bacteria are intrinsically resistant to antibiotics that cannot cross their outer membrane.</li>
</ul>
</li>
<li><strong>Mechanisms:</strong>
<ul>
<li>Lack of target structure (没有靶点结构).</li>
<li>Impermeable to the antibiotic (对药物不通透).</li>
</ul>
</li>
</ul>
<h5 id="2-Acquired-Resistance-获得性耐药">2. Acquired Resistance (获得性耐药)</h5>
<p>A previously sensitive organism becomes resistant.</p>
<ul>
<li><strong>Driver:</strong> <strong>Darwinian Evolution / Natural Selection (自然选择)</strong>.
<ul>
<li>In a large population of bacteria (e.g., $10^8$ cells), a rare mutation may occur.</li>
<li>Applying an antibiotic kills the susceptible population (Susceptible cells).</li>
<li>The resistant mutant survives and proliferates (Selection pressure).</li>
</ul>
</li>
</ul>
<h4 id="3-Mechanisms-of-Resistance-耐药机制-How-the-drug-fails">3. Mechanisms of Resistance (耐药机制) - <em>How the drug fails</em></h4>
<p>There are four main molecular mechanisms by which bacteria resist drugs:</p>
<h5 id="A-Enzymatic-Inactivation-酶活灭活">A. Enzymatic Inactivation (酶活灭活)</h5>
<p>The bacteria produce enzymes that destroy or modify the drug.</p>
<ul>
<li><strong>Example:</strong> <strong>Beta-lactamases (</strong>$\beta$<strong>-内酰胺酶)</strong> hydrolyse the beta-lactam ring of penicillins and cephalosporins.</li>
<li><strong>Counter-strategy:</strong> Use Beta-lactamase inhibitors (e.g., Clavulanic acid).</li>
</ul>
<h5 id="B-Modification-of-the-Target-靶点修饰">B. Modification of the Target (靶点修饰)</h5>
<p>The bacteria alter the binding site so the drug can no longer attach.</p>
<ul>
<li><strong>Example:</strong> Altered PBP (Penicillin Binding Protein) in <strong>MRSA</strong> (Methicillin-Resistant <em>S. aureus</em>).</li>
<li><strong>Example:</strong> Methylation of the ribosome prevents macrolide binding.</li>
</ul>
<h5 id="C-Reduced-Permeability-Downregulation-of-Porins-降低通透性">C. Reduced Permeability / Downregulation of Porins (降低通透性)</h5>
<p>The bacteria stop the drug from entering the cell.</p>
<ul>
<li>Common in <strong>Gram-negative bacteria</strong> (e.g., <em>Pseudomonas aeruginosa</em>).</li>
<li>They close or downregulate <strong>Porin channels (孔蛋白通道)</strong> in the outer membrane.</li>
</ul>
<h5 id="D-Efflux-Pumps-外排泵">D. Efflux Pumps (外排泵)</h5>
<p>The bacteria actively pump the drug out of the cell before it can reach a toxic concentration.</p>
<ul>
<li>These are transmembrane proteins that eject antibiotics.</li>
</ul>
<h5 id="E-Biofilms-生物膜-A-Physiological-Mechanism">E. Biofilms (生物膜) - <em>A Physiological Mechanism</em></h5>
<ul>
<li><strong>Definition:</strong> An aggregate of microorganisms in which cells adhere to each other and/or to a surface.</li>
<li><strong>Examples:</strong> Dental plaque (牙菌斑), infections on catheters, heart valves, hip replacements.</li>
<li><strong>Resistance:</strong> Biofilms are <strong>phenotypically resistant (表型耐药)</strong>, not necessarily genetically resistant.
<ul>
<li>They require up to <strong>1000x higher concentration</strong> of antimicrobial to kill compared to planktonic (floating) bacteria.</li>
<li><em>Mechanism:</em> Slow growth rate, physical barrier matrix, altered microenvironment.</li>
</ul>
</li>
</ul>
<h4 id="4-Transmission-of-Resistance-耐药性的传播-How-genes-move">4. Transmission of Resistance (耐药性的传播) - <em>How genes move</em></h4>
<p>Bacteria can acquire resistance genes via <strong>Horizontal Gene Transfer (HGT/水平基因转移)</strong>.</p>
<ol>
<li><strong>Transformation (转化):</strong>
<ul>
<li>Uptake of “naked” extracellular DNA from the environment (often from dead bacteria) into the cell.</li>
</ul>
</li>
<li><strong>Conjugation (接合):</strong>
<ul>
<li>“Bacterial Mating”. Transfer of DNA (usually <strong>Plasmids</strong>) via direct cell-to-cell contact using a <strong>Pilus (菌毛)</strong>.</li>
<li>This is a major route for the spread of multi-drug resistance plasmids in hospitals.</li>
</ul>
</li>
<li><strong>Transduction (转导):</strong>
<ul>
<li>Transfer of DNA via <strong>Bacteriophages (噬菌体)</strong> (viruses that infect bacteria). The virus accidentally packages bacterial DNA and injects it into a new host.</li>
</ul>
</li>
</ol>
<h4 id="5-Drivers-of-Resistance-耐药性的驱动因素">5. Drivers of Resistance (耐药性的驱动因素)</h4>
<ul>
<li><strong>Overuse and Misuse (过度使用和滥用):</strong> Prescribing antibiotics for viral infections (colds, flu).</li>
<li><strong>Agricultural Use (农业用途):</strong>
<ul>
<li>Using antibiotics as growth promoters (Prophylactic use in livestock).</li>
<li><em>Risk:</em> Resistant bacteria from animals enter the human food chain (Trophallaxis concept).</li>
</ul>
</li>
<li><strong>Inadequate Infection Control:</strong> Poor hygiene in hospitals allows resistant clones to spread.</li>
<li><strong>Global Travel:</strong> Resistance mechanisms (e.g., NDM-1) spread rapidly across continents.</li>
<li><strong>Lack of New Drugs:</strong> The “Discovery Void”. Developing new antibiotics is expensive (~£1 billion) and difficult, leading to a lack of new drug classes since the 1980s.</li>
</ul>
<h5 id="The-“One-Health”-Concept-全健康-同一健康理念">The “One Health” Concept (全健康/同一健康理念)</h5>
<p>Recognizing that human health, animal health, and the environment are interconnected. Antibiotics released into the environment (sewage, manure) affect resistance in humans.</p>
<h4 id="6-Clinical-Consequences-Specific-Pathogens">6. Clinical Consequences &amp; Specific Pathogens</h4>
<h5 id="Key-Resistant-Organisms">Key Resistant Organisms</h5>
<ul>
<li><strong>MRSA:</strong> Methicillin-Resistant <em>Staphylococcus aureus</em>.</li>
<li><strong>VRE:</strong> Vancomycin-Resistant <em>Enterococci</em>.</li>
<li><strong>ESBL:</strong> Extended-Spectrum Beta-Lactamase producing bacteria (break down cephalosporins).</li>
<li><strong>CRE:</strong> Carbapenem-Resistant <em>Enterobacteriaceae</em> (Resistance to “last-resort” drugs).</li>
</ul>
<h5 id="Consequences">Consequences</h5>
<ul>
<li>Treatment failure.</li>
<li>Increased mortality and morbidity.</li>
<li>Prolonged hospital stays.</li>
<li>Increased healthcare costs.</li>
</ul>
<h4 id="7-Antimicrobial-Stewardship-抗微生物药物管理-导向">7. Antimicrobial Stewardship (抗微生物药物管理/导向)</h4>
<p><strong>Definition:</strong> An organisational or healthcare-system-wide approach to promoting and monitoring judicious use of antimicrobials to preserve their future effectiveness.</p>
<h5 id="Key-Strategies-AMS-Strategies">Key Strategies (AMS Strategies)</h5>
<ol>
<li><strong>Diagnosis &amp; Guidelines:</strong>
<ul>
<li>Only prescribe when there is clinical evidence of <strong>bacterial</strong> infection.</li>
<li>Follow local formulary/guidelines (First-line vs Second-line drugs).</li>
</ul>
</li>
<li><strong>Start Smart, Then Focus (精明开始，然后聚焦):</strong>
<ul>
<li><strong>Start Smart:</strong> If a patient is critically ill (e.g., Sepsis), start broad-spectrum antibiotics immediately (within 1 hour) after taking cultures.</li>
<li><strong>Then Focus (The 48-Hour Review):</strong> Review the prescription at <strong>48-72 hours</strong>.
<ul>
<li><strong>Options:</strong>
<ol>
<li><strong>Stop:</strong> If no infection is found.</li>
<li><strong>Switch:</strong> IV to Oral (if patient improves).</li>
<li><strong>Change:</strong> To a narrower spectrum agent based on culture results (De-escalation).</li>
<li><strong>Continue:</strong> If indicated.</li>
<li><strong>OPAT:</strong> Outpatient Parenteral Antibiotic Therapy.</li>
</ol>
</li>
</ul>
</li>
</ul>
</li>
<li><strong>Surgical Prophylaxis (外科预防):</strong>
<ul>
<li>Single dose given <strong>&lt;60 minutes before incision</strong>.</li>
<li>Do not continue for days after surgery (unless infection is present).</li>
</ul>
</li>
<li><strong>Combination Therapy:</strong>
<ul>
<li>Using multiple drugs to reduce the statistical probability of resistance developing (e.g., in <strong>Tuberculosis</strong> treatment).</li>
</ul>
</li>
</ol>
<h5 id="Summary-for-Pharmacists">Summary for Pharmacists</h5>
<ul>
<li>Understand the <strong>mechanism of action</strong> vs <strong>mechanism of resistance</strong>.</li>
<li>Promote <strong>compliance</strong> (completing courses).</li>
<li>Challenge unnecessary prescriptions.</li>
<li>Understand <strong>One Health</strong> and the global nature of the problem.</li>
</ul>
<h3 id="LECTURE8-01-Core-Concept-6-Vaccination">LECTURE8 01 Core Concept 6 Vaccination</h3>
<p>Lecturer: Andrew McBain</p>
<p>Topic: Principles of Vaccination, Immune Response, and UK Schedules</p>
<h4 id="1-Public-Health-公共卫生">1. Public Health (公共卫生)</h4>
<p><strong>Definition:</strong> The prevention and management of diseases and other health conditions through surveillance and promotion of healthy behaviours, communities, and environments.</p>
<h5 id="Key-Contributors-to-Health">Key Contributors to Health</h5>
<p>While infectious diseases (like HIV) or accidents are visible causes of death, many major causes of morbidity (发病率) and mortality (死亡率) are <strong>preventable</strong> through lifestyle changes (diet, smoking).</p>
<h5 id="Public-Health-Measures">Public Health Measures</h5>
<p>Interventions that reduce disease burden include:</p>
<ul>
<li><strong>Sanitation (卫生设施):</strong> Sewage treatment.</li>
<li><strong>Hand washing:</strong> Crucial in hospitals to prevent infection spread.</li>
<li><strong>Barrier contraception:</strong> Prevents sexually transmitted infections (STIs).</li>
<li><strong>Vaccination (疫苗接种):</strong> A major tool for disease prevention.</li>
<li><strong>Antibiotic Stewardship:</strong> Appropriate use of antibiotics.</li>
<li><strong>Needle exchange schemes:</strong> Reduces blood-borne viruses.</li>
</ul>
<h4 id="2-Dynamics-of-Infectious-Disease-传染病动态">2. Dynamics of Infectious Disease (传染病动态)</h4>
<h5 id="Stages-of-Infection">Stages of Infection</h5>
<p>When a person is infected, they progress through specific stages (which may overlap):</p>
<ol>
<li><strong>Infection Point:</strong> Entry of the pathogen.</li>
<li><strong>Incubation Period (潜伏期):</strong> Time between infection and symptom onset.</li>
<li><strong>Latent Period (隐伏期):</strong> Time when the person is infected but not yet infectious (e.g., HIV can be latent for years).</li>
<li><strong>Clinical Disease:</strong> Symptoms are apparent.</li>
<li><strong>Period of Communicability (传染期):</strong> The window during which the host can infect others. <em>Note: This can occur before symptoms appear or after recovery.</em></li>
</ol>
<h5 id="The-Chain-of-Infection-感染链">The Chain of Infection (感染链)</h5>
<p>Transmission relies on a chain. Vaccination breaks the link of the <strong>Susceptible Host (易感宿主)</strong>.</p>
<ol>
<li><strong>Germs/Agent:</strong> Bacteria, Viruses, Parasites.</li>
<li><strong>Reservoir:</strong> Where germs live (people, animals, food, soil).</li>
<li><strong>Portal of Exit:</strong> How germs leave (vomit, saliva, blood, stool).</li>
<li><strong>Mode of Transmission:</strong> Contact, droplets.</li>
<li><strong>Portal of Entry:</strong> Mouth, cuts, eyes.</li>
<li><strong>Susceptible Host:</strong> Babies, elderly, unimmunised people.</li>
</ol>
<h4 id="3-Immunity-Innate-vs-Adaptive-免疫：先天性与适应性">3. Immunity: Innate vs Adaptive (免疫：先天性与适应性)</h4>
<h5 id="Innate-Immunity-先天性免疫">Innate Immunity (先天性免疫)</h5>
<ul>
<li><strong>Definition:</strong> Non-inducible ability to recognise and destroy pathogens. Does <strong>not</strong> require previous exposure.</li>
<li><strong>Characteristics:</strong> No memory, non-specific.</li>
<li><strong>Physical/Chemical Barriers:</strong>
<ul>
<li><strong>Lysozyme (溶菌酶):</strong> In tears/secretions, dissolves bacterial cell walls.</li>
<li><strong>Normal Microbiota (正常菌群):</strong> Compete with pathogens for space/nutrients (Skin, Gut).</li>
<li><strong>Skin:</strong> Physical barrier, fatty acids.</li>
<li><strong>Stomach Acidity:</strong> pH 2 kills most microbes.</li>
<li><strong>Mucociliary Escalator (黏液纤毛阶梯):</strong> Mucus traps microbes; cilia move them out (impaired in smokers).</li>
<li><strong>Flushing action:</strong> Urine flow, blinking (tears).</li>
</ul>
</li>
<li><strong>Cellular Component:</strong> <strong>Phagocytes (吞噬细胞)</strong> (e.g., Neutrophils, Macrophages) recognise common Pathogen-Associated Molecular Patterns (PAMPs) via Pattern Recognition Receptors (PRRs) and engulf them.</li>
</ul>
<h5 id="Adaptive-Immunity-适应性免疫">Adaptive Immunity (适应性免疫)</h5>
<ul>
<li><strong>Definition:</strong> The <strong>acquired ability (获得性能力)</strong> to recognise and destroy a specific pathogen.</li>
<li><strong>Characteristics:</strong> Specificity (recognises antigens), <strong>Memory (记忆)</strong>, Tolerance (does not attack self).</li>
<li><strong>Mechanism:</strong>
<ul>
<li>Relies on <strong>B-cells</strong> and <strong>T-cells</strong>.</li>
<li>Upon exposure to an antigen (Ag), B-cells undergo <strong>Clonal Expansion (克隆扩增)</strong>.</li>
<li>Differentiate into <strong>Plasma Cells</strong> (secrete antibodies) and <strong>Memory Cells</strong>.</li>
<li><strong>Immunological Memory:</strong>
<ul>
<li><em>Primary Response:</em> Slow (days/weeks), weak.</li>
<li><em>Secondary Response:</em> Rapid, robust (stronger), specific. <em>This is the biological basis of vaccination.</em></li>
</ul>
</li>
</ul>
</li>
</ul>
<h5 id="Antibodies-Immunoglobulins-抗体-免疫球蛋白">Antibodies (Immunoglobulins) (抗体/免疫球蛋白)</h5>
<ul>
<li><strong>IgM &amp; IgG:</strong> Found in blood/tissue fluids. Main systemic defence.</li>
<li><strong>IgA:</strong> Found in <strong>Secretions (分泌物)</strong> (mucus, tears, breast milk, gut). Protects mucosal surfaces.</li>
<li><strong>IgE:</strong> Involved in allergy and parasite defence.</li>
<li><strong>IgD:</strong> B-cell receptor.</li>
</ul>
<p><strong>Functions:</strong> Antibodies bind pathogens (Neutralisation), coat them for phagocytosis (Opsonisation), or activate Complement.</p>
<h4 id="4-Types-of-Acquired-Immunity-获得性免疫的类型">4. Types of Acquired Immunity (获得性免疫的类型)</h4>
<table>
<thead>
<tr>
<th><strong>Type</strong></th>
<th><strong>Active (Immune system actively produces antibodies)</strong></th>
<th><strong>Passive (Antibodies received externally)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Natural (自然)</strong></td>
<td><strong>Infection:</strong> Recovery from disease.</td>
<td><strong>Maternal:</strong> Placental transfer (IgG) or Breast milk (IgA). Protects neonates temporarily.</td>
</tr>
<tr>
<td><strong>Artificial (人工)</strong></td>
<td><strong>Vaccination:</strong> Exposure to harmless antigen to induce memory.</td>
<td><strong>Antiserum/Immunoglobulin Injection:</strong> Injection of pre-formed antibodies (e.g., Snake anti-venom, Tetanus immunoglobulin). Immediate but short-lived protection.</td>
</tr>
</tbody>
</table>
<h4 id="5-Vaccine-Strategies-疫苗策略">5. Vaccine Strategies (疫苗策略)</h4>
<p>The goal is to induce active immunity (memory) without causing disease.</p>
<h5 id="Main-Types">Main Types</h5>
<ol>
<li><strong>Live Attenuated (减毒活疫苗):</strong> Pathogen is viable but weakened (virulence reduced).
<ul>
<li><em>Examples:</em> MMR, Sabin Polio (Oral), BCG, Rotavirus, Shingles (Zostavax).</li>
</ul>
</li>
<li><strong>Inactivated / Killed (灭活/死疫苗):</strong> Pathogen is killed (heat/chemicals).
<ul>
<li><em>Examples:</em> Salk Polio (Injection), Pertussis, Flu (most types).</li>
</ul>
</li>
<li><strong>Subunit / Toxoid (亚单位/类毒素):</strong> Only parts of the pathogen or inactivated toxin.
<ul>
<li><em>Examples:</em> Tetanus toxoid, Diphtheria toxoid, Hib, MenB, HPV (Virus-like particle), Hepatitis B.</li>
</ul>
</li>
<li><strong>Newer Technologies:</strong> mRNA (COVID-19), Viral Vector.</li>
</ol>
<h5 id="Comparison-Live-vs-Inactivated-重要对比">Comparison: Live vs Inactivated (重要对比)</h5>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Live Attenuated (e.g., Sabin Polio)</strong></th>
<th><strong>Inactivated (e.g., Salk Polio)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune Response</strong></td>
<td>Stronger, mimics natural infection. Induces <strong>IgA (Mucosal immunity)</strong> and IgG.</td>
<td>Weaker. Induces mainly <strong>IgG (Systemic immunity)</strong>. Little/No IgA.</td>
</tr>
<tr>
<td><strong>Doses</strong></td>
<td>Fewer doses (often single). Replicates in host.</td>
<td>Multiple doses/boosters required.</td>
</tr>
<tr>
<td><strong>Adjuvant (佐剂)</strong></td>
<td>Not usually required.</td>
<td><strong>Required</strong> (e.g., Aluminium salts) to boost response.</td>
</tr>
<tr>
<td><strong>Stability</strong></td>
<td>Unstable. Requires <strong>Cold Chain (冷链)</strong>.</td>
<td>More stable.</td>
</tr>
<tr>
<td><strong>Safety Risk</strong></td>
<td>Risk of <strong>Reversion (返祖)</strong> to virulence (rare). Can infect others. Avoid in immunocompromised.</td>
<td>Safe. Cannot revert or cause disease.</td>
</tr>
</tbody>
</table>
<h5 id="Case-Study-Polio-Vaccines-脊髓灰质炎疫苗">Case Study: Polio Vaccines (脊髓灰质炎疫苗)</h5>
<ul>
<li><strong>Sabin (Oral Polio Vaccine - OPV):</strong> Live. Induces gut immunity (IgA). Prevents the virus replicating in the gut, stopping transmission. <em>Risk:</em> Vaccine-derived polio.</li>
<li><strong>Salk (Inactivated Polio Vaccine - IPV):</strong> Killed (injected). Induces blood immunity (IgG). Prevents the virus reaching the nerves (paralysis), but <strong>does not</strong> prevent gut infection/transmission.</li>
<li><em>Current UK Strategy:</em> Uses <strong>IPV (Salk)</strong> to eliminate the risk of vaccine-derived polio, as wild polio is eliminated in the UK.</li>
</ul>
<h4 id="6-UK-Vaccination-Schedule-UK-免疫计划">6. UK Vaccination Schedule (UK 免疫计划)</h4>
<p><em>Note: Schedules change; this is based on the general principles discussed.</em></p>
<h5 id="Key-Principles">Key Principles</h5>
<ul>
<li><strong>Timing (8, 12, 16 weeks):</strong> Vaccination starts at 2 months. It is not done at birth (except Hep B for risk groups/BCG) because <strong>Maternal Antibodies (母体抗体)</strong> may interfere with the vaccine and the infant’s immune system is still developing.</li>
<li><strong>Herd Immunity (群体免疫):</strong> High vaccination coverage (~80-95%) protects the unvaccinated (e.g., immunocompromised) by breaking the chain of transmission.</li>
</ul>
<h5 id="Specific-Vaccines-Mentioned">Specific Vaccines Mentioned</h5>
<ol>
<li><strong>6-in-1 Vaccine (Hexavalent):</strong> Diphtheria, Tetanus, Pertussis (Whooping cough), Polio (IPV), Hib, Hepatitis B. Given at 8, 12, 16 weeks.</li>
<li><strong>Rotavirus:</strong> Oral vaccine for gastroenteritis.</li>
<li><strong>Meningitis Vaccines (MenB, MenC, MenACWY):</strong> Meningitis is a medical emergency (can kill/disable). High priority.</li>
<li><strong>MMR:</strong> Measles (麻疹), Mumps (流行性腮腺炎), Rubella (风疹).
<ul>
<li><em>Rubella importance:</em> Prevents Congenital Rubella Syndrome (birth defects) if a pregnant woman is infected.</li>
<li><em>Controversy:</em> The Wakefield paper falsely linked MMR to autism, causing a drop in uptake and outbreaks of measles.</li>
</ul>
</li>
<li><strong>HPV (Human Papillomavirus):</strong>
<ul>
<li>Target: Prevents Cervical cancer (females) and Head/Neck cancers (males). Also prevents genital warts.</li>
<li>Given to adolescents (boys and girls now).</li>
</ul>
</li>
<li><strong>Shingles (带状疱疹):</strong> Reactivation of chickenpox virus. Vaccine for older adults (70s).</li>
</ol>
<h3 id="LECTURE10-01-Core-Concept-8-GI-Pharmacology-Therapeutics-H-pylori-and-C-difficile">LECTURE10 01 Core Concept 8 GI Pharmacology &amp; Therapeutics H pylori and C difficile</h3>
<p><strong>Lecturer:</strong> Sarah Knighton</p>
<h4 id="Part-1-Helicobacter-pylori-H-pylori">Part 1: Helicobacter pylori (H. pylori)</h4>
<h5 id="1-Overview-Pathophysiology">1. Overview &amp; Pathophysiology</h5>
<ul>
<li>
<p><strong>Organism:</strong> Gram-negative bacteria (革兰氏阴性菌).</p>
</li>
<li>
<p><strong>Infection Site:</strong> Persistently infects the gastroduodenal mucosa (胃十二指肠黏膜).</p>
</li>
<li>
<p><strong>Consequences:</strong> Infection <em>always</em> causes <strong>gastritis</strong> (胃炎), which can be acute or chronic.</p>
</li>
<li>
<p><strong>Peptic Ulcer Disease (PUD, 消化性溃疡):</strong> <em>H. pylori</em> is the most common cause.</p>
<ul>
<li>~95% of <strong>Duodenal Ulcers</strong> (十二指肠溃疡).</li>
<li>~70-80% of <strong>Gastric Ulcers</strong> (胃溃疡).</li>
</ul>
</li>
<li>
<p><strong>Malignancy Risk:</strong> Linked to gastric cancer and MALT lymphoma (黏膜相关淋巴组织淋巴瘤).</p>
</li>
<li>
<p><strong>Transmission:</strong> Unclear, likely gastro-oral or faeco-oral.</p>
</li>
<li>
<p><strong>Prevalence:</strong> Increases with age; approx. 50% of the global population is infected (often asymptomatic).</p>
</li>
</ul>
<h5 id="2-Clinical-Presentation-of-PUD">2. Clinical Presentation of PUD</h5>
<p>Symptoms can be non-specific (heartburn, bloating, nausea). Key features of ulcer pain:</p>
<ul>
<li><strong>Well-localised</strong> (patients can point to specific spot).</li>
<li><strong>Nature:</strong> Sharp, stabbing, gnawing pain in the midepigastrium (上腹部).</li>
</ul>
<h6 id="Symptom-Comparison-Important-for-Diagnosis">Symptom Comparison (Important for Diagnosis)</h6>
<table>
<thead>
<tr>
<th>Feature</th>
<th>Gastric Ulcer (胃溃疡)</th>
<th>Duodenal Ulcer (十二指肠溃疡)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pain Timing</strong></td>
<td>When stomach is empty.</td>
<td>2-3 hours <em>after</em> eating (post-prandial).</td>
</tr>
<tr>
<td><strong>Effect of Food</strong></td>
<td><strong>Relieved by food</strong> (Food acts as a buffer).</td>
<td><strong>Worsens</strong> 2-3 hours later (Acid/food moves to duodenum).</td>
</tr>
<tr>
<td><strong>Night Pain</strong></td>
<td>Less common.</td>
<td>Can be worse at night-time.</td>
</tr>
</tbody>
</table>
<p><strong>Note:</strong> Host co-factors (e.g., NSAID use) are also critical in ulcer development.</p>
<h6 id="Red-Flags-ALARM-Symptoms">Red Flags (ALARM Symptoms)</h6>
<p>If these are present, urgent referral/investigation is needed to rule out cancer or severe bleeding.</p>
<ul>
<li><strong>A</strong> - <strong>Anaemia</strong> (贫血) (tiredness, SOB).</li>
<li><strong>L</strong> - <strong>Loss of weight</strong> (unintentional).</li>
<li><strong>A</strong> - <strong>Anorexia</strong> (厌食) (unexplained appetite loss).</li>
<li><strong>R</strong> - <strong>Recent onset</strong> of progressive symptoms.</li>
<li><strong>M</strong> - <strong>Melaena</strong> (黑便) / <strong>Haematemesis</strong> (呕血).</li>
<li><strong>S</strong> - <strong>Swallowing problems</strong> (Dysphagia, 吞咽困难).</li>
</ul>
<h5 id="3-Diagnosis">3. Diagnosis</h5>
<p>Confirmation is required before starting eradication therapy.</p>
<h6 id="Diagnostic-Methods">Diagnostic Methods</h6>
<ol>
<li>
<p><strong>Urea Breath Test (UBT, 尿素呼气试验)</strong>: <em>Standard non-invasive test.</em></p>
<ul>
<li>
<p>Patient swallows $^{13}$C-labelled urea.</p>
</li>
<li>
<p>If <em>H. pylori</em> is present, its <strong>urease</strong> (脲酶) breaks urea down into labelled CO$_2$.</p>
</li>
<li>
<p>Labelled CO$_2$ is detected in breath.</p>
</li>
</ul>
</li>
<li>
<p><strong>Stool Antigen Test (SAT)</strong>.</p>
</li>
<li>
<p><strong>Endoscopy (Gastroscopy)</strong>:</p>
<ul>
<li>
<p><strong>CLO Test (Rapid Urease Test):</strong> Biopsy placed in urea solution; colour change indicates pH rise due to ammonia production.</p>
</li>
<li>
<p>Histology/Culture.</p>
</li>
</ul>
</li>
</ol>
<h6 id="Crucial-Drug-Interactions-with-Testing-False-Negatives">Crucial Drug Interactions with Testing (False Negatives)</h6>
<p>Medications can suppress bacteria or urease activity, leading to <strong>false negative</strong> results.</p>
<p>graph TD<br>
A[Patient needs H. pylori Test] --&gt; B{Is patient on meds?}<br>
B – Yes: Antibiotics --&gt; C[Stop 4 weeks before test]<br>
B – Yes: PPIs (e.g., Omeprazole) --&gt; D[Stop 2 weeks before test]<br>
B – No --&gt; E[Proceed with Test]<br>
C --&gt; E<br>
D --&gt; E</p>
<h5 id="4-Management-Eradication-Therapy-根除治疗">4. Management: Eradication Therapy (根除治疗)</h5>
<p><strong>Standard Regimen:</strong> <strong>Triple Therapy</strong> (3 drugs) for <strong>7 Days</strong>, taken <strong>Twice Daily (BD)</strong>.</p>
<ul>
<li><strong>Components:</strong> 1 PPI + 2 Antibiotics.</li>
<li><strong>Adherence:</strong> Critical for success.</li>
</ul>
<h6 id="First-Line-Treatment-Algorithms">First Line Treatment Algorithms</h6>
<table>
<thead>
<tr>
<th>Patient Status</th>
<th>Regimen (All doses BD for 7 days)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No Penicillin Allergy</strong></td>
<td><strong>PPI</strong> (Full Dose) + <strong>Amoxicillin</strong> (1g) + <strong>Clarithromycin</strong> (500mg) OR <strong>Metronidazole</strong> (400mg)</td>
<td>Choose Clarithromycin or Metronidazole based on interactions/history.</td>
</tr>
<tr>
<td><strong>Penicillin Allergy</strong></td>
<td><strong>PPI</strong> (Full Dose) + <strong>Clarithromycin</strong> (500mg) + <strong>Metronidazole</strong> (400mg)</td>
<td>Avoid Amoxicillin.</td>
</tr>
</tbody>
</table>
<ul>
<li><em>Full Dose PPI examples:</em> Lansoprazole 30mg, Omeprazole 20-40mg.</li>
</ul>
<h6 id="Key-Drug-Interactions-Pharmacist’s-Role">Key Drug Interactions (Pharmacist’s Role)</h6>
<ol>
<li>
<p><strong>Clarithromycin + Statins (e.g., Atorvastatin/Simvastatin):</strong></p>
<ul>
<li>
<p><em>Risk:</em> Myopathy/Rhabdomyolysis (Clarithromycin inhibits CYP3A4, increasing statin levels).</p>
</li>
<li>
<p><em>Management:</em> Stop the statin during the 7-day antibiotic course.</p>
</li>
</ul>
</li>
<li>
<p><strong>Metronidazole + Alcohol:</strong></p>
<ul>
<li>
<p><em>Risk:</em> Disulfiram-like reaction (flushing, vomiting).</p>
</li>
<li>
<p><em>Management:</em> Avoid alcohol during treatment and for 48 hours after.</p>
</li>
</ul>
</li>
</ol>
<h6 id="Post-Treatment">Post-Treatment</h6>
<ul>
<li><strong>Retesting:</strong> Not routine if symptoms resolve.</li>
<li><strong>Indications to retest:</strong> Persistent/recurrent symptoms, or complicated ulcer. (Must use UBT, wait 6-8 weeks after treatment).</li>
</ul>
<h4 id="Part-2-Clostridioides-difficile-C-diff">Part 2: Clostridioides difficile (C. diff)</h4>
<h5 id="1-Overview">1. Overview</h5>
<ul>
<li>
<p><strong>Organism:</strong> Gram-positive, spore-forming, anaerobic rod.</p>
</li>
<li>
<p><strong>Pathology:</strong> Often an asymptomatic commensal (2-3% of adults).</p>
</li>
<li>
<p><strong>Antibiotics</strong> suppress normal gut flora $\rightarrow$ <em>C. diff</em> overgrows $\rightarrow$ Produces <strong>toxins</strong>.</p>
<ul>
<li>Toxins cause inflammation, mucosal damage, and <strong>diarrhoea</strong>.</li>
</ul>
</li>
<li>
<p><strong>Severity:</strong> Mild diarrhoea $\rightarrow$ <strong>Pseudomembranous colitis</strong> (伪膜性结肠炎) $\rightarrow$ Bowel perforation $\rightarrow$ Death.</p>
</li>
</ul>
<h5 id="2-Risk-Factors">2. Risk Factors</h5>
<ul>
<li>
<p><strong>Antibiotics (The “4 C’s” are high risk):</strong></p>
<ol>
<li><strong>C</strong>lindamycin</li>
<li><strong>C</strong>ephalosporins (e.g., Ceftriaxone)</li>
<li><strong>C</strong>iprofloxacin (Fluoroquinolones)</li>
<li><strong>C</strong>o-amoxiclav (Broad-spectrum penicillins)</li>
</ol>
</li>
<li>
<p><strong>Medications:</strong> <strong>PPIs</strong> (Acid suppression alters gut environment).</p>
</li>
<li>
<p><strong>Patient Factors:</strong> Age &gt; 65, prolonged hospitalisation, underlying morbidity.</p>
</li>
</ul>
<h5 id="3-Diagnosis-Management">3. Diagnosis &amp; Management</h5>
<ul>
<li><strong>Symptoms:</strong> Unexplained diarrhoea (distinctive smell), abdominal pain, fever, raised WBC (leukocytosis).</li>
<li><strong>Diagnosis:</strong> Stool test for <strong>C. diff Toxin</strong>.</li>
</ul>
<h6 id="Immediate-Management-Protocol-SIGHT-Mnemonic">Immediate Management Protocol (SIGHT Mnemonic)</h6>
<ul>
<li><strong>S</strong> - <strong>Suspect</strong> (if unclear cause of diarrhoea).</li>
<li><strong>I</strong> - <strong>Isolate</strong> patient (within 2 hours).</li>
<li><strong>G</strong> - <strong>Gloves</strong> and aprons (PPE).</li>
<li><strong>H</strong> - <strong>Hand washing</strong> with <strong>soap and water</strong>. (<em>Alcohol gel does NOT kill spores</em>).</li>
<li><strong>T</strong> - <strong>Test</strong> stool immediately.</li>
</ul>
<h6 id="Pharmacological-Management">Pharmacological Management</h6>
<ol>
<li>
<p><strong>Stop Offending Agents:</strong></p>
<ul>
<li>
<p>Stop the causative antibiotic (if clinical condition allows).</p>
</li>
<li>
<p>Stop <strong>PPIs</strong>.</p>
</li>
<li>
<p><strong>STOP Anti-motility drugs (e.g., Loperamide):</strong> These prevent toxin clearance and can cause toxic megacolon.</p>
</li>
</ul>
</li>
<li>
<p><strong>Specific Treatment (NICE Guidelines):</strong></p>
<ul>
<li>
<p><strong>First Line:</strong> <strong>Vancomycin</strong> (Oral) 125mg QDS for 10 days.</p>
<ul>
<li><em>Note:</em> Must be oral (IV Vancomycin does not penetrate the gut lumen effectively).</li>
</ul>
</li>
<li>
<p><strong>Second Line:</strong> <strong>Fidaxomicin</strong> (Oral).</p>
</li>
<li>
<p><strong>Severe/Life-threatening:</strong> Oral Vancomycin + IV Metronidazole.</p>
</li>
</ul>
</li>
<li>
<p><strong>Recurrent/Refractory:</strong></p>
<ul>
<li>
<p><strong>Faecal Microbiota Transplant (FMT, 粪菌移植):</strong> Restore healthy gut flora.</p>
</li>
<li>
<p>IV Immunoglobulin.</p>
</li>
</ul>
</li>
</ol>
<h5 id="Summary-Checklist-for-Revision"><strong>Summary Checklist for Revision</strong></h5>
<ul>
<li>[ ] Understand the Triple Therapy regimen for <em>H. pylori</em> (Doses/Duration).</li>
<li>[ ] Know the washout periods for PPIs (2 weeks) and Antibiotics (4 weeks) before <em>H. pylori</em> testing.</li>
<li>[ ] Identify the interaction between Clarithromycin and Statins.</li>
<li>[ ] Recognize the “4 C’s” antibiotics that trigger <em>C. diff</em>.</li>
<li>[ ] Remember to <strong>stop Loperamide</strong> in <em>C. diff</em> infection.</li>
</ul>
<h3 id="LECTURE14-01-Core-Concept-12-Immune-mediated-inflammatory-disease-IBD-therapeutics">LECTURE14 01 Core Concept 12 Immune-mediated inflammatory disease - IBD therapeutics</h3>
<h4 id="1-Introduction-Epidemiology-简介与流行病学">1. Introduction &amp; Epidemiology (简介与流行病学)</h4>
<ul>
<li><strong>Prevalence:</strong> Affects ~1 in 250 people in the UK. Increasing incidence globally.</li>
<li><strong>Peak Onset:</strong> 15–30 years old (early adulthood).</li>
<li><strong>Etiology (病因):</strong> A complex interaction of <strong>Genetics</strong>, <strong>Environment</strong>, and <strong>Dysregulated Immune Response</strong> to intestinal microbiota.</li>
</ul>
<h5 id="Risk-Factors-Environmental-Triggers">Risk Factors &amp; Environmental Triggers</h5>
<table>
<thead>
<tr>
<th style="text-align:left">Factor</th>
<th style="text-align:left">Crohn’s Disease (CD)</th>
<th style="text-align:left">Ulcerative Colitis (UC)</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Smoking</strong></td>
<td style="text-align:left"><strong>Aggravates disease</strong> (Risk factor)</td>
<td style="text-align:left"><strong>Protective</strong> (Smoking cessation can trigger onset)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Appendectomy</strong></td>
<td style="text-align:left">Increased risk (slightly)</td>
<td style="text-align:left"><strong>Protective</strong> (Reduced risk)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Genetics</strong></td>
<td style="text-align:left">High concordance (NOD2/CARD15 gene)</td>
<td style="text-align:left">Moderate concordance</td>
</tr>
<tr>
<td style="text-align:left"><strong>Diet/Stress</strong></td>
<td style="text-align:left">Triggers exacerbations</td>
<td style="text-align:left">Triggers exacerbations</td>
</tr>
</tbody>
</table>
<h4 id="2-Comparison-Crohn’s-vs-Ulcerative-Colitis-核心区别">2. Comparison: Crohn’s vs. Ulcerative Colitis (核心区别)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">Ulcerative Colitis (UC)</th>
<th style="text-align:left">Crohn’s Disease (CD)</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Location</strong></td>
<td style="text-align:left"><strong>Colon only</strong> (Starts rectum, extends proximally)</td>
<td style="text-align:left"><strong>Anywhere</strong> (Mouth to Anus). Terminal ileum is most common.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Distribution</strong></td>
<td style="text-align:left"><strong>Continuous</strong> inflammation (连续性)</td>
<td style="text-align:left"><strong>Skip lesions</strong> (跳跃性病变 - patchy)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Depth</strong></td>
<td style="text-align:left"><strong>Mucosal</strong> (Superficial - 粘膜层)</td>
<td style="text-align:left"><strong>Transmural</strong> (Full thickness - 全层)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Histology</strong></td>
<td style="text-align:left">Crypt abscesses, goblet cell depletion</td>
<td style="text-align:left"><strong>Granulomas</strong> (肉芽肿), deep fissures</td>
</tr>
<tr>
<td style="text-align:left"><strong>Symptoms</strong></td>
<td style="text-align:left">Bloody diarrhoea, urgency, tenesmus</td>
<td style="text-align:left">Abdominal pain, weight loss, non-bloody diarrhoea</td>
</tr>
<tr>
<td style="text-align:left"><strong>Complications</strong></td>
<td style="text-align:left">Toxic megacolon, Cancer risk</td>
<td style="text-align:left">Fistulas (瘘管), Strictures (狭窄), Abscesses</td>
</tr>
</tbody>
</table>
<h4 id="3-Pathophysiology-病理生理">3. Pathophysiology (病理生理)</h4>
<ul>
<li><strong>Mechanism:</strong> Loss of tolerance to gut bacteria $\rightarrow$ Chronic inflammation.</li>
<li><strong>Key Cytokines:</strong>
<ul>
<li><strong>TNF-$\alpha$:</strong> Central driver of inflammation in both.</li>
<li><strong>Interleukins:</strong> IL-12, IL-23, IL-17, IL-6.</li>
<li><strong>Integrins ($\alpha_4\beta_7$):</strong> Direct leukocytes into the gut tissue.</li>
</ul>
</li>
</ul>
<h4 id="4-Diagnostics-诊断">4. Diagnostics (诊断)</h4>
<ul>
<li><strong>Stool Test:</strong> <strong>Faecal Calprotectin</strong> (Biomarker of neutrophil intestinal inflammation). Helps distinguish IBD from IBS.</li>
<li><strong>Endoscopy:</strong> Colonoscopy with biopsy is the Gold Standard.</li>
<li><strong>Imaging:</strong> MRI/CT (to check for small bowel disease in CD).</li>
</ul>
<h4 id="5-Pharmacology-Drug-Classes-药物类别">5. Pharmacology: Drug Classes (药物类别)</h4>
<h5 id="A-Aminosalicylates-5-ASAs">A. Aminosalicylates (5-ASAs)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Mesalazine (Oral/Rectal)</em>, <em>Sulfasalazine</em>, <em>Olsalazine</em>.</li>
<li><strong>MOA:</strong> Unclear, likely PPAR-$\gamma$ agonist, inhibits NF-$\kappa$B, reduces cytokine production. Topically active on the gut mucosa.</li>
<li><strong>Formulations:</strong> pH-dependent coatings (e.g., Asacol, Pentasa) allow drug release in the colon/ileum to avoid stomach absorption.</li>
<li><strong>Clinical Use:</strong>
<ul>
<li><strong>First-line for Mild-Moderate UC</strong> (Induction &amp; Maintenance).</li>
<li><em>Less effective in Crohn’s Disease.</em></li>
</ul>
</li>
</ul>
<h5 id="B-Corticosteroids-皮质类固醇">B. Corticosteroids (皮质类固醇)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Prednisolone</em> (Oral/IV), <em>Hydrocortisone</em> (IV), <em>Budesonide</em> (Oral/Rectal).</li>
<li><strong>MOA:</strong> Broad anti-inflammatory.</li>
<li><strong>Budesonide:</strong> High first-pass metabolism $\rightarrow$ Low systemic bioavailability $\rightarrow$ Fewer side effects. Used for mild-moderate Ileal Crohn’s.</li>
<li><strong>Clinical Use:</strong>
<ul>
<li><strong>Induction of Remission ONLY</strong> (Acute Flares).</li>
<li><strong>NOT for Maintenance</strong> (Due to long-term toxicity: osteoporosis, diabetes, Cushing’s).</li>
</ul>
</li>
</ul>
<h5 id="C-Thiopurines-Immunomodulators">C. Thiopurines (Immunomodulators)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Azathioprine (AZA)</em>, <em>Mercaptopurine (6-MP)</em>.</li>
<li><strong>MOA:</strong> Purine antimetabolites $\rightarrow$ Inhibit DNA/RNA synthesis in T/B cells $\rightarrow$ Induce T-cell apoptosis.</li>
<li><strong>Clinical Use:</strong>
<ul>
<li><strong>Maintenance Therapy</strong> (Steroid-sparing agents).</li>
<li>Onset of action is slow (<strong>3–6 months</strong>).</li>
</ul>
</li>
<li><strong>Safety:</strong>
<ul>
<li><strong>TPMT Test:</strong> Must check Thiopurine Methyltransferase (TPMT) levels before starting. Low levels $\rightarrow$ High toxicity (Bone marrow suppression).</li>
<li>Monitor FBC and LFTs regularly.</li>
</ul>
</li>
</ul>
<h5 id="D-Methotrexate-MTX">D. Methotrexate (MTX)</h5>
<ul>
<li><strong>MOA:</strong> Folic acid antagonist.</li>
<li><strong>Clinical Use:</strong> Maintenance in <strong>Crohn’s Disease</strong> (if AZA fails/intolerant). Generally not used for UC.</li>
<li><strong>Safety:</strong> Teratogenic (Must use contraception), Hepatotoxic.</li>
</ul>
<h5 id="E-Biologics-Biological-Therapies-Monoclonal-Antibodies">E. Biologics (Biological Therapies - Monoclonal Antibodies)</h5>
<p>Used for Moderate-Severe disease refractory to conventional therapy.</p>
<ol>
<li>
<p><strong>Anti-TNF Agents:</strong></p>
<ul>
<li><em>Infliximab</em> (IV), <em>Adalimumab</em> (SC).</li>
<li><strong>Use:</strong> Induction &amp; Maintenance for both UC and CD.</li>
<li><strong>Risk:</strong> Reactivation of TB/Hepatitis B. Must screen before starting.</li>
<li><strong>Issue:</strong> Immunogenicity (Body creates Anti-Drug Antibodies $\rightarrow$ Loss of response).</li>
</ul>
</li>
<li>
<p><strong>Anti-Integrin Agents (Gut-Selective):</strong></p>
<ul>
<li><em>Vedolizumab</em>.</li>
<li><strong>MOA:</strong> Blocks $\alpha_4\beta_7$ integrin on lymphocytes, preventing them from entering the gut tissue.</li>
<li><strong>Advantage:</strong> Gut-specific, less systemic immunosuppression.</li>
</ul>
</li>
<li>
<p><strong>Anti-IL-12/23 Agents:</strong></p>
<ul>
<li><em>Ustekinumab</em>.</li>
<li><strong>Use:</strong> Particularly effective in Crohn’s Disease.</li>
</ul>
</li>
</ol>
<h5 id="F-JAK-Inhibitors-Small-Molecules">F. JAK Inhibitors (Small Molecules)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Tofacitinib</em>, <em>Filgotinib</em>, <em>Upadacitinib</em>.</li>
<li><strong>MOA:</strong> Oral Janus Kinase inhibitors. Block intracellular signaling pathways for cytokines.</li>
<li><strong>Use:</strong> Moderate-Severe <strong>Ulcerative Colitis</strong>.</li>
<li><strong>Pros:</strong> Oral administration (Tablets), rapid onset (unlike Thiopurines).</li>
<li><strong>Risks:</strong> VTE (Clots), Herpes Zoster (Shingles).</li>
</ul>
<h4 id="6-Management-Strategies-治疗策略">6. Management Strategies (治疗策略)</h4>
<h5 id="Ulcerative-Colitis-Management">Ulcerative Colitis Management</h5>
<ul>
<li><strong>Mild-Moderate (Proctitis/Left-sided):</strong>
<ul>
<li>1st Line: <strong>Topical 5-ASA</strong> (Suppository/Enema).</li>
<li>2nd Line: Oral 5-ASA + Topical 5-ASA.</li>
</ul>
</li>
<li><strong>Moderate-Severe (Extensive):</strong>
<ul>
<li>Oral Steroids (Prednisolone) for induction.</li>
<li>Maintenance: Thiopurines or Biologics (Anti-TNF, Vedolizumab) or JAK inhibitors.</li>
</ul>
</li>
<li><strong>Acute Severe UC (Medical Emergency):</strong>
<ul>
<li>Criteria: $\ge$ 6 bloody stools/day + systemic toxicity (HR&gt;90, Temp&gt;37.8, CRP&gt;45).</li>
<li>Rx: Hospitalisation, <strong>IV Hydrocortisone</strong>.</li>
<li>Rescue Therapy (Day 3 if no response): <strong>Infliximab</strong> or <strong>Ciclosporin</strong>.</li>
</ul>
</li>
</ul>
<h5 id="Crohn’s-Disease-Management">Crohn’s Disease Management</h5>
<ul>
<li><strong>Induction:</strong>
<ul>
<li><strong>Steroids:</strong> Prednisolone or Budesonide.</li>
<li><strong>EEN (Exclusive Enteral Nutrition):</strong> Liquid diet only for 6-8 weeks. <em>First-line induction for children</em> (avoids steroid growth suppression).</li>
</ul>
</li>
<li><strong>Maintenance:</strong>
<ul>
<li><strong>Azathioprine / Mercaptopurine</strong>.</li>
<li><strong>Methotrexate</strong>.</li>
<li><strong>Biologics:</strong> Infliximab, Adalimumab, Ustekinumab.</li>
</ul>
</li>
<li><strong>Surgery:</strong> Not curative (disease can recur at anastomosis site), but used for complications (strictures/fistulas).</li>
</ul>
<h4 id="7-Pharmacist’s-Role-Counselling-药师角色">7. Pharmacist’s Role &amp; Counselling (药师角色)</h4>
<ol>
<li><strong>Smoking:</strong> Strong advice to stop for Crohn’s patients.</li>
<li><strong>Blood Monitoring:</strong> Crucial for Azathioprine (Bone marrow) and Methotrexate (Liver).</li>
<li><strong>Vaccines:</strong>
<ul>
<li>Patients on Biologics/High-dose steroids are immunocompromised.</li>
<li><strong>NO Live Vaccines</strong> (e.g., Yellow Fever, MMR).</li>
<li>Annual Flu jab and Pneumococcal vaccine recommended.</li>
</ul>
</li>
<li><strong>Cancer Risk:</strong> Long-term colitis increases colorectal cancer risk $\rightarrow$ Need surveillance colonoscopies. Long-term Thiopurines slightly increase skin cancer/lymphoma risk.</li>
</ol>
<h3 id="LECTURE17-01-Core-Concept-15-Skin-therapeutics">LECTURE17 01 Core Concept 15 Skin therapeutics</h3>
<p>Lecturer: Mary Rhodes</p>
<h4 id="1-Skin-Structure-Function">1. Skin Structure &amp; Function</h4>
<p><strong>Chinese Term:</strong> 皮肤结构与功能</p>
<h5 id="A-Structure">A. Structure</h5>
<p>The skin is the largest organ (16% of body weight). Key layers involved in these diseases:</p>
<ol>
<li><strong>Epidermis (表皮):</strong>
<ul>
<li><strong>Keratinocytes (角质形成细胞):</strong> The main cell type. They move from the basal layer to the top, flattening and dying to form the barrier (Stratum corneum).</li>
<li><em>Relevance:</em> Psoriasis involves hyperproliferation of these cells.</li>
</ul>
</li>
<li><strong>Dermis (真皮):</strong> Contains blood vessels, nerve endings, sweat glands, sebaceous glands.</li>
<li><strong>Hypodermis (皮下组织):</strong> Subcutaneous fat.</li>
</ol>
<h5 id="B-Key-Functions">B. Key Functions</h5>
<ul>
<li><strong>Barrier:</strong> Protects against bacteria, toxins, dehydration, UV radiation.</li>
<li><strong>Sensory:</strong> Touch, pain, pressure, temperature, <strong>itch (pruritus)</strong>.</li>
<li><strong>Thermoregulation:</strong> Vasodilation/vasoconstriction, sweating.</li>
<li><strong>Synthesis:</strong> Vitamin D production.</li>
<li><strong>Immune Response:</strong> Langerhans cells detect pathogens $\rightarrow$ T-cell activation.</li>
</ul>
<h4 id="2-Atopic-Eczema-Dermatitis">2. Atopic Eczema (Dermatitis)</h4>
<p><strong>Chinese Term:</strong> 特应性湿疹 (皮炎)</p>
<h5 id="A-Epidemiology-Risk-Factors">A. Epidemiology &amp; Risk Factors</h5>
<ul>
<li><strong>Atopic Triad:</strong> Strong link with <strong>Asthma</strong> and <strong>Hay fever</strong> (Allergic Rhinitis).</li>
<li><strong>Onset:</strong> Usually in childhood (&lt; 5 years); can persist or recur in adulthood.</li>
<li><strong>Triggers:</strong>
<ul>
<li><em>External:</em> Soap, detergents, wool, pollen, dust mites, extreme temperatures (cold/heat).</li>
<li><em>Internal:</em> <strong>Stress</strong>, hormones, genetics, food allergies (rarely).</li>
</ul>
</li>
</ul>
<h5 id="B-Pathophysiology-病理生理">B. Pathophysiology (病理生理)</h5>
<ol>
<li><strong>Barrier Defect:</strong> Altered keratinocyte differentiation (filaggrin defect) $\rightarrow$ <strong>Water loss</strong> (Dryness).</li>
<li><strong>Immune Dysregulation:</strong> T-helper cell activation $\rightarrow$ Inflammation.</li>
<li><strong>Result:</strong> Dysfunctional barrier + Hyper-reactivity to irritants.</li>
</ol>
<h5 id="C-Clinical-Features">C. Clinical Features</h5>
<ul>
<li><strong>Symptoms:</strong> Intense <strong>Itch (Pruritus)</strong>, dry skin, inflammation.</li>
<li><strong>Distribution (Location):</strong>
<ul>
<li>Typically affects <strong>Flexures</strong> (insides of elbows, backs of knees - 屈侧).</li>
<li>Face, neck, and hands are also common.</li>
</ul>
</li>
<li><strong>Appearance:</strong> Erythema (redness), papules (丘疹), plaques (斑块). Can become weeping/crusted if infected (<em>S. aureus</em>).</li>
</ul>
<h5 id="D-Management-Strategy">D. Management Strategy</h5>
<p><strong>Goal:</strong> Restore barrier + Reduce inflammation.</p>
<p><strong>1. Emollients (润肤剂)</strong> - <em>Mainstay of treatment</em></p>
<ul>
<li><strong>Role:</strong> Restore skin integrity, prevent water loss, steroid-sparing effect.</li>
<li><strong>Usage:</strong>
<ul>
<li>Apply <strong>frequently and liberally</strong> (4-5 times/day).</li>
<li>Use even when skin is clear.</li>
<li>Apply in direction of hair growth (to avoid folliculitis).</li>
<li><em>Safety:</em> Paraffin-based products are <strong>flammable</strong> (fire risk with smoking).</li>
</ul>
</li>
<li><strong>Formulations:</strong>
<ul>
<li><em>Ointments (软膏):</em> Greasy, no preservatives (less irritation), best for very dry skin.</li>
<li><em>Creams (乳膏):</em> Lighter, absorb quickly, contain preservatives (may sting).</li>
<li><em>Lotions/Gels:</em> Lightest.</li>
</ul>
</li>
<li><em>Avoid:</em> Aqueous Cream (contains Sodium Lauryl Sulphate - irritant).</li>
</ul>
<p><strong>2. Topical Corticosteroids (局部皮质类固醇)</strong> - <em>For Flare-ups</em></p>
<ul>
<li>
<p><strong>Role:</strong> Anti-inflammatory for active flares.</p>
</li>
<li>
<p><strong>Usage:</strong> Apply sparingly, usually OD or BD, max 4 weeks.</p>
</li>
<li>
<p><strong>Dosing Unit:</strong> <strong>Finger Tip Unit (FTU, 指尖单位)</strong>.</p>
<ul>
<li>1 FTU = line of cream from distal crease to tip of index finger (~0.5g).</li>
<li>1 FTU covers an area of <strong>2</strong> flat <strong>hands</strong>.</li>
</ul>
</li>
<li>
<p>Potency Hierarchy (Important for prescribing):</p>
<table>
<thead>
<tr>
<th style="text-align:left">Potency</th>
<th style="text-align:left">Example</th>
<th style="text-align:left">Chinese</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left">Mild</td>
<td style="text-align:left">Hydrocortisone 0.1% - 2.5%</td>
<td style="text-align:left">弱效 (氢化可的松)</td>
</tr>
<tr>
<td style="text-align:left">Moderate</td>
<td style="text-align:left">Clobetasone butyrate (Eumovate)</td>
<td style="text-align:left">中效</td>
</tr>
<tr>
<td style="text-align:left">Potent</td>
<td style="text-align:left">Betamethasone valerate (Betnovate)</td>
<td style="text-align:left">强效</td>
</tr>
<tr>
<td style="text-align:left">Very Potent</td>
<td style="text-align:left">Clobetasol propionate (Dermovate)</td>
<td style="text-align:left">超强效 (Specialist only)</td>
</tr>
</tbody>
</table>
</li>
<li>
<p><strong>Side Effects:</strong> Skin atrophy (thinning), striae (stretch marks), telangiectasia (thread veins), rebound flare upon stopping.</p>
</li>
</ul>
<p><strong>3. Second-Line &amp; Adjuncts</strong></p>
<ul>
<li><strong>Topical Calcineurin Inhibitors (e.g., Tacrolimus, Pimecrolimus):</strong>
<ul>
<li><em>Use:</em> If steroids are ineffective or unacceptable risk (e.g., on face/neck).</li>
</ul>
</li>
<li><strong>Antihistamines:</strong>
<ul>
<li><em>Sedating</em> (e.g., Chlorphenamine): If itch disturbs sleep (short term 7-14 days).</li>
<li><em>Non-sedating:</em> Generally not recommended unless urticaria is present.</li>
</ul>
</li>
<li><strong>Bandages/Wet Wraps:</strong> For severe cases (Specialist).</li>
</ul>
<h4 id="3-Psoriasis-Chronic-Plaque">3. Psoriasis (Chronic Plaque)</h4>
<p><strong>Chinese Term:</strong> 银屑病 (寻常型)</p>
<h5 id="A-Pathophysiology">A. Pathophysiology</h5>
<ul>
<li><strong>Hyperproliferation:</strong> Keratinocytes grow too fast (turnover days instead of weeks).</li>
<li><strong>Inflammation:</strong> T-cell mediated autoimmune response.</li>
<li><strong>Vascular changes:</strong> Dilated capillaries (leads to redness/bleeding).</li>
</ul>
<h5 id="B-Clinical-Features">B. Clinical Features</h5>
<ul>
<li><strong>Symptoms:</strong> Well-defined red <strong>plaques</strong> with <strong>silvery/white scales</strong> (银白色鳞屑). Less itchy than eczema.</li>
<li><strong>Distribution:</strong>
<ul>
<li>Typically affects <strong>Extensors</strong> (outside of elbows, knees - 伸侧).</li>
<li>Scalp, lower back, buttocks.</li>
</ul>
</li>
<li><strong>Nail Changes:</strong> Pitting (点状凹陷), onycholysis (separation from nail bed).</li>
<li><strong>Complications:</strong>
<ul>
<li><strong>Psoriatic Arthritis (银屑病关节炎):</strong> Joint pain.</li>
<li><strong>Metabolic Syndrome:</strong> Increased risk of CVD (Cardiovascular Disease), obesity, diabetes.</li>
<li><strong>Mental Health:</strong> Depression/Anxiety.</li>
</ul>
</li>
</ul>
<h5 id="C-Management-Strategy">C. Management Strategy</h5>
<p><strong>1. Topical Therapies (First Line)</strong></p>
<ul>
<li><strong>Emollients:</strong> Reduce scaling and dryness.</li>
<li><strong>Vitamin D Analogues (e.g., Calcipotriol):</strong>
<ul>
<li><em>Mechanism:</em> Inhibits keratinocyte proliferation.</li>
<li><em>Note:</em> Often combined with steroids (e.g., Dovobet).</li>
</ul>
</li>
<li><strong>Coal Tar (煤焦油):</strong> Anti-inflammatory and anti-scaling. Smells and stains.</li>
<li><strong>Dithranol:</strong> Effective but stains skin purple/brown. Used for difficult plaques.</li>
<li><strong>Topical Steroids:</strong> For flares, usually combined with Vit D or coal tar.</li>
</ul>
<p><strong>2. Phototherapy (光疗)</strong></p>
<ul>
<li>UVB or PUVA (Psoralen + UVA).</li>
</ul>
<p><strong>3. Systemic/Biologic Therapy (Severe Cases - Specialist)</strong></p>
<ul>
<li>Methotrexate, Ciclosporin, Acitretin.</li>
<li>Biologics (e.g., Adalimumab, Secukinumab).</li>
</ul>
<p><strong>Comparison: Eczema vs. Psoriasis</strong></p>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Eczema (湿疹)</strong></th>
<th><strong>Psoriasis (银屑病)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Site</strong></td>
<td><strong>Flexures</strong> (inside elbow/knee)</td>
<td><strong>Extensors</strong> (outside elbow/knee)</td>
</tr>
<tr>
<td><strong>Itch</strong></td>
<td>Intense (Define feature)</td>
<td>Mild or absent</td>
</tr>
<tr>
<td><strong>Appearance</strong></td>
<td>Indistinct borders, dry, weeping</td>
<td>Well-defined plaques, silvery scales</td>
</tr>
<tr>
<td><strong>Pathology</strong></td>
<td>Barrier defect + Allergy</td>
<td>Hyperproliferation</td>
</tr>
</tbody>
</table>
<h4 id="4-Acne-Vulgaris">4. Acne Vulgaris</h4>
<p><strong>Chinese Term:</strong> 寻常痤疮</p>
<h5 id="A-Pathophysiology-2">A. Pathophysiology</h5>
<ol>
<li><strong>Hormones:</strong> Androgens increase <strong>Sebum</strong> (oil) production.</li>
<li><strong>Hyperkeratinisation:</strong> Dead skin cells block the follicle (Comedonegenesis).</li>
<li><strong>Bacteria:</strong> Colonisation by <em><strong>Cutibacterium acnes</strong></em> (<em>C. acnes</em>).</li>
<li><strong>Inflammation:</strong> Pus formation.</li>
</ol>
<h5 id="B-Clinical-Features-2">B. Clinical Features</h5>
<ul>
<li><strong>Comedones (粉刺):</strong> Blackheads (open) and Whiteheads (closed).</li>
<li><strong>Inflammatory:</strong> Papules, Pustules (pus-filled).</li>
<li><strong>Severe:</strong> Nodules, Cysts (risk of scarring).</li>
<li><strong>Sites:</strong> Face, back, chest (seborrhoeic areas).</li>
</ul>
<h5 id="C-Management-Strategy-2">C. Management Strategy</h5>
<p><em>Take</em> time to work (up to 8 weeks for <em>improvement).</em></p>
<p><strong>Lifestyle Advice:</strong></p>
<ul>
<li>Do not over-clean (irritates skin).</li>
<li>Do not squeeze/pick (scarring risk).</li>
<li>Use non-comedogenic products.</li>
</ul>
<p><strong>Pharmacological Step-Up:</strong></p>
<table>
<thead>
<tr>
<th><strong>Severity</strong></th>
<th><strong>Treatment Options</strong></th>
<th><strong>Chinese Notes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild to Moderate</strong></td>
<td><strong>Topical Retinoids</strong> (Adapalene)  + <strong>Benzoyl Peroxide (BPO)</strong></td>
<td><strong>维A酸类 + 过氧化苯甲酰</strong>  BPO会导致头发/衣物漂白 (Bleaching)</td>
</tr>
<tr>
<td><strong>Moderate</strong></td>
<td><strong>Topical Antibiotic</strong> (Clindamycin)  + BPO / Retinoid  <em>(Do not use monotherapy antibiotic due to resistance)</em></td>
<td><strong>局部抗生素</strong>  必须联合使用以防耐药</td>
</tr>
<tr>
<td><strong>Moderate (Widespread)</strong></td>
<td><strong>Oral Antibiotics</strong> (Lymecycline/Doxycycline)  + Topical BPO/Retinoid  <em>(Max 3 months usually)</em></td>
<td><strong>口服抗生素</strong> (四环素类)  注意光敏性 (Photosensitivity)</td>
</tr>
<tr>
<td><strong>Severe</strong></td>
<td><strong>Oral Isotretinoin</strong> (Roaccutane)  <em>Specialist Prescribing Only</em></td>
<td><strong>异维A酸</strong>  有极强致畸性 (Teratogenic) - 必须避孕</td>
</tr>
</tbody>
</table>
<p><strong>Women:</strong> Combined Oral Contraceptives (COC) can help (Dianette).</p>
<h4 id="5-Differential-Diagnosis-Crucial-for-Diagnosis">5. Differential Diagnosis (Crucial for Diagnosis)</h4>
<p><strong>Chinese Term:</strong> 鉴别诊断</p>
<p>You must distinguish inflammatory conditions from infections:</p>
<ul>
<li><strong>Fungal Infection (Ringworm/Tinea):</strong>
<ul>
<li><em>Signs:</em> Asymmetrical, defined active edge (ring shape), central clearing. Itchy but often shiny/macerated if in folds.</li>
</ul>
</li>
<li><strong>Contact Dermatitis:</strong>
<ul>
<li><em>Signs:</em> Localised to contact site (e.g., watch strap, belt buckle, nickel allergy).</li>
</ul>
</li>
<li><strong>Scabies (疥疮):</strong>
<ul>
<li><em>Signs:</em> Intense itch (worse at night), burrows (fingers, wrists, genitals). Contagious.</li>
</ul>
</li>
<li><strong>Shingles (带状疱疹):</strong>
<ul>
<li><em>Signs:</em> Dermatomal distribution (stops at midline), painful vesicles/blisters, malaise.</li>
</ul>
</li>
<li><strong>Rosacea (酒渣鼻):</strong>
<ul>
<li><em>Signs:</em> Facial redness/flushing, papules but <strong>NO comedones</strong> (unlike acne).</li>
</ul>
</li>
</ul>
<h3 id="LECTURE20-01-Core-Concept-17-Childhood-viral-disease">LECTURE20 01 Core Concept 17 Childhood viral disease</h3>
<p><strong>Lecturer:</strong> Gavin Humphreys</p>
<h4 id="1-General-Principles-基本原则">1. General Principles (基本原则)</h4>
<ul>
<li><strong>Pathogens (病原体):</strong> Viruses are genetic material (DNA or RNA) encapsulated in protein.</li>
<li><strong>Vulnerability (易感性):</strong> Children are highly susceptible due to developing immune systems and behavioural factors (poor hygiene, close contact in nurseries).</li>
<li><strong>Transmission (传播):</strong> Most childhood viruses discussed are propagated via respiratory routes or faecal-oral transmission.</li>
</ul>
<h4 id="2-Chickenpox-Varicella-Zoster-Virus-VZV-水痘">2. Chickenpox (Varicella-Zoster Virus / VZV - 水痘)</h4>
<h5 id="Pathogenicity-Mechanism-致病性与机制">Pathogenicity &amp; Mechanism (致病性与机制)</h5>
<ul>
<li><strong>Virus Type:</strong> DNA virus.</li>
<li><strong>Transmission:</strong>
<ul>
<li><strong>Primary Route:</strong> Respiratory (Airborne/Aerosol) - 呼吸道传播.</li>
<li><strong>Infectivity:</strong> $R_0$ (Reproductive number) is 8–10 (Highly infectious).</li>
</ul>
</li>
<li><strong>Pathogenesis Pathway:</strong>
<ol>
<li><strong>Entry:</strong> Inhalation into the Upper Respiratory Tract (URT).</li>
<li><strong>Viraemia (病毒血症):</strong> Replicates in T-cells (T-cell viraemia).</li>
<li><strong>Skin Infection:</strong> Transports via blood to skin, causing vesicle formation.</li>
<li><strong>Latency (潜伏):</strong> Virus moves via retrograde transport to sensory nerve cell bodies (Dorsal Root Ganglion).</li>
<li><strong>Reactivation:</strong> Can reactivate later in life as <strong>Shingles (带状疱疹 / Zoster)</strong>, often due to stress or immunocompromise.</li>
</ol>
</li>
</ul>
<h5 id="Epidemiology-流行病学">Epidemiology (流行病学)</h5>
<ul>
<li><strong>UK Context:</strong> Endemic (constantly present). Seasonal peak in March–May.</li>
<li><strong>Prevalence:</strong> 90% of adults are immune. 75% of cases occur in &lt;5 year olds.</li>
<li><strong>Mortality:</strong> Rare (c.20 deaths/annum in UK), but risk increases significantly with age (adults).</li>
</ul>
<h5 id="Clinical-Features-临床特征">Clinical Features (临床特征)</h5>
<ul>
<li><strong>Incubation Period:</strong> 10–21 days.</li>
<li><strong>Symptoms:</strong>
<ul>
<li><strong>Prodromal:</strong> Acute, non-specific onset (fever, malaise).</li>
<li><strong>Rash:</strong> Characteristic fluid-filled <strong>vesicles (水疱)</strong>.</li>
<li><strong>Progression:</strong> Vesicles dry to form granular scabs approx. 4 days post-onset.</li>
</ul>
</li>
<li><strong>Infectious Period:</strong> From onset until <strong>all scabs are dry</strong>.</li>
</ul>
<h5 id="Management-Pharmacy-Clinical-Focus-治疗与管理">Management (Pharmacy &amp; Clinical Focus - 治疗与管理)</h5>
<ul>
<li><strong>Antivirals:</strong> <strong>Aciclovir (阿昔洛韦)</strong> is generally <strong>not</strong> recommended for healthy children. It is considered for individuals &gt;14 years or adults due to higher complication risks.</li>
<li><strong>Symptomatic Relief:</strong>
<ul>
<li><strong>Itch (止痒):</strong> Topical calamine lotion or Chlorphenamine (antihistamine) if &gt;1 year old.</li>
<li><strong>Pain/Fever:</strong> Paracetamol.</li>
</ul>
</li>
<li><strong>Non-Pharmacological Advice:</strong>
<ul>
<li>Fluid intake to prevent dehydration.</li>
<li>Keep nails short to prevent excoriation and <strong>secondary bacterial infection (继发性细菌感染)</strong>.</li>
<li>Avoid school/nursery until vesicles have crusted over.</li>
</ul>
</li>
<li><strong>Risk Groups:</strong> Pregnant women, smokers, and immunocompromised individuals are at higher risk of complications like viral pneumonia.</li>
</ul>
<h5 id="Vaccination-Strategy-疫苗策略">Vaccination Strategy (疫苗策略)</h5>
<ul>
<li><strong>Vaccine:</strong> Live attenuated (Varilrix® or Varivax®).</li>
<li><strong>UK Schedule:</strong> <strong>Not</strong> routine. Available privately (~£150) or for specific risk groups.</li>
<li><strong>Debate:</strong> The UK avoids routine vaccination to ensure the virus circulates, providing natural “boosting” to adults to prevent Shingles, though this is scientifically controversial and likely to change.</li>
</ul>
<h4 id="3-Rotavirus-轮状病毒">3. Rotavirus (轮状病毒)</h4>
<h5 id="Pathogenicity">Pathogenicity</h5>
<ul>
<li><strong>Virus Type:</strong> RNA virus with a triple-layer protein capsule.</li>
<li><strong>Stability:</strong> Highly environmentally stable; can survive on surfaces for days.</li>
<li><strong>Transmission:</strong> <strong>Faecal-oral (粪-口传播)</strong>. Extremely low infectious dose (approx. 10 particles).</li>
<li><strong>Mechanism of Diarrhoea:</strong>
<ol>
<li>Replication in small intestine.</li>
<li><strong>Villous Atrophy (绒毛萎缩):</strong> Lysis of cells causes villi to collapse.</li>
<li><strong>Osmotic Imbalance:</strong> Activation of chloride channels leads to water influx into the gut.</li>
</ol>
</li>
</ul>
<h5 id="Clinical-Features">Clinical Features</h5>
<ul>
<li><strong>Symptoms:</strong> Severe diarrhoea (lasting 3–8 days), vomiting, stomach cramps, mild fever.</li>
<li><strong>Red Flags (Clinical Alerts - 需紧急就医指征):</strong>
<ul>
<li>Reduced urine output (Dehydration).</li>
<li>Altered responsiveness (Lethargy).</li>
<li>Tachycardia or tachypnoea.</li>
</ul>
</li>
</ul>
<h5 id="Management">Management</h5>
<ul>
<li><strong>Treatment:</strong> No specific antivirals.</li>
<li><strong>Supportive:</strong>
<ul>
<li><strong>Oral Rehydration Salts (ORS):</strong> Critical to manage dehydration.</li>
<li>Infection Control: Strict handwashing; exclusion from school/childcare for <strong>48 hours</strong> after the last symptom.</li>
</ul>
</li>
</ul>
<h5 id="Vaccination">Vaccination</h5>
<ul>
<li><strong>Vaccine:</strong> <strong>Rotarix</strong> (Live-attenuated, Oral).</li>
<li><strong>Schedule:</strong> 2 doses at 8 weeks and 12 weeks of age.</li>
<li><strong>Contraindications:</strong>
<ul>
<li><strong>SCID (Severe Combined Immunodeficiency):</strong> Screened before administration.</li>
<li><strong>In Utero Drug Exposure:</strong> Infants whose mothers took TNF-$\alpha$ inhibitors during pregnancy should defer vaccination (live vaccine risk).</li>
</ul>
</li>
<li><strong>Adverse Reaction:</strong> <strong>Intussusception (肠套叠)</strong> – rare risk (1 in 100,000) where the bowel folds in on itself.</li>
</ul>
<h4 id="4-Measles-麻疹-Rubeola">4. Measles (麻疹 / Rubeola)</h4>
<h5 id="Pathogenicity-Epidemiology">Pathogenicity &amp; Epidemiology</h5>
<ul>
<li><strong>Virus Type:</strong> RNA virus.</li>
<li><strong>Transmission:</strong> Airborne/Respiratory.</li>
<li><strong>Infectivity:</strong> <strong>$R_0 = 18$</strong> (Extremely high). Requires 95% herd immunity to halt spread.</li>
<li><strong>UK Status:</strong> Endemic transmission re-established due to vaccine hesitancy (Wakefield scandal).</li>
</ul>
<h5 id="Clinical-Features-2">Clinical Features</h5>
<ul>
<li><strong>Incubation:</strong> 10 days.</li>
<li><strong>Symptoms:</strong>
<ul>
<li><strong>Prodromal:</strong> Fever, malaise, cough.</li>
<li><strong>Rash:</strong> Erythematous, <strong>maculopapular (斑邱疹)</strong> rash appearing 3–4 days post-infection.</li>
</ul>
</li>
<li><strong>Complications:</strong>
<ul>
<li><strong>Hospitalisation:</strong> Common in infants (&lt;1y) and adults (&gt;25y).</li>
<li><strong>Pneumonia:</strong> Occurs in 1/20 cases.</li>
<li><strong>SSPE (Sub-acute Sclerosing Pan-encephalitis):</strong> Rare, fatal, progressive brain inflammation occurring years after infection.</li>
</ul>
</li>
</ul>
<h5 id="Management-2">Management</h5>
<ul>
<li><strong>Notification:</strong> <strong>Notifiable disease (法定传染病)</strong>. Pharmacists/Clinicians must inform the local Health Protection Team (HPT) immediately.</li>
<li><strong>Treatment:</strong> Supportive (fluids, paracetamol/ibuprofen).</li>
<li><strong>Isolation:</strong> Avoid susceptible individuals (pregnant, immunocompromised).</li>
</ul>
<h4 id="5-Mumps-Rubella-流行性腮腺炎与风疹">5. Mumps &amp; Rubella (流行性腮腺炎与风疹)</h4>
<h5 id="Mumps-流行性腮腺炎">Mumps (流行性腮腺炎)</h5>
<ul>
<li><strong>Symptoms:</strong> Swelling of the <strong>parotid glands (腮腺)</strong> (“Bull neck”), fever, headache, joint pain.</li>
<li><strong>Asymptomatic:</strong> 1 in 6 cases.</li>
<li><strong>Status:</strong> Notifiable disease.</li>
</ul>
<h5 id="Rubella-German-Measles-风疹">Rubella (German Measles / 风疹)</h5>
<ul>
<li><strong>Symptoms:</strong> Generally mild. Low-grade fever, sore throat.</li>
<li><strong>Rash:</strong> Distinctive rough/sandpaper texture.</li>
<li><strong>Congenital Risk:</strong> Dangerous for pregnant women (Congenital Rubella Syndrome).</li>
</ul>
<h4 id="6-MMR-Vaccination-Controversy">6. MMR Vaccination &amp; Controversy</h4>
<ul>
<li><strong>Vaccine:</strong> <strong>MMRvaxPro</strong> or <strong>Priorix</strong> (Live attenuated).</li>
<li><strong>Schedule:</strong>
<ul>
<li>Dose 1: 1 year old.</li>
<li>Dose 2: 3 years and 4 months.</li>
</ul>
</li>
<li><strong>Efficacy:</strong> 99% after two doses.</li>
<li><strong>The Wakefield Scandal (1998):</strong> A fraudulent paper (retracted) linked MMR to autism. This caused vaccination rates to drop to ~80% in the early 2000s, leading to the resurgence of measles.</li>
</ul>
<h4 id="Summary-Table-复习总结表">Summary Table (复习总结表)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Disease</th>
<th style="text-align:left">Pathogen Type</th>
<th style="text-align:left">Transmission</th>
<th style="text-align:left">Key Symptoms</th>
<th style="text-align:left">Management/Vaccine Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Chickenpox</strong> (Varicella)</td>
<td style="text-align:left">DNA (VZV)</td>
<td style="text-align:left">Respiratory (Primary)</td>
<td style="text-align:left">Vesicular rash (水疱), fever.</td>
<td style="text-align:left">Not routine in UK. Aciclovir only for severe risk/adults.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Rotavirus</strong></td>
<td style="text-align:left">RNA</td>
<td style="text-align:left">Faecal-Oral</td>
<td style="text-align:left">Severe diarrhoea, dehydration.</td>
<td style="text-align:left"><strong>Red Flags:</strong> Reduced urine, lethargy. Vaccine: Oral, Live (Rotarix).</td>
</tr>
<tr>
<td style="text-align:left"><strong>Measles</strong></td>
<td style="text-align:left">RNA</td>
<td style="text-align:left">Airborne ($R_0=18$)</td>
<td style="text-align:left">Maculopapular rash (斑邱疹), cough.</td>
<td style="text-align:left"><strong>Notifiable.</strong> High hospitalisation rate. MMR Vaccine.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Mumps</strong></td>
<td style="text-align:left">RNA</td>
<td style="text-align:left">Respiratory</td>
<td style="text-align:left">Parotid gland swelling (腮腺肿大).</td>
<td style="text-align:left"><strong>Notifiable.</strong> MMR Vaccine.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Rubella</strong></td>
<td style="text-align:left">RNA</td>
<td style="text-align:left">Respiratory</td>
<td style="text-align:left">Rough rash, mild fever.</td>
<td style="text-align:left"><strong>Notifiable.</strong> Risk in pregnancy. MMR Vaccine.</td>
</tr>
</tbody>
</table>
<h2 id="Core-Concept-Respiratory-System">Core Concept - Respiratory System</h2>
<h3 id="LECTURE26-01-Core-Concept-23-Lung-Physiology-and-function">LECTURE26 01 Core Concept 23 Lung Physiology and function</h3>
<h4 id="1-Functions-of-the-Respiratory-System-呼吸系统的功能">1. Functions of the Respiratory System (呼吸系统的功能)</h4>
<ul>
<li><strong>Gas Exchange (气体交换):</strong> Intake of $O_2$ for metabolism and removal of $CO_2$ (waste product).</li>
<li><strong>Regulation of Body pH (pH调节):</strong> By retaining or eliminating $CO_2$, the lungs regulate blood pH (Respiratory Acidosis/Alkalosis).</li>
<li><strong>Protection (保护):</strong> Filtering pathogens and irritants; mucociliary escalator.</li>
<li><strong>Vocalization (发声):</strong> Air moving across vocal cords.</li>
</ul>
<h4 id="2-Structure-Anatomy-结构与解剖">2. Structure &amp; Anatomy (结构与解剖)</h4>
<h5 id="A-The-Airways-气道">A. The Airways (气道)</h5>
<p>Divided into two zones:</p>
<ol>
<li>
<p><strong>Conducting Zone (传导区):</strong></p>
<ul>
<li><strong>Components:</strong> Nose, Pharynx, Larynx, Trachea, Bronchi, Bronchioles (Terminal).</li>
<li><strong>Function:</strong> Warm, humidify, and filter air. <strong>No gas exchange</strong> occurs here (Anatomical Dead Space).</li>
<li><strong>Lining:</strong> Ciliated epithelium with goblet cells (secrete mucus to trap particles).</li>
</ul>
</li>
<li>
<p><strong>Respiratory Zone (呼吸区):</strong></p>
<ul>
<li><strong>Components:</strong> Respiratory Bronchioles, Alveolar Ducts, <strong>Alveoli</strong>.</li>
<li><strong>Function:</strong> Site of gas exchange.</li>
</ul>
</li>
</ol>
<h5 id="B-The-Alveoli-肺泡">B. The Alveoli (肺泡)</h5>
<ul>
<li>Huge surface area (~70 $m^2$) for diffusion.</li>
<li><strong>Type I Alveolar Cells:</strong> Flat epithelial cells; form the main structure for gas exchange (thin barrier).</li>
<li><strong>Type II Alveolar Cells:</strong> Secrete <strong>Surfactant (表面活性剂)</strong>.
<ul>
<li><em>Surfactant Function:</em> Reduces surface tension of water in alveoli, preventing alveolar collapse (atelectasis) and increasing compliance.</li>
</ul>
</li>
<li><strong>Alveolar Macrophages:</strong> Engulf foreign particles.</li>
</ul>
<h4 id="3-Mechanics-of-Breathing-呼吸力学">3. Mechanics of Breathing (呼吸力学)</h4>
<p><strong>Principle:</strong> Air moves from high pressure to low pressure.<br>
<strong>Boyle’s Law (波义耳定律):</strong> $P_1V_1 = P_2V_2$. Pressure is inversely proportional to Volume.</p>
<h5 id="A-Inspiration-吸气-Active-Process">A. Inspiration (吸气) - Active Process</h5>
<ol>
<li><strong>Muscles Contract:</strong> Diaphragm flattens (moves down), External Intercostal muscles lift ribs up and out.</li>
<li><strong>Volume Increases:</strong> Thoracic cavity expands.</li>
<li><strong>Pressure Decreases:</strong> Intrapulmonary pressure drops below atmospheric pressure (negative pressure).</li>
<li><strong>Air Flow:</strong> Air rushes <strong>IN</strong>.</li>
</ol>
<h5 id="B-Expiration-呼气-Passive-Process-at-rest">B. Expiration (呼气) - Passive Process (at rest)</h5>
<ol>
<li><strong>Muscles Relax:</strong> Diaphragm moves up, ribs move down.</li>
<li><strong>Elastic Recoil:</strong> Lungs recoil inward.</li>
<li><strong>Volume Decreases:</strong> Thoracic cavity shrinks.</li>
<li><strong>Pressure Increases:</strong> Intrapulmonary pressure rises above atmospheric pressure.</li>
<li><strong>Air Flow:</strong> Air flows <strong>OUT</strong>.
<ul>
<li><em>Forced Expiration:</em> Uses internal intercostals and abdominal muscles (Active).</li>
</ul>
</li>
</ol>
<h5 id="C-Intrapleural-Pressure-胸膜腔内压">C. Intrapleural Pressure (胸膜腔内压)</h5>
<ul>
<li>Always <strong>negative</strong> (sub-atmospheric) relative to alveolar pressure.</li>
<li>This “suction” keeps the lungs inflated and attached to the chest wall.</li>
<li><strong>Pneumothorax (气胸):</strong> If air enters the pleural space, the negative pressure is lost, and the lung collapses.</li>
</ul>
<h4 id="4-Lung-Volumes-Capacities-肺容积与容量-Spirometry">4. Lung Volumes &amp; Capacities (肺容积与容量 - Spirometry)</h4>
<ul>
<li><strong>Tidal Volume (TV, 潮气量):</strong> Volume of air moved during a normal breath (~500 ml).</li>
<li><strong>Inspiratory Reserve Volume (IRV, 吸气储备量):</strong> Max volume inhaled <em>after</em> a normal inspiration.</li>
<li><strong>Expiratory Reserve Volume (ERV, 呼气储备量):</strong> Max volume exhaled <em>after</em> a normal expiration.</li>
<li><strong>Residual Volume (RV, 残气量):</strong> Volume remaining in lungs after max expiration (prevents collapse). <em>Cannot be measured by simple spirometry.</em></li>
</ul>
<p><strong>Capacities (Combinations):</strong></p>
<ul>
<li><strong>Vital Capacity (VC, 肺活量):</strong> $TV + IRV + ERV$. Total exchangeable air.</li>
<li><strong>Total Lung Capacity (TLC, 肺总量):</strong> $VC + RV$.</li>
<li><strong>Functional Residual Capacity (FRC):</strong> $ERV + RV$. Volume at the end of normal expiration.</li>
</ul>
<p><strong>Diagnostic Ratios (FEV1/FVC):</strong></p>
<ul>
<li><strong>FEV1:</strong> Forced Expiratory Volume in 1 second.</li>
<li><strong>FVC:</strong> Forced Vital Capacity.</li>
<li><strong>Ratio &lt; 0.70:</strong> Indicates <strong>Obstructive Disease</strong> (e.g., COPD, Asthma) – air cannot get out fast enough.</li>
<li><strong>Ratio Normal/High:</strong> Indicates <strong>Restrictive Disease</strong> (e.g., Fibrosis) – lung volume is small, but airways are open.</li>
</ul>
<h4 id="5-Gas-Exchange-Transport-气体交换与运输">5. Gas Exchange &amp; Transport (气体交换与运输)</h4>
<h5 id="A-Diffusion">A. Diffusion</h5>
<p>Driven by <strong>Partial Pressure Gradients ($P_{gas}$)</strong>.</p>
<ul>
<li><strong>Oxygen:</strong> Alveoli ($PO_2$ ~100 mmHg) $\rightarrow$ Blood ($PO_2$ ~40 mmHg).</li>
<li><strong>Carbon Dioxide:</strong> Blood ($PCO_2$ ~46 mmHg) $\rightarrow$ Alveoli ($PCO_2$ ~40 mmHg).</li>
</ul>
<h5 id="B-Oxygen-Transport">B. Oxygen Transport</h5>
<ul>
<li><strong>98.5% bound to Hemoglobin (Hb):</strong> Oxyhemoglobin ($HbO_2$).
<ul>
<li>One Hb molecule binds 4 $O_2$ molecules.</li>
</ul>
</li>
<li><strong>1.5% Dissolved in Plasma:</strong> Only dissolved $O_2$ contributes to partial pressure.</li>
<li><strong>Oxygen-Hb Dissociation Curve:</strong> Sigmoidal shape.
<ul>
<li><em>Right Shift (Release $O_2$ to tissues):</em> Caused by High $CO_2$, High Acid (Low pH), High Temp, High 2,3-DPG (Bohr Effect).</li>
</ul>
</li>
</ul>
<h5 id="C-Carbon-Dioxide-Transport">C. Carbon Dioxide Transport</h5>
<ol>
<li><strong>Bicarbonate Ion ($HCO_3^-$):</strong> ~70% (Major route).
<ul>
<li>Equation: $CO_2 + H_2O \rightleftharpoons H_2CO_3 \rightleftharpoons H^+ + HCO_3^-$.</li>
<li>(Catalysed by Carbonic Anhydrase in RBCs).</li>
</ul>
</li>
<li><strong>Carbaminohemoglobin:</strong> ~23% (Bound to Hb protein, not heme).</li>
<li><strong>Dissolved in Plasma:</strong> ~7%.</li>
</ol>
<h4 id="6-Control-of-Breathing-呼吸调节">6. Control of Breathing (呼吸调节)</h4>
<p><strong>Respiratory Centres:</strong> Located in the <strong>Brainstem</strong> (Medulla Oblongata and Pons).</p>
<h5 id="Chemoreceptors-化学感受器">Chemoreceptors (化学感受器)</h5>
<p>The primary drive for breathing is <strong>$CO_2$</strong> levels (not Oxygen).</p>
<ol>
<li>
<p><strong>Central Chemoreceptors (Medulla):</strong></p>
<ul>
<li>Detect changes in <strong>CSF pH</strong> (indirectly measure blood $PCO_2$).</li>
<li>High arterial $PCO_2$ $\rightarrow$ $CO_2$ crosses blood-brain barrier $\rightarrow$ Lowers pH $\rightarrow$ Stimulates breathing to blow off $CO_2$.</li>
</ul>
</li>
<li>
<p><strong>Peripheral Chemoreceptors (Carotid &amp; Aortic Bodies):</strong></p>
<ul>
<li>Detect changes in arterial <strong>$PO_2$, $PCO_2$, and pH</strong>.</li>
<li>Only stimulated by significant hypoxia ($PO_2$ &lt; 60 mmHg).</li>
</ul>
</li>
</ol>
<h4 id="Summary-Table-Physiology-Parameters">Summary Table (Physiology Parameters)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Parameter</th>
<th style="text-align:left">Normal Value (Approx)</th>
<th style="text-align:left">Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Tidal Volume</strong></td>
<td style="text-align:left">500 mL</td>
<td style="text-align:left">Normal breath</td>
</tr>
<tr>
<td style="text-align:left"><strong>Respiratory Rate</strong></td>
<td style="text-align:left">12-20 bpm</td>
<td style="text-align:left">Breaths per minute</td>
</tr>
<tr>
<td style="text-align:left"><strong>Arterial $PO_2$</strong></td>
<td style="text-align:left">80-100 mmHg</td>
<td style="text-align:left">Partial pressure of O2</td>
</tr>
<tr>
<td style="text-align:left"><strong>Arterial $PCO_2$</strong></td>
<td style="text-align:left">35-45 mmHg</td>
<td style="text-align:left">Primary driver of ventilation</td>
</tr>
<tr>
<td style="text-align:left"><strong>Blood pH</strong></td>
<td style="text-align:left">7.35 - 7.45</td>
<td style="text-align:left">Regulated by lungs (fast) and kidneys (slow)</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE23-01-Core-Concept-20-Pharmacology-of-respiratory-therapeutics">LECTURE23 01 Core Concept 20 Pharmacology of respiratory therapeutics</h3>
<h4 id="1-Physiological-Control-of-Airway-Smooth-Muscle-气道平滑肌的生理调节">1. Physiological Control of Airway Smooth Muscle (气道平滑肌的生理调节)</h4>
<p>Airway tone is determined by the balance between constriction and relaxation pathways.</p>
<h5 id="A-Parasympathetic-Nervous-System-副交感神经-The-Dominant-Constrictor">A. Parasympathetic Nervous System (副交感神经) - <strong>The Dominant Constrictor</strong></h5>
<ul>
<li><strong>Mechanism:</strong> The Vagus nerve releases <strong>Acetylcholine (ACh)</strong>.</li>
<li><strong>Receptor:</strong> ACh binds to <strong>Muscarinic M3 receptors</strong> on airway smooth muscle.</li>
<li><strong>Effect:</strong> Bronchoconstriction (收缩) and increased mucus secretion.</li>
<li><strong>Relevance:</strong> This is the primary reversible component in COPD (high vagal tone).</li>
</ul>
<h5 id="B-Sympathetic-Nervous-System-交感神经-The-Relaxer">B. Sympathetic Nervous System (交感神经) - <strong>The Relaxer</strong></h5>
<ul>
<li><strong>Anatomy:</strong> There is very <em>sparse</em> direct sympathetic innervation to airway smooth muscle in humans.</li>
<li><strong>Mechanism:</strong> Instead, circulating <strong>Adrenaline (Epinephrine)</strong> activates receptors.</li>
<li><strong>Receptor:</strong> <strong>Beta-2 ($\beta_2$) Adrenergic receptors</strong> are abundant on airway smooth muscle (and immune cells like mast cells).</li>
<li><strong>Effect:</strong> Bronchodilation (舒张) and inhibition of mediator release.</li>
</ul>
<h5 id="C-NANC-System-Non-adrenergic-non-cholinergic">C. NANC System (Non-adrenergic, non-cholinergic)</h5>
<ul>
<li><strong>Inhibitory (i-NANC):</strong> Releases Nitric Oxide (NO) and VIP $\rightarrow$ Bronchodilation.</li>
<li><strong>Excitatory (e-NANC):</strong> Releases Substance P and Neurokinin A $\rightarrow$ Bronchoconstriction (Neurogenic inflammation).</li>
</ul>
<h4 id="2-Bronchodilators-支气管扩张剂">2. Bronchodilators (支气管扩张剂)</h4>
<h5 id="A-Beta-2-Adrenoceptor-Agonists-beta-2-受体激动剂">A. Beta-2 Adrenoceptor Agonists ($\beta_2$受体激动剂)</h5>
<p>The most effective bronchodilators.</p>
<p><strong>Mechanism of Action (MOA):</strong></p>
<ol>
<li>Agonist binds to the <strong>$\beta_2$ receptor</strong> (a GPCR coupled to $G_s$).</li>
<li>Activates <strong>Adenylyl Cyclase (AC)</strong>.</li>
<li>Increases intracellular <strong>cAMP</strong> (cyclic AMP).</li>
<li>Activates <strong>Protein Kinase A (PKA)</strong>.</li>
<li><strong>Downstream Effects:</strong>
<ul>
<li>Lowers intracellular Calcium ($Ca^{2+}$).</li>
<li>Inhibits <strong>Myosin Light Chain Kinase (MLCK)</strong>.</li>
<li>Opens Potassium channels ($K^+$) causing hyperpolarization.</li>
<li><strong>Result:</strong> Smooth Muscle Relaxation.</li>
</ul>
</li>
</ol>
<p><strong>Classification:</strong></p>
<ul>
<li><strong>SABA (Short-Acting):</strong> <em>Salbutamol (Albuterol), Terbutaline</em>.
<ul>
<li>Hydrophilic (亲水性).</li>
<li>Rapid onset, short duration (4-6h). Used for <strong>rescue</strong>.</li>
</ul>
</li>
<li><strong>LABA (Long-Acting):</strong> <em>Salmeterol, Formoterol</em>.
<ul>
<li>Lipophilic (亲脂性).</li>
<li><strong>Salmeterol MOA:</strong> Has a long lipophilic tail that anchors into an “exosite” near the receptor, allowing the active head to repeatedly bind and unbind. Slow onset, long duration (12h).</li>
<li><strong>Formoterol MOA:</strong> Dissolves in the lipid membrane and slowly leaches out to the receptor. Rapid onset (like SABA) but long duration.</li>
</ul>
</li>
</ul>
<p><strong>Adverse Effects (Side Effects):</strong></p>
<ul>
<li><strong>Tremor (震颤):</strong> Activation of $\beta_2$ receptors in skeletal muscle.</li>
<li><strong>Tachycardia/Palpitations (心动过速):</strong> Cross-reactivity with $\beta_1$ receptors in the heart (at high doses) or reflex tachycardia from vasodilation.</li>
<li><strong>Hypokalaemia (低血钾):</strong> Drives $K^+$ into cells.</li>
<li><strong>Tolerance (Down-regulation):</strong> Overuse can lead to receptor internalization.</li>
</ul>
<h5 id="B-Muscarinic-Antagonists-Anticholinergics-抗胆碱能药物">B. Muscarinic Antagonists (Anticholinergics - 抗胆碱能药物)</h5>
<p>Primarily used in COPD, increasingly in Asthma.</p>
<p><strong>Mechanism of Action (MOA):</strong></p>
<ul>
<li>Competitively block <strong>M3 receptors</strong> on airway smooth muscle.</li>
<li>Inhibit the constricting effect of Acetylcholine (ACh).</li>
<li>Reduce mucus hypersecretion.</li>
</ul>
<p><strong>Classification:</strong></p>
<ul>
<li><strong>SAMA (Short-Acting):</strong> <em>Ipratropium Bromide</em>.
<ul>
<li>Non-selective blocker (blocks M1, M2, M3). Blocking M2 (autoreceptor) can potentially increase ACh release, limiting efficacy.</li>
<li>Duration ~4-6h.</li>
</ul>
</li>
<li><strong>LAMA (Long-Acting):</strong> <em>Tiotropium</em>.
<ul>
<li><strong>Kinetic Selectivity:</strong> Dissociates very slowly from M3 receptors (long duration &gt;24h) but rapidly from M2 receptors. This makes it superior to Ipratropium.</li>
</ul>
</li>
<li><strong>Clinical Note:</strong> More effective in <strong>COPD</strong> (where vagal tone is a major factor) than in Asthma (where inflammation is key).</li>
</ul>
<h5 id="C-Methylxanthines-甲基黄嘌呤类">C. Methylxanthines (甲基黄嘌呤类)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Theophylline, Aminophylline (IV form)</em>.</li>
<li><strong>Mechanism of Action (Complex &amp; Multiple):</strong>
<ol>
<li><strong>PDE Inhibition:</strong> Inhibits Phosphodiesterase (PDE3/4) $\rightarrow$ Prevents breakdown of cAMP $\rightarrow$ Sustains bronchodilation.</li>
<li><strong>Adenosine Antagonism:</strong> Blocks Adenosine receptors (which usually cause bronchoconstriction).</li>
<li><strong>HDAC Activation:</strong> Increases Histone Deacetylase activity $\rightarrow$ Reverses steroid resistance (Anti-inflammatory effect).</li>
</ol>
</li>
<li><strong>Limitations:</strong> <strong>Narrow Therapeutic Index</strong> (requires blood monitoring). Side effects include arrhythmias, seizures, nausea. Metabolised by CYP450 (lots of interactions).</li>
</ul>
<h4 id="3-Anti-Inflammatory-Agents-抗炎药物">3. Anti-Inflammatory Agents (抗炎药物)</h4>
<h5 id="A-Corticosteroids-皮质类固醇-The-Cornerstone-of-Asthma-Tx">A. Corticosteroids (皮质类固醇) - The Cornerstone of Asthma Tx</h5>
<p><strong>Mechanism of Action (Genomic):</strong><br>
Steroids are lipophilic and enter the cell cytoplasm to bind the <strong>Glucocorticoid Receptor (GR)</strong>. The complex moves to the nucleus.</p>
<ol>
<li><strong>Transactivation (Switching Genes ON):</strong>
<ul>
<li>Increases production of <strong>Lipocortin (Annexin A1)</strong>.</li>
<li>Lipocortin inhibits <strong>Phospholipase A2 (PLA2)</strong>, stopping the Arachidonic Acid cascade (blocking Prostaglandins and Leukotrienes at the source).</li>
<li>Upregulates $\beta_2$ receptor expression (counteracts tolerance).</li>
</ul>
</li>
<li><strong>Transrepression (Switching Genes OFF):</strong>
<ul>
<li>Inhibits transcription factors like <strong>NF-$\kappa$B</strong>.</li>
<li>Reduces production of pro-inflammatory cytokines (IL-4, IL-5, TNF-$\alpha$, GM-CSF).</li>
<li>Reduces recruitment of Eosinophils and T-cells.</li>
</ul>
</li>
</ol>
<p><strong>Side Effects:</strong></p>
<ul>
<li><strong>Local (Inhaled):</strong> Oral Candidiasis (Thrush - 鹅口疮), Dysphonia (hoarseness). <em>Counselling: Rinse mouth after use.</em></li>
<li><strong>Systemic (Oral/High Dose):</strong> Adrenal suppression, Osteoporosis, Diabetes, Hypertension, Growth suppression in children.</li>
</ul>
<h5 id="B-Leukotriene-Receptor-Antagonists-LTRAs">B. Leukotriene Receptor Antagonists (LTRAs)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Montelukast, Zafirlukast</em>.</li>
<li><strong>Pathophysiology:</strong> Leukotrienes (CysLTs) are potent constrictors produced by mast cells/eosinophils. They are 1000x more potent than histamine.</li>
<li><strong>Mechanism:</strong> Competitively block the <strong>CysLT1 receptor</strong>.</li>
<li><strong>Clinical Use:</strong> Oral tablets. Particularly effective for <strong>Aspirin-sensitive asthma</strong> and <strong>Exercise-induced asthma</strong>. Add-on therapy.</li>
</ul>
<h5 id="C-Mast-Cell-Stabilisers-Chromones">C. Mast Cell Stabilisers (Chromones)</h5>
<ul>
<li><strong>Drugs:</strong> <em>Sodium Cromoglicate, Nedocromil</em>.</li>
<li><strong>Mechanism:</strong> Stabilise mast cell membranes by blocking chloride channels, preventing degranulation (release of histamine).</li>
<li><strong>Use:</strong> Weak effect. Mainly used in children or mild allergic asthma. Prophylactic only.</li>
</ul>
<h5 id="D-Biologics-Monoclonal-Antibodies-单克隆抗体">D. Biologics (Monoclonal Antibodies - 单克隆抗体)</h5>
<p>For severe, refractory eosinophilic asthma.</p>
<ul>
<li><strong>Omalizumab (Xolair):</strong> Anti-<strong>IgE</strong>. Binds to free IgE, preventing it from binding to mast cells. Prevents degranulation.</li>
<li><strong>Mepolizumab / Reslizumab:</strong> Anti-<strong>IL-5</strong>. IL-5 is the major cytokine for Eosinophil survival and activation. Reduces eosinophil counts.</li>
</ul>
<h4 id="4-Summary-Table-of-Receptors">4. Summary Table of Receptors</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Drug Class</th>
<th style="text-align:left">Target Receptor</th>
<th style="text-align:left">Action</th>
<th style="text-align:left">Result</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>SABA/LABA</strong></td>
<td style="text-align:left">$\beta_2$-Adrenergic</td>
<td style="text-align:left">Agonist</td>
<td style="text-align:left">$\uparrow$ cAMP $\rightarrow$ Relaxation</td>
</tr>
<tr>
<td style="text-align:left"><strong>SAMA/LAMA</strong></td>
<td style="text-align:left">Muscarinic M3</td>
<td style="text-align:left">Antagonist</td>
<td style="text-align:left">Blocks ACh $\rightarrow$ Prevents Constriction</td>
</tr>
<tr>
<td style="text-align:left"><strong>Steroids</strong></td>
<td style="text-align:left">Glucocorticoid (Nuclear)</td>
<td style="text-align:left">Agonist</td>
<td style="text-align:left">Gene transcription modulation $\rightarrow$ Anti-inflammatory</td>
</tr>
<tr>
<td style="text-align:left"><strong>LTRAs</strong></td>
<td style="text-align:left">CysLT1</td>
<td style="text-align:left">Antagonist</td>
<td style="text-align:left">Blocks Leukotrienes $\rightarrow$ Prevents Constriction/Inflammation</td>
</tr>
<tr>
<td style="text-align:left"><strong>Omalizumab</strong></td>
<td style="text-align:left">Circulating IgE</td>
<td style="text-align:left">Binder</td>
<td style="text-align:left">Prevents Mast Cell Activation</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE42-01-Core-Concept-Lecture-Asthma-therapeutics">LECTURE42 01 Core Concept Lecture - Asthma therapeutics</h3>
<h4 id="1-Definition-Pathophysiology-定义与病理生理">1. Definition &amp; Pathophysiology (定义与病理生理)</h4>
<h5 id="Definition">Definition</h5>
<ul>
<li>A chronic inflammatory disorder of the airways (气道慢性炎症).</li>
<li>Characterized by <strong>Reversible</strong> airflow obstruction (可逆性气流阻塞).</li>
<li><strong>Key Symptoms:</strong>
<ul>
<li>Wheeze (喘息 - 呼气时的高音调哨声).</li>
<li>Breathlessness (呼吸困难).</li>
<li>Chest tightness (胸闷).</li>
<li>Cough (咳嗽 - 尤以夜间或清晨为甚).</li>
</ul>
</li>
</ul>
<h5 id="Pathophysiology">Pathophysiology</h5>
<ol>
<li><strong>Bronchoconstriction (支气管收缩):</strong> Smooth muscle contraction leading to narrowing of airways.</li>
<li><strong>Inflammation (炎症):</strong> Oedema (水肿) and mucus hypersecretion (粘液分泌过多).</li>
<li><strong>Airway Remodelling (气道重塑):</strong> Without proper treatment, chronic inflammation leads to permanent structural changes (fibrosis), resulting in irreversible obstruction.</li>
</ol>
<h5 id="Phases-of-Asthma-Attack">Phases of Asthma Attack</h5>
<ul>
<li><strong>Early Phase (Immediate):</strong> Triggered by allergens (IgE mediated). Mast cells degranulate $\rightarrow$ Histamine/Leukotrienes release $\rightarrow$ Bronchospasm.</li>
<li><strong>Late Phase (Hours later):</strong> Influx of inflammatory cells (Eosinophils, Th2 lymphocytes). Causes edema and mucus plugging. <strong>Corticosteroids target this phase.</strong></li>
</ul>
<h4 id="2-Diagnosis-诊断">2. Diagnosis (诊断)</h4>
<p>There is a significant divergence between NICE and BTS/SIGN guidelines regarding diagnosis.</p>
<h5 id="NICE-Guidelines-Algorithm-based">NICE Guidelines (Algorithm-based)</h5>
<p>Focuses on objective testing first.</p>
<ol>
<li><strong>FeNO (Fractional exhaled Nitric Oxide):</strong> Measures eosinophilic inflammation.
<ul>
<li>Positive if $\ge$ 40 ppb (adults).</li>
</ul>
</li>
<li><strong>Spirometry (肺量计):</strong>
<ul>
<li>Obstructive picture: <strong>FEV1/FVC ratio &lt; 70%</strong>.</li>
</ul>
</li>
<li><strong>Bronchodilator Reversibility (BDR):</strong>
<ul>
<li>Improvement in FEV1 of $\ge$ 12% AND $\ge$ 200ml after SABA.</li>
</ul>
</li>
</ol>
<h5 id="BTS-SIGN-Guidelines-Clinical-based">BTS/SIGN Guidelines (Clinical-based)</h5>
<p>Focuses on clinical probability.</p>
<ul>
<li><strong>High Probability:</strong> Typical symptoms + history $\rightarrow$ <strong>Trial of treatment</strong> (Give inhaled corticosteroids for 6 weeks and review).</li>
<li><strong>Intermediate Probability:</strong> Perform Spirometry/BDR.</li>
<li><strong>Low Probability:</strong> Investigate other causes.</li>
</ul>
<h4 id="3-Pharmacology-Drug-Classes-药物类别">3. Pharmacology: Drug Classes (药物类别)</h4>
<h5 id="A-Bronchodilators-支气管扩张剂-“Relievers”">A. Bronchodilators (支气管扩张剂) - “Relievers”</h5>
<h6 id="1-Beta-2-Agonists-beta-2-激动剂">1. Beta-2 Agonists ($\beta_2$激动剂)</h6>
<ul>
<li><strong>Mechanism (MOA):</strong> Stimulate $\beta_2$ receptors in lung smooth muscle $\rightarrow$ Increase cAMP $\rightarrow$ Relaxation (Bronchodilation).</li>
<li><strong>SABA (Short-Acting):</strong> <em>Salbutamol, Terbutaline</em>.
<ul>
<li>Onset: Rapid (&lt;5 min). Duration: 4-6 hours.</li>
<li>Use: “As needed” (PRN) for symptom relief.</li>
</ul>
</li>
<li><strong>LABA (Long-Acting):</strong> <em>Salmeterol, Formoterol</em>.
<ul>
<li>Duration: ~12 hours.</li>
<li><strong>CRITICAL SAFETY NOTE:</strong> LABAs must <strong>NEVER</strong> be used as monotherapy in asthma. Always combine with ICS to prevent masking inflammation while risk of death increases.</li>
<li><em>Formoterol</em> is unique: Rapid onset (can be used for relief in MART therapy) + Long duration.</li>
</ul>
</li>
</ul>
<h6 id="2-Antimuscarinics-抗胆碱能药物">2. Antimuscarinics (抗胆碱能药物)</h6>
<ul>
<li><strong>Mechanism:</strong> Block M3 muscarinic receptors $\rightarrow$ Inhibit Acetylcholine-induced constriction.</li>
<li><strong>LAMA (Long-Acting):</strong> <em>Tiotropium</em>.
<ul>
<li>Use: Add-on therapy in severe asthma (Step 4/5).</li>
</ul>
</li>
<li><strong>SAMA (Short-Acting):</strong> <em>Ipratropium</em>.
<ul>
<li>Use: Mainly in Acute Asthma (Nebulised).</li>
</ul>
</li>
</ul>
<h6 id="3-Methylxanthines">3. Methylxanthines</h6>
<ul>
<li><strong>Drug:</strong> <em>Theophylline / Aminophylline</em>.</li>
<li><strong>Use:</strong> Oral add-on (rarely used now due to narrow therapeutic index and interactions).</li>
</ul>
<h5 id="B-Anti-inflammatories-抗炎药-“Preventers”">B. Anti-inflammatories (抗炎药) - “Preventers”</h5>
<h6 id="1-Corticosteroids-皮质类固醇">1. Corticosteroids (皮质类固醇)</h6>
<ul>
<li><strong>Mechanism:</strong>
<ul>
<li>Enter cell nucleus $\rightarrow$ Bind to Glucocorticoid Response Elements (GRE).</li>
<li><strong>Upregulate</strong> anti-inflammatory proteins (Lipocortin).</li>
<li><strong>Downregulate</strong> pro-inflammatory cytokines (IL-4, IL-5).</li>
<li>Reduce airway responsiveness.</li>
</ul>
</li>
<li><strong>ICS (Inhaled):</strong> <em>Beclometasone, Budesonide, Fluticasone</em>.
<ul>
<li>The cornerstone of asthma maintenance.</li>
<li><strong>Side Effects:</strong> Oral candidiasis (thrush - advise rinsing mouth), hoarse voice.</li>
</ul>
</li>
<li><strong>OCS (Oral):</strong> <em>Prednisolone</em>.
<ul>
<li>Use: Acute attacks (Rescue) or Maintenance in Step 5 (Severe).</li>
</ul>
</li>
</ul>
<h6 id="2-Leukotriene-Receptor-Antagonists-LTRA">2. Leukotriene Receptor Antagonists (LTRA)</h6>
<ul>
<li><strong>Drug:</strong> <em>Montelukast</em>.</li>
<li><strong>Mechanism:</strong> Blocks Cysteinyl-Leukotriene receptors (CysLT1) $\rightarrow$ Reduces inflammation and bronchoconstriction.</li>
<li><strong>Use:</strong> Oral tablet, useful for exercise-induced asthma or allergic rhinitis comorbidity.</li>
</ul>
<h6 id="3-Biologics-Monoclonal-Antibodies">3. Biologics (Monoclonal Antibodies)</h6>
<ul>
<li><em>Omalizumab</em> (Anti-IgE).</li>
<li><em>Mepolizumab</em> (Anti-IL5).</li>
<li>Use: Severe, specialist-managed eosinophilic asthma.</li>
</ul>
<h4 id="4-Chronic-Management-The-Stepwise-Approach-阶梯治疗">4. Chronic Management: The Stepwise Approach (阶梯治疗)</h4>
<p>Based on BTS/SIGN (Adults). The goal is complete control: no daytime symptoms, no night wakening, no limitations.</p>
<ul>
<li>
<p><strong>Step 1: Mild Intermittent Asthma</strong></p>
<ul>
<li><strong>SABA</strong> (Salbutamol) as needed.</li>
<li><em>Note:</em> Recent global guidelines (GINA) suggest low dose ICS-formoterol prn even at Step 1 to reduce exacerbation risk, but standard UK practice often starts with SABA.</li>
</ul>
</li>
<li>
<p><strong>Step 2: Regular Preventer</strong></p>
<ul>
<li>Indication: Using SABA &gt; 3 times/week, or night symptoms &gt; 1/week.</li>
<li>Add <strong>Low Dose ICS</strong> (e.g., Beclometasone 200-400mcg/day).</li>
</ul>
</li>
<li>
<p><strong>Step 3: Initial Add-on</strong></p>
<ul>
<li>Add <strong>LABA</strong> (Standard: Fixed-dose combination inhaler, e.g., Seretide or Fostair).</li>
<li><em>If LABA helps but control is inadequate:</em> Continue LABA and increase ICS to medium dose.</li>
<li><em>If LABA doesn’t help:</em> Stop LABA and try <strong>LTRA</strong> (Montelukast).</li>
</ul>
</li>
<li>
<p><strong>Step 4: Persistent Poor Control</strong></p>
<ul>
<li><strong>Medium Dose ICS + LABA</strong>.</li>
<li>Consider adding: <strong>LTRA</strong>, or <strong>LAMA</strong> (Tiotropium), or Theophylline.</li>
<li><strong>MART Therapy (Maintenance and Reliever Therapy):</strong> Using a combination inhaler containing <em>ICS + Formoterol</em> for both maintenance (twice daily) AND relief (instead of Salbutamol). This is very effective as it increases steroid load automatically when symptoms worsen.</li>
</ul>
</li>
<li>
<p><strong>Step 5: Severe Asthma</strong></p>
<ul>
<li>Refer to specialist.</li>
<li>High dose ICS.</li>
<li>Oral Steroids (Prednisolone).</li>
<li>Biologics (Omalizumab).</li>
</ul>
</li>
</ul>
<h4 id="5-Acute-Asthma-Management-急性哮喘管理">5. Acute Asthma Management (急性哮喘管理)</h4>
<h5 id="Assessment-of-Severity">Assessment of Severity</h5>
<ul>
<li><strong>Moderate:</strong> PEF 50-75% best/predicted. Able to speak.</li>
<li><strong>Severe:</strong> PEF 33-50%. Can’t complete sentences. Pulse &gt;110. RR &gt;25.</li>
<li><strong>Life-Threatening:</strong> PEF &lt;33%. Silent chest (no wheeze audible due to no air movement). Cyanosis. Hypotension. Confusion. <strong>“33-92-CHEST”</strong> (PEF&lt;33, Sat&lt;92, Cyanosis/Hypotension/Exhaustion/Silent Chest/Tachycardia).</li>
</ul>
<h5 id="Immediate-Treatment-“O-SHIT”-Mnemonic">Immediate Treatment (“O SHIT” Mnemonic)</h5>
<ol>
<li><strong>O</strong>xygen: High flow (maintain saturation 94-98%).</li>
<li><strong>S</strong>albutamol: Nebulised (5mg). Repeat back-to-back.</li>
<li><strong>H</strong>ydrocortisone: IV (or Prednisolone Oral 40-50mg). <strong>Steroids are crucial to stop the late-phase reaction.</strong></li>
<li><strong>I</strong>pratropium: Nebulised (0.5mg). Added to Salbutamol for severe cases.</li>
<li><strong>T</strong>heophylline / Magnesium Sulfate: IV (Senior decision).</li>
</ol>
<h4 id="6-Inhaler-Technique-Adherence-吸入技术与依从性">6. Inhaler Technique &amp; Adherence (吸入技术与依从性)</h4>
<p>Poor technique is a major cause of treatment failure.</p>
<ul>
<li><strong>pMDI (Pressurized Metered Dose Inhaler):</strong>
<ul>
<li>Requires coordination (“Press and breathe”).</li>
<li>Use with a <strong>Spacer (储雾罐)</strong>: Increases lung deposition, reduces oropharyngeal deposition (less thrush).</li>
</ul>
</li>
<li><strong>DPI (Dry Powder Inhaler):</strong>
<ul>
<li>Requires strong inspiratory flow (Breath actuated).</li>
<li>Examples: Accuhaler, Turbohaler.</li>
</ul>
</li>
<li><strong>Pharmacist Role:</strong> Check technique at every opportunity (Medicine Use Review / NMS).</li>
</ul>
<h3 id="LECTURE31-01-Core-Concept-27-COPD-treatment-and-management">LECTURE31 01 Core Concept 27 COPD treatment and management</h3>
<p><strong>Lecturer:</strong> [Refer to Transcript]</p>
<h4 id="1-Definition-Pathophysiology-定义与病理生理-2">1. Definition &amp; Pathophysiology (定义与病理生理)</h4>
<ul>
<li><strong>Definition:</strong> A common, preventable, and treatable disease characterised by <strong>persistent respiratory symptoms</strong> and <strong>airflow limitation</strong> due to airway and/or alveolar abnormalities (usually caused by exposure to noxious particles/gases).</li>
<li><strong>Key Components:</strong>
<ul>
<li><strong>Chronic Bronchitis (慢性支气管炎):</strong> Inflammation and mucus hypersecretion (“Blue Bloaters”).</li>
<li><strong>Emphysema (肺气肿):</strong> Destruction of alveolar walls, loss of elastic recoil (“Pink Puffers”).</li>
</ul>
</li>
<li><strong>Reversibility:</strong> Unlike Asthma, airflow limitation in COPD is <strong>not fully reversible</strong> (不可完全逆转).</li>
</ul>
<h4 id="2-Diagnosis-Assessment-诊断与评估">2. Diagnosis &amp; Assessment (诊断与评估)</h4>
<h5 id="A-Diagnosis-Criteria">A. Diagnosis Criteria</h5>
<ul>
<li><strong>Spirometry (肺活量测定):</strong> Essential for diagnosis.</li>
<li><strong>Key Metric:</strong> Post-bronchodilator <strong>FEV1/FVC &lt; 0.70</strong> confirms persistent airflow limitation.</li>
</ul>
<h5 id="B-Assessment-Tools">B. Assessment Tools</h5>
<p>The goal is to determine the severity of airflow limitation, symptoms, and risk of exacerbations.</p>
<p><strong>1. Severity of Airflow Limitation (GOLD 1-4 Grades):</strong><br>
Based on post-bronchodilator FEV1 (in patients with FEV1/FVC &lt; 0.70):</p>
<ul>
<li><strong>GOLD 1 (Mild):</strong> FEV1 $\ge$ 80% predicted.</li>
<li><strong>GOLD 2 (Moderate):</strong> 50% $\le$ FEV1 &lt; 80%.</li>
<li><strong>GOLD 3 (Severe):</strong> 30% $\le$ FEV1 &lt; 50%.</li>
<li><strong>GOLD 4 (Very Severe):</strong> FEV1 &lt; 30%.</li>
</ul>
<p><strong>2. Symptom Assessment:</strong></p>
<ul>
<li><strong>mMRC (Modified Medical Research Council Dyspnoea Scale):</strong> Assess breathlessness (0–4 scale).</li>
<li><strong>CAT (COPD Assessment Test):</strong> Comprehensive symptom assessment (Score 0–40).</li>
</ul>
<p><strong>3. The “ABE” Assessment Tool (GOLD 2023 Update):</strong><br>
Used to guide <strong>initial</strong> pharmacological treatment.</p>
<ul>
<li><strong>Group A (Low Symptom, Low Risk):</strong> 0–1 exacerbations (no hospital), mMRC 0–1, CAT &lt;10.</li>
<li><strong>Group B (High Symptom, Low Risk):</strong> 0–1 exacerbations (no hospital), mMRC $\ge$2, CAT $\ge$10.</li>
<li><strong>Group E (Exacerbation Prone - “Any Symptom”):</strong> $\ge$2 moderate exacerbations <strong>OR</strong> $\ge$1 leading to hospitalisation (irrespective of symptoms). <em>Replaces old groups C &amp; D.</em></li>
</ul>
<h4 id="3-Pharmacological-Management-药物治疗">3. Pharmacological Management (药物治疗)</h4>
<h5 id="Drug-Classes-药物类别">Drug Classes (药物类别)</h5>
<table>
<thead>
<tr>
<th style="text-align:left">Class</th>
<th style="text-align:left">Acronym</th>
<th style="text-align:left">Examples</th>
<th style="text-align:left">MOA / Clinical Use</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Short-Acting Beta Agonist</strong></td>
<td style="text-align:left"><strong>SABA</strong></td>
<td style="text-align:left">Salbutamol, Terbutaline</td>
<td style="text-align:left">Rescue relief (as needed).</td>
</tr>
<tr>
<td style="text-align:left"><strong>Short-Acting Muscarinic Antagonist</strong></td>
<td style="text-align:left"><strong>SAMA</strong></td>
<td style="text-align:left">Ipratropium</td>
<td style="text-align:left">Rescue relief.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Long-Acting Beta Agonist</strong></td>
<td style="text-align:left"><strong>LABA</strong></td>
<td style="text-align:left">Salmeterol, Formoterol, Indacaterol</td>
<td style="text-align:left">Maintenance bronchodilation.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Long-Acting Muscarinic Antagonist</strong></td>
<td style="text-align:left"><strong>LAMA</strong></td>
<td style="text-align:left">Tiotropium, Umeclidinium, Aclidinium</td>
<td style="text-align:left">Maintenance. often superior to LABA in preventing exacerbations.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Inhaled Corticosteroids</strong></td>
<td style="text-align:left"><strong>ICS</strong></td>
<td style="text-align:left">Fluticasone, Budesonide</td>
<td style="text-align:left">Anti-inflammatory. <strong>Never used as monotherapy</strong> in COPD.</td>
</tr>
</tbody>
</table>
<h5 id="Initial-Treatment-Algorithm-GOLD-2023">Initial Treatment Algorithm (GOLD 2023)</h5>
<ul>
<li><strong>Group A:</strong> A Bronchodilator (short or long-acting).</li>
<li><strong>Group B:</strong> <strong>LABA + LAMA</strong> (Dual bronchodilation is now preferred over monotherapy for symptomatic patients).</li>
<li><strong>Group E:</strong> <strong>LABA + LAMA</strong> (Standard) <strong>OR</strong> LABA + LAMA + ICS (if blood eosinophils $\ge$ 300 cells/$\mu$L).</li>
</ul>
<h5 id="Role-of-ICS-吸入性皮质类固醇的作用">Role of ICS (吸入性皮质类固醇的作用)</h5>
<ul>
<li><strong>Indication:</strong> Consider if history of hospitalisation for exacerbations, $\ge$2 moderate exacerbations/year, or <strong>Blood Eosinophils $\ge$ 300 cells/$\mu$L</strong>.</li>
<li><strong>Contraindication:</strong> Avoid if repeated pneumonia events, blood eosinophils &lt; 100 cells/$\mu$L, or history of mycobacterial infection.</li>
<li><strong>Risk:</strong> Increased risk of pneumonia (肺炎).</li>
</ul>
<h4 id="4-Management-Cycle-Follow-up-管理循环与随访">4. Management Cycle &amp; Follow-up (管理循环与随访)</h4>
<p><strong>The Management Cycle:</strong> Review $\rightarrow$ Assess $\rightarrow$ Adjust.</p>
<h5 id="Follow-up-Pathways">Follow-up Pathways</h5>
<p>If the patient is still symptomatic or exacerbating despite initial treatment:</p>
<ol>
<li>
<p><strong>Dyspnoea Pathway (呼吸困难为主):</strong></p>
<ul>
<li>If on Monotherapy (LABA or LAMA) $\rightarrow$ Escalate to <strong>LABA + LAMA</strong>.</li>
<li>If on LABA + LAMA $\rightarrow$ Switch inhaler device or molecule; investigate other causes (e.g., heart failure).</li>
</ul>
</li>
<li>
<p><strong>Exacerbation Pathway (急性加重为主):</strong></p>
<ul>
<li>If on Monotherapy $\rightarrow$ Escalate to <strong>LABA + LAMA</strong>.</li>
<li>If on LABA + LAMA and <strong>Eos $\ge$ 300</strong> $\rightarrow$ Escalate to <strong>LABA + LAMA + ICS</strong> (Triple Therapy).</li>
<li>If on LABA + LAMA and <strong>Eos &lt; 100</strong> $\rightarrow$ Consider Azithromycin (in former smokers) or Roflumilast (if chronic bronchitis).</li>
</ul>
</li>
</ol>
<h4 id="5-Acute-Exacerbations-of-COPD-AECOPD-急性加重">5. Acute Exacerbations of COPD (AECOPD - 急性加重)</h4>
<ul>
<li><strong>Definition:</strong> Acute worsening of respiratory symptoms that results in additional therapy.</li>
<li><strong>Triggers:</strong> Viral infections (Rhinovirus, Influenza), bacterial infections, pollution.</li>
<li><strong>Management:</strong>
<ol>
<li><strong>Bronchodilators:</strong> Increase frequency of SABA (with or without SAMA).</li>
<li><strong>Systemic Corticosteroids:</strong> Prednisolone 40mg for 5 days (shortens recovery time, improves oxygenation).</li>
<li><strong>Antibiotics:</strong> Indicated <strong>ONLY</strong> if the patient has the <strong>3 Cardinal Symptoms (Anthonisen Criteria)</strong>:
<ul>
<li>Increased dyspnoea (呼吸困难加重)</li>
<li>Increased sputum volume (痰量增加)</li>
<li>Increased sputum purulence (脓痰 - <strong>Key indication</strong>)</li>
<li><em>Or if requiring mechanical ventilation.</em></li>
<li><em>Common choice:</em> Amoxicillin, Doxycycline, or Clarithromycin (5-7 days).</li>
</ul>
</li>
</ol>
</li>
</ul>
<h4 id="6-Non-Pharmacological-Management-非药物治疗">6. Non-Pharmacological Management (非药物治疗)</h4>
<ul>
<li><strong>Smoking Cessation (戒烟):</strong> The <strong>single most effective</strong> intervention to slow the decline in lung function and stop progression.</li>
<li><strong>Vaccinations:</strong> Influenza (Annual), Pneumococcal (PCV20/PPSV23), COVID-19, Tdap/Zoster (GOLD 2023/24 updates).</li>
<li><strong>Pulmonary Rehabilitation (肺康复):</strong> Highly effective for reducing dyspnoea and improving quality of life (Groups B &amp; E).</li>
<li><strong>Inhaler Technique:</strong> Critical check at every visit. Poor technique leads to therapeutic failure.</li>
</ul>
<h4 id="Summary-Table-Review-Checklist">Summary Table (Review Checklist)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">COPD</th>
<th style="text-align:left">Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Onset</strong></td>
<td style="text-align:left">Usually &gt;40 years</td>
<td style="text-align:left">Often childhood</td>
</tr>
<tr>
<td style="text-align:left"><strong>Smoking History</strong></td>
<td style="text-align:left">Common (&gt;10 pack-years)</td>
<td style="text-align:left">Variable</td>
</tr>
<tr>
<td style="text-align:left"><strong>Symptoms</strong></td>
<td style="text-align:left">Persistent, progressive</td>
<td style="text-align:left">Variable, intermittent</td>
</tr>
<tr>
<td style="text-align:left"><strong>Reversibility</strong></td>
<td style="text-align:left"><strong>Never fully reversible</strong></td>
<td style="text-align:left">Usually reversible</td>
</tr>
<tr>
<td style="text-align:left"><strong>First Line Tx</strong></td>
<td style="text-align:left"><strong>Bronchodilators (LAMA/LABA)</strong></td>
<td style="text-align:left"><strong>Anti-inflammatory (ICS)</strong></td>
</tr>
<tr>
<td style="text-align:left"><strong>ICS Monotherapy</strong></td>
<td style="text-align:left"><strong>Contraindicated</strong></td>
<td style="text-align:left">Common/Standard</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE32-01-Core-Concept-28-Respiratory-infections">LECTURE32 01 Core Concept 28 Respiratory infections</h3>
<h4 id="1-Core-Concepts-Pathophysiology-核心概念与病理">1. Core Concepts &amp; Pathophysiology (核心概念与病理)</h4>
<ul>
<li><strong>Definition:</strong> Infection of the lower respiratory tract causing inflammation of the alveolar sacs, which fill with fluid or pus (consolidation).</li>
<li><strong>Key Pathogen:</strong> <strong>Streptococcus pneumoniae (肺炎链球菌)</strong> is the most common cause.
<ul>
<li><em>Characteristics:</em> Gram-positive, alpha-haemolytic, diplococci (pairs).</li>
<li><em>Polysaccharide Capsule:</em> A key virulence factor that protects it from phagocytosis.</li>
</ul>
</li>
<li><strong>Other Pathogens:</strong>
<ul>
<li><em>Haemophilus influenzae</em> (common in COPD).</li>
<li><strong>Atypical Bacteria (非典型菌):</strong> <em>Mycoplasma pneumoniae</em>, <em>Legionella pneumophila</em> (Require macrolides as they lack a cell wall or are intracellular).</li>
<li><em>Viruses:</em> Influenza, Rhinovirus, COVID-19.</li>
</ul>
</li>
</ul>
<h4 id="2-Clinical-Presentation-临床表现">2. Clinical Presentation (临床表现)</h4>
<h5 id="Symptoms-症状">Symptoms (症状)</h5>
<ul>
<li><strong>Cough:</strong> Usually productive (purulent/green/yellow sputum).</li>
<li><strong>Pleuritic Chest Pain (胸膜炎性胸痛):</strong> Sharp pain worsened by breathing.</li>
<li><strong>Fever &amp; Rigors:</strong> Shivering/chills.</li>
<li><strong>Dyspnoea (呼吸困难).</strong></li>
</ul>
<h5 id="Signs-体征">Signs (体征)</h5>
<ul>
<li><strong>Tachypnoea (呼吸急促):</strong> Respiratory rate &gt; 20 bpm.</li>
<li><strong>Tachycardia (心动过速).</strong></li>
<li><strong>Dullness to Percussion (叩诊浊音):</strong> Indicates fluid/consolidation in lungs.</li>
<li><strong>Bronchial Breathing:</strong> Harsh breath sounds.</li>
</ul>
<h5 id="Diagnosis-诊断">Diagnosis (诊断)</h5>
<ul>
<li><strong>Chest X-ray (CXR):</strong> Gold standard. Shows <strong>Lobar Consolidation (大叶性实变)</strong>.</li>
<li><strong>Microbiology:</strong> Sputum culture, Blood culture.</li>
<li><strong>Urinary Antigen Test:</strong> Specific for <em>S. pneumoniae</em> and <em>Legionella</em>.</li>
<li><strong>Blood Tests:</strong> Elevated CRP (&gt;100 mg/L usually bacterial) and Neutrophilia.</li>
</ul>
<h4 id="3-Risk-Stratification-CURB-65-Score-风险分层">3. Risk Stratification: CURB-65 Score (风险分层)</h4>
<p>This is the standard tool used in the UK to determine severity and place of care.</p>
<table>
<thead>
<tr>
<th style="text-align:left">Acronym</th>
<th style="text-align:left">Criteria</th>
<th style="text-align:left">Point</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>C</strong></td>
<td style="text-align:left"><strong>Confusion</strong> (Abbreviated Mental Test score $\le$ 8/10)</td>
<td style="text-align:left">1</td>
</tr>
<tr>
<td style="text-align:left"><strong>U</strong></td>
<td style="text-align:left"><strong>Urea</strong> &gt; 7 mmol/L (Renal impairment/Dehydration)</td>
<td style="text-align:left">1</td>
</tr>
<tr>
<td style="text-align:left"><strong>R</strong></td>
<td style="text-align:left"><strong>Respiratory Rate</strong> $\ge$ 30 /min</td>
<td style="text-align:left">1</td>
</tr>
<tr>
<td style="text-align:left"><strong>B</strong></td>
<td style="text-align:left"><strong>Blood Pressure</strong> (SBP &lt; 90 or DBP $\le$ 60 mmHg)</td>
<td style="text-align:left">1</td>
</tr>
<tr>
<td style="text-align:left"><strong>65</strong></td>
<td style="text-align:left"><strong>Age</strong> $\ge$ 65 years</td>
<td style="text-align:left">1</td>
</tr>
</tbody>
</table>
<h5 id="Management-based-on-Score">Management based on Score</h5>
<ul>
<li><strong>Score 0-1 (Low Risk):</strong> Treat at <strong>Home</strong> (Oral antibiotics). mortality &lt;3%.</li>
<li><strong>Score 2 (Moderate Risk):</strong> Consider <strong>Hospital</strong> admission (Short stay). mortality ~9%.</li>
<li><strong>Score 3-5 (High Risk):</strong> Urgent <strong>Hospital</strong> admission (Consider ICU). mortality 15-40%.</li>
</ul>
<h4 id="4-Pharmacological-Management-药物治疗">4. Pharmacological Management (药物治疗)</h4>
<p><strong>Principle:</strong> Start antibiotics within <strong>4 hours</strong> of diagnosis. Duration is typically <strong>5 days</strong> for mild/moderate cases.</p>
<h5 id="A-Low-Severity-CURB-65-0-or-1">A. Low Severity (CURB-65 = 0 or 1)</h5>
<ul>
<li><strong>First Line:</strong> <strong>Amoxicillin</strong> 500mg TDS PO (Oral).
<ul>
<li><em>MOA:</em> Penicillin, inhibits bacterial cell wall synthesis.</li>
</ul>
</li>
<li><strong>Penicillin Allergy:</strong>
<ul>
<li><strong>Doxycycline</strong> 200mg loading dose then 100mg OD.</li>
<li><em>OR</em> <strong>Clarithromycin</strong> 500mg BD.</li>
</ul>
</li>
</ul>
<h5 id="B-Moderate-Severity-CURB-65-2">B. Moderate Severity (CURB-65 = 2)</h5>
<ul>
<li><strong>Treatment:</strong> <strong>Amoxicillin</strong> (Oral) + <strong>Clarithromycin</strong> (Oral).
<ul>
<li><em>Or Doxycycline alone if allergic.</em></li>
<li><em>Rationale:</em> The Macrolide (Clarithromycin) is added to cover <strong>Atypical organisms</strong> (like <em>Legionella/Mycoplasma</em>) which Penicillins cannot kill.</li>
</ul>
</li>
</ul>
<h5 id="C-High-Severity-CURB-65-3-5">C. High Severity (CURB-65 = 3-5)</h5>
<ul>
<li><strong>Treatment:</strong> <strong>Co-amoxiclav</strong> (IV) + <strong>Clarithromycin</strong> (IV/Oral).
<ul>
<li><em>Rationale:</em> Broad spectrum coverage including beta-lactamase producers (<em>S. aureus</em>, <em>H. influenzae</em>) and atypicals.</li>
</ul>
</li>
<li><strong>Penicillin Allergy:</strong> Levofloxacin (Fluoroquinolone) - <em>Note: Safety concerns regarding tendonitis/aortic aneurysm.</em></li>
</ul>
<h5 id="D-Supportive-Care">D. Supportive Care</h5>
<ul>
<li>Oxygen (maintain Saturation &gt; 94%).</li>
<li>IV Fluids (for dehydration/shock).</li>
<li>Analgesia (Paracetamol/NSAIDs) for pleuritic pain.</li>
<li><strong>Stop Smoking:</strong> Essential advice.</li>
</ul>
<h4 id="5-Prevention-预防">5. Prevention (预防)</h4>
<h5 id="Vaccination-2">Vaccination</h5>
<ul>
<li><strong>Pneumococcal Polysaccharide Vaccine (PPV / Pneumovax 23):</strong>
<ul>
<li>Covers 23 serotypes.</li>
<li><strong>Target Group:</strong> All adults $\ge$ 65 years, and “At Risk” groups (Chronic Heart/Lung/Liver/Kidney disease, Diabetes, Immunosuppression, Asplenia).</li>
<li>Usually a single lifetime dose (repeat every 5 years only for Asplenia/Kidney disease).</li>
</ul>
</li>
<li><strong>PCV13 (Prevenar):</strong> Conjugate vaccine, part of childhood immunisation.</li>
</ul>
<h5 id="Influenza-Vaccine">Influenza Vaccine</h5>
<ul>
<li>Annual vaccination is crucial as secondary bacterial pneumonia often follows the flu (“Post-viral pneumonia”).</li>
</ul>
<h4 id="Summary-Table-Cheatsheet">Summary Table (Cheatsheet)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Severity (CURB-65)</th>
<th style="text-align:left">Place of Care</th>
<th style="text-align:left">First Line Antibiotic (UK)</th>
<th style="text-align:left">Penicillin Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Mild (0-1)</strong></td>
<td style="text-align:left">Home</td>
<td style="text-align:left"><strong>Amoxicillin</strong> (Oral)</td>
<td style="text-align:left">Doxycycline / Clarithromycin</td>
</tr>
<tr>
<td style="text-align:left"><strong>Mod (2)</strong></td>
<td style="text-align:left">Hospital</td>
<td style="text-align:left"><strong>Amoxicillin + Clarithromycin</strong></td>
<td style="text-align:left">Doxycycline / Levofloxacin</td>
</tr>
<tr>
<td style="text-align:left"><strong>Severe (3-5)</strong></td>
<td style="text-align:left">Hospital / ICU</td>
<td style="text-align:left"><strong>Co-amoxiclav (IV) + Clarithromycin</strong></td>
<td style="text-align:left">Levofloxacin</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Clinical Pearl:</strong> Always check recent travel history. If a patient has recently stayed in a hotel with air conditioning and presents with pneumonia + hyponatraemia (low sodium) + confusion, suspect <strong>Legionella</strong> (Legionnaires’ disease) and ensure a Macrolide or Quinolone is used.</p>
</blockquote>
<h3 id="LECTURE27-01-Core-Concept-24-Inhaled-formulations-excipients-testing">LECTURE27 01 Core Concept 24 Inhaled formulations, excipients &amp; testing</h3>
<p><strong>Core Goal:</strong> To deliver the drug to the correct part of the lung (Targeting) while avoiding the throat (Side effects) and ensuring the formulation is stable and deliverable.</p>
<h4 id="1-Pulmonary-Physiology-Deposition-Physics-肺生理与沉积物理">1. Pulmonary Physiology &amp; Deposition Physics (肺生理与沉积物理)</h4>
<h5 id="The-Target-Zones">The Target Zones</h5>
<ul>
<li><strong>Conducting Zone (传导区):</strong> Trachea to Terminal Bronchioles. Lined with ciliated epithelium and mucus (Mucociliary escalator clearance).</li>
<li><strong>Respiratory Zone (呼吸区):</strong> Respiratory Bronchioles to Alveoli. Huge surface area (~100 $m^2$), thin barrier. <strong>Site of systemic absorption.</strong></li>
<li><strong>Clearance:</strong>
<ul>
<li>Upper airways: Mucociliary clearance (swallowed).</li>
<li>Alveoli: Macrophages (phagocytosis).</li>
</ul>
</li>
</ul>
<h5 id="Aerodynamic-Diameter-d-a-空气动力学直径">Aerodynamic Diameter ($d_a$ - 空气动力学直径)</h5>
<ul>
<li>Particles are irregular. We describe them as an <strong>equivalent sphere</strong> of unit density ($1 g/cm^3$) that settles at the same velocity as the particle in question.</li>
<li><strong>Formula:</strong> $d_a = d_g \sqrt{\frac{\rho}{\rho_0} \cdot \frac{1}{\chi}}$
<ul>
<li>$d_g$: Geometric diameter.</li>
<li>$\rho$: Particle density.</li>
<li>$\chi$: Shape factor (Spheres = 1, Flakes &gt; 1).</li>
</ul>
</li>
<li><strong>Key implication:</strong> A small, heavy particle behaves the same as a large, light particle.</li>
<li><strong>The “Magic Range”:</strong> <strong>1 – 5 $\mu m$</strong> is ideal for deep lung deposition.</li>
</ul>
<h5 id="Mechanisms-of-Particle-Deposition-颗粒沉积机制">Mechanisms of Particle Deposition (颗粒沉积机制)</h5>
<ol>
<li><strong>Inertial Impaction (惯性撞击):</strong>
<ul>
<li><strong>Where:</strong> Upper airways (Throat/Trachea) &amp; Bifurcations.</li>
<li><strong>Mechanism:</strong> Large particles (&gt;5-10 $\mu m$) or High velocity. Momentum prevents them from following the airstream curve.</li>
<li><strong>Result:</strong> Swallowed (Local side effects, e.g., oral thrush from steroids).</li>
</ul>
</li>
<li><strong>Gravitational Sedimentation (重力沉降):</strong>
<ul>
<li><strong>Where:</strong> Small airways/Bronchioles (Low airflow velocity).</li>
<li><strong>Mechanism:</strong> Gravity pulls particles down. Governed by <strong>Stokes’ Law</strong>.</li>
<li><strong>Optimal size:</strong> 1-5 $\mu m$.</li>
<li><strong>Clinical Tip:</strong> This is why we tell patients to <strong>“Hold their breath”</strong> (increases time for sedimentation).</li>
</ul>
</li>
<li><strong>Brownian Diffusion (布朗扩散):</strong>
<ul>
<li><strong>Where:</strong> Alveoli.</li>
<li><strong>Mechanism:</strong> Random motion of very small particles (&lt;0.5 $\mu m$).</li>
<li><strong>Issue:</strong> Many are exhaled before they touch the wall.</li>
</ul>
</li>
</ol>
<h4 id="2-Inhaler-Devices-Formulations-装置与制剂">2. Inhaler Devices &amp; Formulations (装置与制剂)</h4>
<h5 id="A-Pressurised-Metered-Dose-Inhalers-pMDIs-压力定量吸入器">A. Pressurised Metered Dose Inhalers (pMDIs - 压力定量吸入器)</h5>
<ul>
<li><strong>Principle:</strong> Drug dissolved or suspended in a liquid propellant held under pressure. Actuation releases a metered volume which flash-evaporates, leaving drug particles.</li>
<li><strong>Excipients:</strong>
<ul>
<li><strong>Propellants:</strong>
<ul>
<li><em>Old:</em> CFCs (Chlorofluorocarbons) - Banned (Ozone layer).</li>
<li><em>Current:</em> <strong>HFAs</strong> (Hydrofluoroalkanes - HFA-134a, HFA-227).</li>
</ul>
</li>
<li><strong>Co-solvents:</strong> <strong>Ethanol</strong>. HFAs are poor solvents, so ethanol helps dissolve the drug or surfactant.</li>
<li><strong>Surfactants:</strong> Oleic acid, Sorbitan trioleate. Lubricate the valve and stabilise suspensions (prevent caking).</li>
</ul>
</li>
<li><strong>Challenges:</strong>
<ul>
<li><strong>Coordination:</strong> Patient must press and breathe simultaneously. Solution: Spacers (储雾罐) or Breath-Actuated pMDIs (Easi-Breathe).</li>
<li><strong>Cold Freon Effect:</strong> The chilling sensation of evaporating propellant hits the back of the throat, causing the patient to stop inhaling.</li>
<li><strong>Spray Velocity:</strong> High velocity leads to high throat deposition (Impaction).</li>
</ul>
</li>
</ul>
<h5 id="B-Dry-Powder-Inhalers-DPIs-干粉吸入器">B. Dry Powder Inhalers (DPIs - 干粉吸入器)</h5>
<ul>
<li><strong>Principle:</strong> Breath-actuated. The patient’s inspiratory effort provides the energy to de-agglomerate the powder.</li>
<li><strong>Formulation Strategies:</strong>
<ol>
<li><strong>Carrier-Based Systems (Most common):</strong>
<ul>
<li><strong>Micronised Drug (1-5 $\mu m$):</strong> Very cohesive, flows poorly, sticks together.</li>
<li><strong>Coarse Carrier (e.g., Lactose Monohydrate, 50-100 $\mu m$):</strong> Flows well.</li>
<li><strong>Mechanism:</strong> Drug particles adhere to the surface of lactose. During inhalation, turbulence knocks the drug off the carrier. The carrier hits the throat (swallowed), drug goes to lungs.</li>
</ul>
</li>
<li><strong>Pelletised/Spheroids:</strong> Soft aggregates of drug alone (e.g., Bricanyl Turbohaler).</li>
</ol>
</li>
<li><strong>Forces involved:</strong>
<ul>
<li><em>Adhesion:</em> Van der Waals, Electrostatic, Capillary forces (Drug sticking to carrier).</li>
<li><em>Detachment:</em> Drag force and Lift force (Airflow trying to pull drug off).</li>
</ul>
</li>
<li><strong>Resistance:</strong> DPIs have different internal resistance. High resistance requires lower inspiratory flow rate to generate turbulence.</li>
</ul>
<h5 id="C-Nebulisers-雾化器">C. Nebulisers (雾化器)</h5>
<ul>
<li><strong>Principle:</strong> Convert liquid solution/suspension into a continuous mist.</li>
<li><strong>Types:</strong>
<ul>
<li><strong>Jet Nebuliser:</strong> Uses compressed gas (Bernoulli principle). Noisy, cools the liquid.</li>
<li><strong>Ultrasonic:</strong> Uses piezoelectric crystal. Silent, but <strong>heats up</strong> (bad for proteins/DNA).</li>
<li><strong>Vibrating Mesh:</strong> Liquid pushed through a mesh. Efficient, portable, expensive.</li>
</ul>
</li>
<li><strong>Formulation:</strong>
<ul>
<li><strong>Sterile</strong> (Essential).</li>
<li><strong>Isotonic</strong> (Prevent bronchoconstriction).</li>
<li><strong>pH controlled</strong> (&gt;5).</li>
<li><strong>Preservative-free</strong> (Sulfites/Benzalkonium chloride can cause bronchospasm).</li>
</ul>
</li>
</ul>
<h4 id="3-Quality-Control-Testing-质量控制与测试">3. Quality Control &amp; Testing (质量控制与测试)</h4>
<p>Regulatory bodies (BP/USP) require strict testing of aerodynamic performance.</p>
<h5 id="Apparatus-测试仪器">Apparatus (测试仪器)</h5>
<ol>
<li><strong>Twin Impinger (Glass):</strong>
<ul>
<li>Simple, two chambers (Upper airway vs Lower airway).</li>
<li><em>Limit:</em> Only gives a coarse “Respirable Fraction”. Doesn’t give a full size distribution.</li>
</ul>
</li>
<li><strong>Andersen Cascade Impactor (ACI):</strong>
<ul>
<li>8 stages (Metal plates).</li>
<li>Air flows through progressively smaller holes, increasing velocity. Particles impact on plates based on inertia.</li>
<li><em>Standard:</em> Long history of use.</li>
</ul>
</li>
<li><strong>Next Generation Impactor (NGI):</strong>
<ul>
<li>7 stages + MOC (Micro-Orifice Collector).</li>
<li>Designed specifically for pharma. Horizontal layout, easy to automate.</li>
<li><strong>Gold Standard</strong> for modern testing.</li>
</ul>
</li>
</ol>
<h5 id="Key-Data-Metrics-数据指标">Key Data Metrics (数据指标)</h5>
<p>From the impactor data (Mass of drug on each stage), we calculate:</p>
<ul>
<li><strong>Mass Median Aerodynamic Diameter (MMAD):</strong> The midpoint diameter (50% of particles by mass are larger, 50% are smaller). Ideally 1-5 $\mu m$.</li>
<li><strong>Geometric Standard Deviation (GSD):</strong> Measures the spread (polydispersity). GSD = 1 is monodisperse (all same size). GSD &gt; 1.2 is polydisperse.</li>
<li><strong>Fine Particle Dose (FPD):</strong> The absolute <em>mass</em> of drug &lt; 5 $\mu m$.</li>
<li><strong>Fine Particle Fraction (FPF):</strong> The <em>percentage</em> of the emitted dose that is &lt; 5 $\mu m$.
<ul>
<li>$FPF = \frac{\text{Fine Particle Dose}}{\text{Total Emitted Dose}} \times 100%$</li>
</ul>
</li>
</ul>
<h5 id="Summary-Table-Device-Comparison">Summary Table: Device Comparison</h5>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">pMDI</th>
<th style="text-align:left">DPI</th>
<th style="text-align:left">Nebuliser</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>State</strong></td>
<td style="text-align:left">Solution/Suspension + Gas</td>
<td style="text-align:left">Solid Powder</td>
<td style="text-align:left">Solution/Suspension</td>
</tr>
<tr>
<td style="text-align:left"><strong>Actuation</strong></td>
<td style="text-align:left">Press &amp; Breathe (Coordination needed)</td>
<td style="text-align:left">Breath-Actuated (Patient effort needed)</td>
<td style="text-align:left">Continuous breathing</td>
</tr>
<tr>
<td style="text-align:left"><strong>Delivery Efficiency</strong></td>
<td style="text-align:left">Low (~10-20% lung dep) without spacer</td>
<td style="text-align:left">Variable (depends on inspiratory flow)</td>
<td style="text-align:left">High volume delivery possible</td>
</tr>
<tr>
<td style="text-align:left"><strong>Portability</strong></td>
<td style="text-align:left">High</td>
<td style="text-align:left">High</td>
<td style="text-align:left">Low (usually)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Propellant</strong></td>
<td style="text-align:left">Yes (HFA)</td>
<td style="text-align:left">No</td>
<td style="text-align:left">No</td>
</tr>
</tbody>
</table>
<h2 id="Core-Concept-Science-Formulations">Core Concept - Science &amp; Formulations</h2>
<h3 id="LECTURE21-01-Core-Concept-18-Sterilisation-processing">LECTURE21 01 Core Concept 18 Sterilisation processing</h3>
<p>Lecturer: Dr David Allison</p>
<h4 id="1-Introduction-Definitions">1. Introduction &amp; Definitions</h4>
<p><strong>Chinese Term:</strong> 介绍与定义</p>
<h5 id="A-Approaches-to-Manufacturing">A. Approaches to Manufacturing</h5>
<ol>
<li><strong>Terminal Sterilisation (终端灭菌):</strong>
<ul>
<li>Product is assembled, packaged, and then sterilised in its final container.</li>
<li><em>Preferred method</em> if the product is heat stable.</li>
</ul>
</li>
<li><strong>Aseptic Processing (无菌工艺):</strong>
<ul>
<li>Product is assembled from sterile components under controlled “clean” conditions (free of microorganisms).</li>
<li>Used when the product cannot withstand terminal sterilisation (e.g., heat-labile antibiotics).</li>
</ul>
</li>
</ol>
<h5 id="B-Definitions">B. Definitions</h5>
<ul>
<li><strong>Sterile</strong> (无菌): Free of <strong>viable</strong> microorganisms (无活微生物).</li>
<li><strong>Sterilisation (灭菌):</strong> The process of <strong>killing</strong> or <strong>removing</strong> all viable microorganisms.</li>
</ul>
<blockquote>
<p><strong>Key Concept:</strong> A simple product (e.g., antibiotic vial) might require multiple sterilisation steps:</p>
<ul>
<li>Solution $\rightarrow$ Filtration (Heat labile).</li>
<li>Vial $\rightarrow$ Dry Heat.</li>
<li>Stopper $\rightarrow$ Autoclaving or Gamma Radiation.</li>
</ul>
</blockquote>
<h4 id="2-Traditional-Sterilisation-Methods">2. Traditional Sterilisation Methods</h4>
<p><strong>Chinese Term:</strong> 传统灭菌方法</p>
<p>Methods are classified into two categories:</p>
<ol>
<li><strong>Removal (去除):</strong> Filtration.</li>
<li><strong>Destructive (破坏/杀灭):</strong> Heat, Chemical (Gas), Radiation.</li>
</ol>
<h5 id="A-Filtration-Removal-Mechanism">A. Filtration (Removal Mechanism)</h5>
<p><strong>Chinese Term:</strong> 过滤灭菌</p>
<ul>
<li><strong>Mechanism:</strong> Passage of fluid (liquid/gas) across a filter to remove contaminating solutes/microbes.</li>
<li><strong>Pore Size Requirement:</strong> <strong>0.22</strong> $\mu m$ (or smaller) is required to remove bacteria.</li>
</ul>
<p><strong>Filter Types Comparison:</strong></p>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Depth Filters (深层过滤器)</strong></th>
<th><strong>Screen (Absolute) Filters (膜/筛网过滤器)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pore Size</strong></td>
<td>Non-fixed, variable (不固定)</td>
<td>Uniform, fixed (e.g., 0.22 $\mu m$)</td>
</tr>
<tr>
<td><strong>Mechanism</strong></td>
<td>Inertial impaction (trapped inside)</td>
<td>Direct interception (lodged on surface)</td>
</tr>
<tr>
<td><strong>Capacity</strong></td>
<td>High retentative capacity</td>
<td>Easily blocked</td>
</tr>
<tr>
<td><strong>Durability</strong></td>
<td>Robust, cheap</td>
<td>Fragile, expensive (5-10x cost)</td>
</tr>
<tr>
<td><strong>Sterility</strong></td>
<td><strong>Cannot</strong> guarantee sterility</td>
<td><strong>Can</strong> produce sterile filtrate</td>
</tr>
</tbody>
</table>
<h4 id="3-Inactivation-Kinetics-The-Maths-of-Killing">3. Inactivation Kinetics (The Maths of Killing)</h4>
<p><strong>Chinese Term:</strong> 灭菌动力学</p>
<p>When microbes are exposed to a lethal agent (heat/radiation), they die at a predictable rate.</p>
<h5 id="A-The-Kill-Curve">A. The Kill Curve</h5>
<ol>
<li><strong>Linear Plot:</strong> Shows an <strong>asymptote curve</strong> (fixed proportion killed per time unit). Never technically hits zero.</li>
<li><strong>Semi-log Plot (Log Survivors vs. Time):</strong> Produces a <strong>straight line</strong>.
<ul>
<li>This allows us to calculate death rates.</li>
</ul>
</li>
</ol>
<h5 id="B-D-Value-Decimal-Reduction-Time">B. D-Value (Decimal Reduction Time)</h5>
<p><strong>Chinese Term:</strong> D值 (十倍减少时间)</p>
<ul>
<li><strong>Definition:</strong> The time taken, at a <em>fixed</em> temperature (or dose), to reduce the microbial population by <strong>90%</strong> (i.e., a <strong>1-log cycle reduction</strong>).</li>
<li><strong>Significance:</strong> Measures the <em>resistance</em> of an organism. Higher D-value = More resistant organism.</li>
</ul>
<h5 id="C-Sterility-Assurance-Level-SAL">C. Sterility Assurance Level (SAL)</h5>
<p><strong>Chinese Term:</strong> 无菌保证水平</p>
<ul>
<li>Since “zero” survivors cannot be plotted on a log scale, we define a statistical probability of sterility.</li>
<li><strong>Target SAL:</strong> $10^{-6}$ (Probability of 1 non-sterile unit in 1,000,000 units).</li>
<li><strong>Calculation:</strong>
<ul>
<li>If Initial Bioburden = $10^2$</li>
<li>Target SAL = $10^{-6}$</li>
<li>Total Reduction Needed = 8 log cycles ($2 - (-6) = 8$).</li>
<li>Total Processing Time = $8 \times \text{D-value}$.</li>
</ul>
</li>
</ul>
<blockquote>
<p><strong>Factors affecting Sterilisation Time:</strong></p>
<ol>
<li><strong>D-value:</strong> Higher resistance requires longer time.</li>
<li><strong>Bioburden (生物负载):</strong> Higher initial population requires longer time.</li>
</ol>
</blockquote>
<h4 id="4-Destructive-Methods-Details">4. Destructive Methods Details</h4>
<h5 id="A-Heat-Sterilisation">A. Heat Sterilisation</h5>
<p><strong>Chinese Term:</strong> 热灭菌</p>
<p><strong>1. Moist Heat (Steam) - Autoclave (湿热/高压蒸汽灭菌):</strong></p>
<ul>
<li><strong>Mechanism:</strong> Protein coagulation and hydrolysis (蛋白质凝固和水解).</li>
<li><strong>Conditions:</strong> Steam under pressure (temps &gt; $100^\circ\text{C}$).</li>
<li><strong>Pros:</strong> Rapid, safe, reliable, easy to monitor. Most widely used.</li>
<li><strong>Autoclave Cycle Stages:</strong>
<ol>
<li>Air Removal (Crucial! Air pockets prevent reaching $&gt;100^\circ\text{C}$).</li>
<li>Heating.</li>
<li><strong>Holding Period</strong> (Sterilisation phase).</li>
<li>Cooling.</li>
<li>Drying.</li>
</ol>
</li>
<li><strong>Common Pharmacopoeial Cycles:</strong>
<ul>
<li>$121^\circ\text{C}$ <strong>for 15 mins</strong> (Aqueous products, standard cycle).</li>
<li>$134^\circ\text{C}$ <strong>for 3 mins</strong> (Porous loads, surgical dressings).</li>
</ul>
</li>
</ul>
<p><strong>2. Dry Heat (干热灭菌):</strong></p>
<ul>
<li><strong>Mechanism:</strong> Oxidative processes (氧化作用).</li>
<li><strong>Uses:</strong> Glassware, oils, dry powders (items that steam can’t penetrate or would damage).</li>
<li><strong>Conditions:</strong> Higher temperatures and longer times than moist heat (e.g., $160^\circ\text{C}$ for 2 hrs).</li>
</ul>
<h5 id="B-Ethylene-Oxide-EtO">B. Ethylene Oxide (EtO)</h5>
<p><strong>Chinese Term:</strong> 环氧乙烷灭菌</p>
<ul>
<li><strong>Type:</strong> Chemical Gas Sterilant.</li>
<li><strong>Mechanism:</strong> <strong>Alkylation</strong> of proteins and nucleic acids (烷基化作用).</li>
<li><strong>Uses:</strong> Heat-sensitive <strong>Single-use medical devices</strong> (syringes, catheters).</li>
<li><strong>Critical Parameters:</strong> Concentration, Temperature, Humidity, Time.</li>
<li><strong>Disadvantages:</strong>
<ul>
<li><strong>Toxic residues</strong> (requires desorption/aeration).</li>
<li><strong>Explosive</strong> gas.</li>
<li>Harder to validate than heat.</li>
</ul>
</li>
<li><strong>Biological Indicator:</strong> <em>Bacillus subtilis</em> (spores) - used to validate the process because they are highly resistant to EtO.</li>
</ul>
<h5 id="C-Radiation-Briefly-mentioned">C. Radiation (Briefly mentioned)</h5>
<ul>
<li><strong>Ionising Radiation (Gamma):</strong> Uses Cobalt-60 isotope. Good for dry medical devices.</li>
<li><em>Lecturer Note:</em> “There will not be an exam question based on radiation.”</li>
</ul>
<h4 id="5-Alternative-Technologies">5. Alternative Technologies</h4>
<p><strong>Chinese Term:</strong> 新型/替代技术</p>
<ol>
<li><strong>X-Ray Irradiation:</strong> Ionising, low power, used for contact lenses.</li>
<li><strong>Pulsed Light:</strong> Broad spectrum white light (UV content), surface sterilisation.</li>
<li><strong>Microwaves:</strong> Intense heating, short cycles. Solutions/Contact lenses.</li>
<li><strong>Gas</strong> Plasma (气体等离子体):
<ul>
<li>Mixture of ions/free radicals (e.g., from $H_2O_2$).</li>
<li><strong>Advantage:</strong> Safer alternative to EtO (non-explosive, no toxic residues).</li>
<li>Used for medical devices.</li>
</ul>
</li>
</ol>
<h4 id="6-Quality-Assurance-Testing">6. Quality Assurance &amp; Testing</h4>
<p><strong>Chinese Term:</strong> 质量保证与测试</p>
<p>How do we prove a product is sterile?</p>
<h5 id="A-Bioburden-Estimation">A. Bioburden Estimation</h5>
<ul>
<li><strong>Definition:</strong> The number of microorganisms on/in a product <em>before</em> sterilisation.</li>
<li><strong>Purpose:</strong> Determines the challenge level to calculate the required dose/time.</li>
</ul>
<h5 id="B-Test-for-Sterility-vs-Test-of-Sterility">B. Test <em>for</em> Sterility vs Test <em>of</em> Sterility</h5>
<ul>
<li><strong>Test</strong> <em><strong>for</strong></em> <strong>Sterility:</strong> Testing the <strong>end product</strong> (destructive test on a sample batch). Answer is Pass/Fail.</li>
<li><strong>Test</strong> <em><strong>of</strong></em> <strong>Sterility:</strong> Testing performed during <strong>validation/development</strong>. Exposing product to a <em>fraction</em> of the process to determine kill rates (D-values).</li>
</ul>
<h5 id="C-Pyrogen-Testing-Endotoxins">C. Pyrogen Testing (Endotoxins)</h5>
<p><strong>Chinese Term:</strong> 热原 (内毒素) 检测</p>
<ul>
<li><strong>Pyrogen:</strong> Fever-causing substance.</li>
<li><strong>Main Source:</strong> <strong>Lipid A</strong> component of <strong>Lipopolysaccharide (LPS)</strong> from the outer membrane of <strong>Gram-negative bacteria</strong>.</li>
<li><strong>Problem:</strong> Bacteria can be killed (sterile), but dead cell fragments (Endotoxins) remain and can be fatal if injected.</li>
</ul>
<p><strong>The LAL Test (鲎试剂试验):</strong></p>
<ul>
<li><strong>Full Name:</strong> Limulus Amebocyte Lysate.</li>
<li><strong>Source:</strong> Blood of the <strong>Horseshoe Crab</strong> (<em>Limulus polyphemus</em>).</li>
<li><strong>Mechanism:</strong> In the presence of Endotoxin, the lysate forms a <strong>Gel Clot</strong> (凝胶).</li>
<li><strong>Types:</strong>
<ol>
<li><strong>Gel Clot:</strong> Simple +/- result (Clot forms = Positive for endotoxin).</li>
<li><strong>Chromogenic:</strong> Colour change, allows <strong>quantification</strong> (measuring intensity).</li>
</ol>
</li>
</ul>
<h4 id="Summary-Checklist">Summary Checklist</h4>
<ul>
<li>[ ] Can you define $D_{value}$ and $SAL$ ($10^{-6}$)?</li>
<li>[ ] Do you know the difference between Depth and Screen filters?</li>
<li>[ ] Can you list the 4 stages of an autoclave cycle?</li>
<li>[ ] Why is Ethylene Oxide dangerous? (Explosive/Toxic residues).</li>
<li>[ ] What is the LAL test used for? (Detecting Lipid A/Endotoxin from Gram -ve bacteria).</li>
</ul>
<h3 id="LECTURE33-01-Core-Concept-29-Particle-Sizing-and-size-distribution">LECTURE33 01 Core Concept 29 Particle Sizing and size distribution</h3>
<h4 id="1-Why-Measure-Particle-Size-为什么要测量粒径">1. Why Measure Particle Size? (为什么要测量粒径?)</h4>
<p>Particle size influences critical pharmaceutical properties:</p>
<ul>
<li><strong>Dissolution Rate (溶出速率):</strong> Smaller particles = larger surface area = faster dissolution (Noyes-Whitney Equation).</li>
<li><strong>Bioavailability (生物利用度):</strong> Faster dissolution often leads to better absorption.</li>
<li><strong>Stability (稳定性):</strong> In suspensions, larger particles settle faster (Stokes’ Law). Ostwald ripening can occur in fine suspensions.</li>
<li><strong>Processability (加工性能):</strong> Affects flowability (crucial for tableting) and mixing homogeneity.</li>
</ul>
<h4 id="2-Describing-Particle-Size-粒径的描述">2. Describing Particle Size (粒径的描述)</h4>
<p>Since particles are irregular, we measure a property (e.g., volume, settling speed) and relate it to a sphere that would produce the same result.</p>
<ul>
<li><strong>Equivalent Sphere Diameter:</strong> The diameter of a sphere that behaves the same way as the particle in the chosen measurement method.
<ul>
<li><em>Volume Equivalent Diameter ($d_v$):</em> Sphere with the same volume.</li>
<li><em>Stokes’ Diameter ($d_{st}$):</em> Sphere with the same settling velocity.</li>
<li><em>Projected Area Diameter ($d_a$):</em> Sphere with the same projected area (Microscopy).</li>
</ul>
</li>
</ul>
<h4 id="3-Measurement-Techniques-测量技术">3. Measurement Techniques (测量技术)</h4>
<h5 id="A-Sieving-筛分法">A. Sieving (筛分法)</h5>
<ul>
<li><strong>Range:</strong> Coarse particles (&gt; 50 $\mu m$ typically, down to 38 $\mu m$).</li>
<li><strong>Method:</strong> Mechanical agitation of nested sieves.</li>
<li><strong>Pros:</strong> Simple, cheap, robust.</li>
<li><strong>Cons:</strong> Low resolution, cannot measure sprays/emulsions, can cause attrition (particles breaking).</li>
</ul>
<h5 id="B-Microscopy-显微镜法">B. Microscopy (显微镜法)</h5>
<ul>
<li><strong>Range:</strong> $1 \mu m$ - $150 \mu m$ (Optical).</li>
<li><strong>Method:</strong> Direct observation.</li>
<li><strong>Distribution:</strong> Gives a <strong>Number Distribution</strong> (counts individual particles).</li>
<li><strong>Pros:</strong> Allows visualisation of particle <strong>shape</strong> (agglomerates vs primary particles).</li>
<li><strong>Cons:</strong> Slow, examines small sample size (poor representation), 2D projection only.</li>
</ul>
<h5 id="C-Laser-Diffraction-激光衍射法-Industry-Standard">C. Laser Diffraction (激光衍射法 - Industry Standard)</h5>
<ul>
<li><strong>Range:</strong> Wide range ($0.02 \mu m$ - $2000 \mu m$).</li>
<li><strong>Method:</strong> Particles pass through a laser beam; light scatters at angles inversely proportional to particle size (Large particles $\to$ Small angles; Small particles $\to$ Large angles).</li>
<li><strong>Theory:</strong> Uses <strong>Mie Theory</strong> (requires refractive index) or Fraunhofer approximation.</li>
<li><strong>Distribution:</strong> Gives a <strong>Volume Distribution</strong> (equivalent to mass if density is constant).</li>
<li><strong>Pros:</strong> Fast, reproducible, wide dynamic range.</li>
</ul>
<h5 id="D-Dynamic-Light-Scattering-DLS-动态光散射">D. Dynamic Light Scattering (DLS) (动态光散射)</h5>
<ul>
<li><strong>Range:</strong> Sub-micron / Nanoparticles (&lt; $1 \mu m$).</li>
<li><strong>Method:</strong> Measures <strong>Brownian motion</strong>. Smaller particles move faster.</li>
<li><strong>Result:</strong> Hydrodynamic radius.</li>
</ul>
<h4 id="4-Data-Analysis-Distributions-数据分析与分布">4. Data Analysis &amp; Distributions (数据分析与分布)</h4>
<h5 id="Number-vs-Volume-Weighting-数量分布-vs-体积分布">Number vs. Volume Weighting (数量分布 vs 体积分布)</h5>
<ul>
<li><strong>Number Distribution:</strong> All particles have equal weighting (1 particle = 1 count). <em>Example: Microscopy.</em></li>
<li><strong>Volume/Mass Distribution:</strong> Larger particles have massive weighting because Volume $\propto r^3$.
<ul>
<li><em>Clinical Note:</em> A few large lumps in an IV emulsion might be negligible by number (0.01%) but could constitute 90% of the volume and cause an embolism. <strong>Laser diffraction (Volume)</strong> is safer for detecting these large tails.</li>
</ul>
</li>
</ul>
<h5 id="Key-Parameters-关键参数">Key Parameters (关键参数)</h5>
<ul>
<li><strong>$D_{10}, D_{50}, D_{90}$:</strong> Percentiles based on the cumulative distribution (Undersize).
<ul>
<li><strong>$D_{v50}$ (Median):</strong> 50% of the sample volume is smaller than this size.</li>
<li><strong>$D_{v90}$:</strong> 90% is smaller (indicates the coarse end of the distribution).</li>
<li><strong>$D_{v10}$:</strong> 10% is smaller (indicates the fine end).</li>
</ul>
</li>
<li><strong>Span (Width of distribution):</strong><br>
$$\text{Span} = \frac{D_{90} - D_{10}}{D_{50}}$$
<ul>
<li>A smaller span indicates a narrower (more monodisperse) distribution.</li>
</ul>
</li>
</ul>
<h5 id="Mean-Diameters-平均径">Mean Diameters (平均径)</h5>
<ul>
<li><strong>$D[4,3]$ (Volume Moment Mean):</strong> Sensitive to large particles. Similar to the centre of gravity of the volume distribution.</li>
<li><strong>$D[3,2]$ (Sauter Mean Diameter):</strong> Surface area moment mean. Relevant for dissolution and bioavailability studies (surface sensitive).</li>
</ul>
<h4 id="5-Summary-Checklist-复习清单">5. Summary Checklist (复习清单)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Method</th>
<th style="text-align:left">Range</th>
<th style="text-align:left">Distribution Type</th>
<th style="text-align:left">Key Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Sieving</strong></td>
<td style="text-align:left">&gt;50 $\mu m$</td>
<td style="text-align:left">Mass</td>
<td style="text-align:left">Simple, measures “sieve diameter” (width).</td>
</tr>
<tr>
<td style="text-align:left"><strong>Microscopy</strong></td>
<td style="text-align:left">1-150 $\mu m$</td>
<td style="text-align:left"><strong>Number</strong></td>
<td style="text-align:left">Sees shape; slow; 2D only.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Laser Diffraction</strong></td>
<td style="text-align:left">0.02-2000 $\mu m$</td>
<td style="text-align:left"><strong>Volume</strong></td>
<td style="text-align:left">Fast; standard for most drugs; assumes spherical.</td>
</tr>
<tr>
<td style="text-align:left"><strong>DLS</strong></td>
<td style="text-align:left">&lt;1 $\mu m$ (Nano)</td>
<td style="text-align:left">Intensity/Volume</td>
<td style="text-align:left">Measures Brownian motion; for nanoparticles.</td>
</tr>
</tbody>
</table>
<ul>
<li>[ ] <strong>Can you calculate Span?</strong> Formula: $(D_{90} - D_{10}) / D_{50}$.</li>
<li>[ ] <strong>Why convert Number to Volume?</strong> To understand the mass contribution of large particles. A $10\mu m$ particle has $1000 \times$ the volume of a $1\mu m$ particle.</li>
</ul>
<h3 id="LECTURE6-01-Core-Concept-3-Mass-Spectrometry-of-medicines-and-drug-substances">LECTURE6 01 Core Concept 3 Mass Spectrometry of medicines and drug substances</h3>
<h4 id="1-Core-Principles-核心原理">1. Core Principles (核心原理)</h4>
<h5 id="Definition-Function">Definition &amp; Function</h5>
<ul>
<li><strong>Mass Spectrometry (MS)</strong> is an analytical technique used to measure the <strong>mass-to-charge ratio ($m/z$)</strong> of ions[cite: 21].</li>
<li>It acts effectively as a “molecular weighing scale” for atoms and molecules[cite: 19].</li>
<li><strong>Key Output:</strong> A mass spectrum (plot of intensity vs. $m/z$).</li>
</ul>
<h5 id="The-“Black-Box”-Components-仪器组件">The “Black Box” Components (仪器组件)</h5>
<p>A standard MS system consists of five main stages[cite: 23, 24]:</p>
<ol>
<li><strong>Sample Inlet (进样系统):</strong> Introduces the sample (solid, liquid, or vapour).</li>
<li><strong>Ion Source (离子源):</strong> Converts neutral molecules into charged ions (Ionisation).</li>
<li><strong>Mass Analyser (质量分析器):</strong> Separates ions based on their $m/z$ ratio.</li>
<li><strong>Detector (检测器):</strong> Counts the ions and measures signal intensity.</li>
<li><strong>Data System:</strong> Processes signals into a spectrum.</li>
</ol>
<blockquote>
<p><strong>Critical Requirement - High Vacuum (高真空):</strong><br>
The entire system (Source $\to$ Detector) operates under a high vacuum ($10^{-5}$ to $10^{-7}$ torr). This prevents ions from colliding with air molecules, which would scatter them and prevent them from reaching the detector[cite: 26].</p>
</blockquote>
<h4 id="2-Ionisation-Techniques-电离技术">2. Ionisation Techniques (电离技术)</h4>
<p>The choice of ionisation determines whether you see the whole molecule (Molecular Ion) or structural fragments.</p>
<h5 id="A-Electron-Impact-EI-Hard-Ionisation-硬电离">A. Electron Impact (EI) - Hard Ionisation (硬电离)</h5>
<ul>
<li><strong>Mechanism:</strong> High-energy electrons (70eV) bombard the sample in the vapour phase[cite: 30, 31].</li>
<li><strong>Result:</strong> Extensive <strong>fragmentation (碎片化)</strong> occurs.</li>
<li><strong>Application:</strong>
<ul>
<li>Provides a “fingerprint” for structural identification[cite: 31].</li>
<li>Used in <strong>GC-MS</strong> (Gas Chromatography-MS) for volatile, thermally stable drugs[cite: 46].</li>
</ul>
</li>
<li><strong>Limitation:</strong> Often destroys the Molecular Ion ($M^+$), making it hard to determine molecular weight[cite: 31].</li>
</ul>
<h5 id="B-Chemical-Ionisation-CI-Softer-Ionisation-较软电离">B. Chemical Ionisation (CI) - Softer Ionisation (较软电离)</h5>
<ul>
<li><strong>Mechanism:</strong> Uses a reagent gas (e.g., methane, ammonia) to transfer a proton to the analyte[cite: 34].</li>
<li><strong>Result:</strong> Less fragmentation; typically observes the protonated molecular ion $[M+H]^+$.</li>
<li><strong>Application:</strong> Confirming molecular weight when EI fragments too much.</li>
</ul>
<h5 id="C-Electrospray-Ionisation-ESI-Soft-Ionisation-软电离">C. Electrospray Ionisation (ESI) - Soft Ionisation (软电离)</h5>
<ul>
<li><strong>Mechanism:</strong> Sample is sprayed from a capillary at high voltage; solvent evaporates, leaving charged ions[cite: 38].</li>
<li><strong>Result:</strong> Very little fragmentation. Can produce <strong>multiply charged ions</strong> ($[M+nH]^{n+}$)[cite: 41].</li>
<li><strong>Clinical Relevance:</strong>
<ul>
<li>The standard interface for <strong>LC-MS</strong> (Liquid Chromatography-MS).</li>
<li>Essential for analyzing <strong>biologicals</strong> (proteins, peptides, monoclonal antibodies) because it allows large masses to be detected within the range of standard analysers[cite: 40, 41].</li>
</ul>
</li>
</ul>
<h5 id="D-MALDI-Matrix-Assisted-Laser-Desorption-Ionisation">D. MALDI (Matrix Assisted Laser Desorption Ionisation)</h5>
<ul>
<li><strong>Mechanism:</strong> Sample is mixed with a matrix and hit with a laser[cite: 43].</li>
<li><strong>Application:</strong> Large biomolecules (polymers, proteins). Usually singly charged ions.</li>
</ul>
<h4 id="3-Mass-Analysers-质量分析器">3. Mass Analysers (质量分析器)</h4>
<p>After ionisation, ions are separated by their $m/z$ ratio.</p>
<table>
<thead>
<tr>
<th style="text-align:left">Analyser Type</th>
<th style="text-align:left">Mechanism</th>
<th style="text-align:left">Key Features</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Magnetic Sector</strong></td>
<td style="text-align:left">Uses a magnetic field to bend ion paths[cite: 52].</td>
<td style="text-align:left">Historical standard; high resolution but slow and bulky.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Quadrupole (四极杆)</strong></td>
<td style="text-align:left">Uses 4 parallel rods with oscillating voltages[cite: 53].</td>
<td style="text-align:left">The “Workhorse” of pharma labs. Cheap, robust, fast. Acts as a mass filter.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Time of Flight (TOF)</strong></td>
<td style="text-align:left">Measures time taken for ions to drift down a flight tube[cite: 54].</td>
<td style="text-align:left"><strong>Unlimited mass range</strong>; extremely fast; high sensitivity. Ideal for biomolecules.</td>
</tr>
</tbody>
</table>
<h4 id="4-Analysis-Interpretation-谱图解析">4. Analysis &amp; Interpretation (谱图解析)</h4>
<h5 id="Resolution-分辨率">Resolution (分辨率)</h5>
<ul>
<li><strong>Low Resolution (Unit Mass):</strong> Can distinguish $m/z$ 200 from 201. Good for general confirmation[cite: 60].</li>
<li><strong>High Resolution (Accurate Mass):</strong> Can distinguish $m/z$ 28.0187 ($N_2$) from 28.0061 ($CO$)[cite: 62].
<ul>
<li><em>Clinical Relevance:</em> Essential for determining <strong>elemental composition</strong> and identifying unknown impurities or metabolites.</li>
</ul>
</li>
</ul>
<h5 id="Isotope-Patterns-同位素模式">Isotope Patterns (同位素模式)</h5>
<p>Elements exist as mixtures of isotopes, creating characteristic patterns in the spectrum.</p>
<ul>
<li><strong>Chlorine (Cl):</strong> Exists as $^{35}Cl$ and $^{37}Cl$ in a <strong>3:1 ratio</strong>[cite: 66].
<ul>
<li><em>Pattern:</em> Look for two peaks separated by 2 mass units with intensities of 100% and 33%.</li>
</ul>
</li>
<li><strong>Bromine (Br):</strong> Exists as $^{79}Br$ and $^{81}Br$ in a <strong>1:1 ratio</strong>[cite: 67].
<ul>
<li><em>Pattern:</em> Look for two peaks separated by 2 mass units of roughly equal height (“Twin Towers”).</li>
</ul>
</li>
<li><strong>Carbon ($^{13}C$):</strong> 1.1% natural abundance. Creates a small “satellite” peak at $M+1$[cite: 69].</li>
</ul>
<h5 id="Fragmentation-Rules">Fragmentation Rules</h5>
<ul>
<li><strong>Nitrogen Rule (氮规则):</strong>
<ul>
<li>Odd Molecular Weight = Odd number of Nitrogen atoms.</li>
<li>Even Molecular Weight = Even (or zero) Nitrogen atoms[cite: 74].</li>
</ul>
</li>
<li><strong>Stevenson’s Rule:</strong> Fragmentation favours the formation of the most stable cation (e.g., tertiary carbocations &gt; primary)[cite: 77].</li>
</ul>
<h4 id="5-Summary-Pharmaceutical-Applications">5. Summary: Pharmaceutical Applications</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Technique</th>
<th style="text-align:left">Coupling</th>
<th style="text-align:left">Sample Type</th>
<th style="text-align:left">Primary Use in Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>EI-MS</strong></td>
<td style="text-align:left">GC-MS</td>
<td style="text-align:left">Volatile, Thermally Stable</td>
<td style="text-align:left">Identification of raw materials, residual solvents, volatile impurities.</td>
</tr>
<tr>
<td style="text-align:left"><strong>ESI-MS</strong></td>
<td style="text-align:left">LC-MS</td>
<td style="text-align:left">Polar, Non-volatile, Labile</td>
<td style="text-align:left"><strong>Bioanalysis</strong> (drugs in plasma), Peptide mapping, Metabolite ID.</td>
</tr>
<tr>
<td style="text-align:left"><strong>MALDI</strong></td>
<td style="text-align:left">N/A (Solid)</td>
<td style="text-align:left">High MW Biomolecules</td>
<td style="text-align:left">QC of large proteins/polymers.</td>
</tr>
</tbody>
</table>
<h4 id="6-Exam-Focus-Self-Check">6. Exam Focus / Self-Check</h4>
<ul>
<li>[ ] Can you identify a Chlorine or Bromine atom just by looking at the mass spectrum isotope pattern?</li>
<li>[ ] Explain why a vacuum is necessary in MS.</li>
<li>[ ] Distinguish between “Hard” (EI) and “Soft” (ESI) ionisation and when to use each.</li>
<li>[ ] Why is ESI preferred for biological drugs (proteins)? (Answer: Multiple charging brings high mass into detectable range).</li>
</ul>
<h3 id="LECTURE13-01-Core-Concept-11-NMR-spectroscopy-of-drug-substances">LECTURE13 01 Core Concept 11 NMR spectroscopy of drug substances</h3>
<h4 id="1-Core-Principles-核心原理-2">1. Core Principles (核心原理)</h4>
<h5 id="The-Basis-of-NMR">The Basis of NMR</h5>
<ul>
<li><strong>Nuclear Spin (核自旋):</strong> Certain nuclei behave like tiny magnets. This property is required for NMR.
<ul>
<li><strong>Condition:</strong> Nuclei must have an <strong>odd mass number</strong> or <strong>odd atomic number</strong> to possess spin.</li>
<li><strong>Pharma-relevant Nuclei:</strong> $^1H$ (Proton), $^{13}C$ (Carbon-13), $^{19}F$ (Fluorine), $^{31}P$ (Phosphorus).</li>
<li><strong>Non-active:</strong> $^{12}C$ and $^{16}O$ do not have spin and are invisible in NMR.</li>
</ul>
</li>
</ul>
<h5 id="The-Mechanism">The Mechanism</h5>
<ol>
<li><strong>Magnetic Field ($B_0$):</strong> Without a field, nuclear spins are random. In a strong external magnetic field, they align <strong>with</strong> (Alpha $\alpha$, lower energy) or <strong>against</strong> (Beta $\beta$, higher energy) the field.</li>
<li><strong>Resonance (共振):</strong> We apply <strong>Radiofrequency (RF)</strong> radiation. When the RF frequency matches the energy gap ($\Delta E$) between $\alpha$ and $\beta$ states, the nucleus “flips” spin. This absorption of energy is resonance.</li>
<li><strong>Relaxation:</strong> The nucleus returns to the ground state, emitting a signal (FID) which is processed into a spectrum.</li>
</ol>
<h4 id="2-Interpreting-the-Proton-NMR-Spectrum-1H-NMR">2. Interpreting the Proton NMR Spectrum ($^1H$-NMR)</h4>
<p>Interpretation relies on three main parameters: <strong>Position, Intensity, and Shape</strong>.</p>
<h5 id="A-Chemical-Shift-Position-delta-ppm-化学位移">A. Chemical Shift (Position) - $\delta$ (ppm) (化学位移)</h5>
<ul>
<li><strong>Definition:</strong> Indicates the electronic environment of the proton. Measured relative to a reference standard, <strong>TMS</strong> (Tetramethylsilane), set at 0 ppm.</li>
<li><strong>Shielding vs. Deshielding (屏蔽与去屏蔽):</strong>
<ul>
<li><strong>Shielded (High field/Upfield):</strong> High electron density around the nucleus shields it from the external magnet. Signals appear at <strong>lower ppm</strong> (right side).
<ul>
<li><em>Example:</em> Saturated alkanes ($CH_3$, $CH_2$) $\approx$ 0.9 - 1.5 ppm.</li>
</ul>
</li>
<li><strong>Deshielded (Low field/Downfield):</strong> Electronegative atoms (O, N, Halogens) pull electrons away. The nucleus feels the magnet more strongly. Signals appear at <strong>higher ppm</strong> (left side).
<ul>
<li><em>Example:</em> Aldehyde protons ($\approx$ 9-10 ppm), Carboxylic acids ($\approx$ 10-12 ppm).</li>
</ul>
</li>
</ul>
</li>
<li><strong>Aromatic Ring Current:</strong> Circulating electrons in benzene rings create a magnetic field that reinforces the external field, causing strong deshielding ($\approx$ 6.5 - 8 ppm).</li>
</ul>
<h5 id="B-Integration-Intensity-积分">B. Integration (Intensity) (积分)</h5>
<ul>
<li><strong>Rule:</strong> The area under the peak is directly proportional to the <strong>number of protons</strong> contributing to that signal.</li>
<li><strong>Usage:</strong> Used to determine the ratio of H atoms in the molecule (e.g., a ratio of 3:2:3 suggests a $CH_3-CH_2-CH_3$ fragment).</li>
</ul>
<h5 id="C-Spin-Spin-Splitting-Shape-自旋-自旋裂分">C. Spin-Spin Splitting (Shape) (自旋-自旋裂分)</h5>
<ul>
<li><strong>Cause:</strong> Protons are influenced by the magnetic alignment of <strong>neighbouring</strong> protons (on adjacent carbons, typically 3 bonds away).</li>
<li><strong>The $n + 1$ Rule:</strong> If a proton has <strong>$n$</strong> equivalent neighbours, its signal splits into <strong>$n + 1$</strong> peaks.</li>
<li><strong>Multiplicity Patterns:</strong>
<ul>
<li><strong>Singlet (s):</strong> 0 neighbours (e.g., isolated $CH_3$ or $OH$).</li>
<li><strong>Doublet (d):</strong> 1 neighbour ($1:1$ intensity).</li>
<li><strong>Triplet (t):</strong> 2 neighbours ($1:2:1$ intensity).</li>
<li><strong>Quartet (q):</strong> 3 neighbours ($1:3:3:1$ intensity).</li>
<li><strong>Multiplet (m):</strong> Complex splitting pattern.</li>
</ul>
</li>
<li><strong>Coupling Constant ($J$):</strong> The distance (in Hz) between split peaks. It is constant regardless of the magnetic field strength and provides info on connectivity.</li>
</ul>
<blockquote>
<p><strong>Note on Labile Protons:</strong> Protons on O or N (OH, NH) often appear as broad singlets and do not split neighbouring protons due to rapid exchange with the solvent.</p>
</blockquote>
<h4 id="3-Practical-Considerations">3. Practical Considerations</h4>
<h5 id="Solvents-溶剂">Solvents (溶剂)</h5>
<ul>
<li><strong>Problem:</strong> Common organic solvents contain Hydrogen, which would swamp the drug’s signal.</li>
<li><strong>Solution:</strong> Use <strong>Deuterated Solvents (氘代溶剂)</strong> where Hydrogen ($^1H$) is replaced by Deuterium ($^2H$). Deuterium has a different resonance frequency and is “invisible” in $^1H$-NMR.</li>
<li><strong>Common Examples:</strong>
<ul>
<li>$CDCl_3$ (Deuterated Chloroform) - Most common.</li>
<li>$DMSO-d_6$ (Deuterated Dimethyl Sulfoxide).</li>
<li>$D_2O$ (Deuterium Oxide/Heavy Water).</li>
</ul>
</li>
</ul>
<h4 id="4-Carbon-13-NMR-13-C-NMR">4. Carbon-13 NMR ($^{13}C$-NMR)</h4>
<ul>
<li><strong>Abundance:</strong> $^{13}C$ is only 1.1% natural abundance (unlike 99% for $^1H$). Signals are much weaker and require more scans.</li>
<li><strong>Range:</strong> Larger chemical shift range (0 - 220 ppm).</li>
<li><strong>Decoupling:</strong> Spectra are usually <strong>Proton Decoupled</strong>.
<ul>
<li><strong>Result:</strong> All carbon signals appear as <strong>Singlets</strong>. There is no splitting.</li>
</ul>
</li>
<li><strong>Integration:</strong> Generally <strong>not</strong> used because relaxation times vary greatly; peak height does not reliably represent carbon count.</li>
</ul>
<h4 id="5-Summary-Table-Typical-Chemical-Shifts-1H">5. Summary Table: Typical Chemical Shifts ($^1H$)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Proton Type</th>
<th style="text-align:left">Structure</th>
<th style="text-align:left">Approx. Shift ($\delta$ ppm)</th>
<th style="text-align:left">Key Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Alkyl</strong></td>
<td style="text-align:left">$R-CH_3$</td>
<td style="text-align:left">0.9 - 1.5</td>
<td style="text-align:left">Upfield (Shielded)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Allylic</strong></td>
<td style="text-align:left">$C=C-CH_3$</td>
<td style="text-align:left">1.7 - 2.5</td>
<td style="text-align:left">Next to double bond</td>
</tr>
<tr>
<td style="text-align:left"><strong>Alpha to Carbonyl</strong></td>
<td style="text-align:left">$O=C-CH$</td>
<td style="text-align:left">2.0 - 2.7</td>
<td style="text-align:left">Deshielded by C=O</td>
</tr>
<tr>
<td style="text-align:left"><strong>Electronegative Adj.</strong></td>
<td style="text-align:left">$O-CH$, $Cl-CH$</td>
<td style="text-align:left">3.0 - 4.5</td>
<td style="text-align:left">Deshielded by O/Halogen</td>
</tr>
<tr>
<td style="text-align:left"><strong>Alkenyl</strong></td>
<td style="text-align:left">$C=CH$</td>
<td style="text-align:left">4.5 - 6.5</td>
<td style="text-align:left">Double bond region</td>
</tr>
<tr>
<td style="text-align:left"><strong>Aromatic</strong></td>
<td style="text-align:left">$Ar-H$</td>
<td style="text-align:left">6.5 - 8.0</td>
<td style="text-align:left"><strong>Ring Current Effect</strong></td>
</tr>
<tr>
<td style="text-align:left"><strong>Aldehyde</strong></td>
<td style="text-align:left">$O=C-H$</td>
<td style="text-align:left">9.0 - 10.0</td>
<td style="text-align:left">Very downfield</td>
</tr>
<tr>
<td style="text-align:left"><strong>Carboxylic Acid</strong></td>
<td style="text-align:left">$O=C-OH$</td>
<td style="text-align:left">10.0 - 12.0</td>
<td style="text-align:left">Most deshielded</td>
</tr>
</tbody>
</table>
<h4 id="6-Exam-Focus-考试重点">6. Exam Focus (考试重点)</h4>
<ul>
<li>[ ] <strong>Identify the Solvent:</strong> Can you explain why $CDCl_3$ is used instead of $CHCl_3$? (Answer: To avoid massive solvent proton peaks interfering with the sample) .</li>
<li>[ ] <strong>Predict Splitting:</strong> Given a structure like Ethanol ($CH_3CH_2OH$), predict the splitting:
<ul>
<li>$CH_3$: Triplet (2 neighbours on $CH_2$).</li>
<li>$CH_2$: Quartet (3 neighbours on $CH_3$).</li>
</ul>
</li>
<li>[ ] <strong>Reference Standard:</strong> What is TMS? (Tetramethylsilane, defined as 0 ppm, inert, volatile) .</li>
<li>[ ] <strong>Structure Elucidation:</strong> Be prepared to match a simple spectrum to a drug structure (e.g., Paracetamol or Aspirin) by counting protons (Integration) and checking neighbours (Splitting).</li>
</ul>
<h3 id="LECTURE22-01-Core-Concept-19-NMR-spectroscopy-of-drug-substances-2">LECTURE22 01 Core Concept 19 NMR spectroscopy of drug substances 2</h3>
<p><strong>Lecturer:</strong></p>
<h4 id="1-Coupling-Constants-J-Values-偶合常数">1. Coupling Constants ($J$ Values) - 偶合常数</h4>
<p>The <strong>Coupling Constant ($J$)</strong> provides critical information about the connectivity and stereochemistry of a molecule.</p>
<ul>
<li><strong>Definition:</strong> The distance between the split peaks in a multiplet, measured in <strong>Hertz (Hz)</strong>.</li>
<li><strong>Key Feature:</strong> unlike chemical shift ($\delta$), the $J$ value is <strong>independent</strong> of the external magnetic field strength ($B_0$). A 7 Hz doublet on a 300 MHz instrument is still 7 Hz on a 600 MHz instrument.</li>
</ul>
<h5 id="Stereochemistry-The-Karplus-Curve-立体化学与Karplus曲线">Stereochemistry &amp; The Karplus Curve (立体化学与Karplus曲线)</h5>
<p>The magnitude of the vicinal coupling constant ($^3J$) depends on the <strong>dihedral angle (二面角)</strong> between the two C-H bonds.</p>
<ul>
<li><strong>Karplus Relationship:</strong>
<ul>
<li><strong>90° Angle:</strong> $J \approx 0$ Hz (No splitting).</li>
<li><strong>0° or 180° Angle:</strong> Maximum coupling ($J$ is large).</li>
</ul>
</li>
<li><strong>Application in Alkenes (烯烃):</strong>
<ul>
<li><strong>Cis-alkenes ($Z$):</strong> Protons are closer (angle $\approx$ 0°), typically $J \approx 10$ Hz.</li>
<li><strong>Trans-alkenes ($E$):</strong> Protons are anti-periplanar (angle $\approx$ 180°), typically $J \approx 16$ Hz.</li>
<li><em>Exam Tip:</em> Use $J$ values to distinguish geometric isomers of drugs.</li>
</ul>
</li>
<li><strong>Aromatic Systems (芳香环):</strong>
<ul>
<li><strong>Ortho ($J_{ortho}$):</strong> $\approx$ 8 Hz (Strong coupling).</li>
<li><strong>Meta ($J_{meta}$):</strong> $\approx$ 2 Hz (Weak/Fine splitting).</li>
<li><strong>Para ($J_{para}$):</strong> $&lt; 1$ Hz (Often not visible).</li>
</ul>
</li>
</ul>
<h4 id="2-Identifying-Labile-Protons-The-D-2O-Shake-重水交换">2. Identifying Labile Protons: The $D_2O$ Shake (重水交换)</h4>
<p>Signals from protons attached to heteroatoms (OH, NH, SH, COOH) can be broad or confusing.</p>
<ul>
<li><strong>Mechanism:</strong> These protons are “labile” (acidic) and exchange rapidly with solvent protons.</li>
<li><strong>Method:</strong>
<ol>
<li>Run standard $^1H$ NMR.</li>
<li>Add Deuterium Oxide ($D_2O$) and shake the tube.</li>
<li><strong>Result:</strong> The labile $H$ is replaced by $D$ ($R-OH \rightarrow R-OD$). Since Deuterium is invisible in $^1H$ NMR, the <strong>signal disappears</strong>.</li>
</ol>
</li>
<li><strong>Utility:</strong> Confirms the presence of Alcohol, Amine, or Carboxylic acid functional groups.</li>
</ul>
<h4 id="3-Carbon-13-NMR-13-C-NMR-碳谱">3. Carbon-13 NMR ($^{13}C$ NMR) - 碳谱</h4>
<h5 id="Key-Differences-from-1H-NMR">Key Differences from $^1H$ NMR</h5>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">Proton ($^1H$)</th>
<th style="text-align:left">Carbon ($^{13}C$)</th>
<th style="text-align:left">Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Natural Abundance</strong></td>
<td style="text-align:left">~99%</td>
<td style="text-align:left"><strong>1.1%</strong></td>
<td style="text-align:left">$^{13}C$ is a “dilute” spin system; $^{12}C$ is invisible.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Sensitivity</strong></td>
<td style="text-align:left">High</td>
<td style="text-align:left"><strong>Low</strong></td>
<td style="text-align:left">Requires more sample and longer acquisition times (more scans).</td>
</tr>
<tr>
<td style="text-align:left"><strong>Chemical Shift</strong></td>
<td style="text-align:left">0–14 ppm</td>
<td style="text-align:left"><strong>0–220 ppm</strong></td>
<td style="text-align:left">Greater dispersion; less peak overlap.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Coupling</strong></td>
<td style="text-align:left">Yes (H-H)</td>
<td style="text-align:left"><strong>No</strong> (Decoupled)</td>
<td style="text-align:left">Spectra appear as singlet lines.</td>
</tr>
</tbody>
</table>
<h5 id="Interpretation-Rules">Interpretation Rules</h5>
<ul>
<li><strong>Proton Decoupling (质子去偶):</strong> Standard $^{13}C$ spectra are run in “broadband decoupled” mode to remove C-H splitting. Every chemically equivalent Carbon appears as a <strong>single sharp line</strong>.</li>
<li><strong>No Integration:</strong> Peak height does not strictly correlate with the number of carbons (due to relaxation time differences), so we do not integrate $^{13}C$ signals.</li>
<li><strong>Shift Regions:</strong>
<ul>
<li><strong>0–50 ppm:</strong> Aliphatic ($CH_3, CH_2, CH$).</li>
<li><strong>100–160 ppm:</strong> Aromatic / Alkenes.</li>
<li><strong>160–220 ppm:</strong> Carbonyls ($C=O$), specifically Ketones/Aldehydes (&gt;190 ppm) and Acids/Esters (~170 ppm).</li>
</ul>
</li>
</ul>
<h4 id="4-Advanced-Structural-Techniques">4. Advanced Structural Techniques</h4>
<h5 id="DEPT-135-Distortionless-Enhancement-by-Polarization-Transfer">DEPT-135 (Distortionless Enhancement by Polarization Transfer)</h5>
<p>A sequence used to distinguish between $CH_3$, $CH_2$, $CH$, and Quaternary Carbons ($C_q$).</p>
<table>
<thead>
<tr>
<th style="text-align:left">Carbon Type</th>
<th style="text-align:left">DEPT-135 Signal Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>$CH$ and $CH_3$</strong></td>
<td style="text-align:left"><strong>Positive</strong> (Up/Normal)</td>
</tr>
<tr>
<td style="text-align:left"><strong>$CH_2$</strong></td>
<td style="text-align:left"><strong>Negative</strong> (Inverted/Down)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Quaternary ($C_q$)</strong></td>
<td style="text-align:left"><strong>Invisible</strong> (No signal)</td>
</tr>
</tbody>
</table>
<ul>
<li><em>Note:</em> By comparing the standard $^{13}C$ spectrum (shows all C) with the DEPT-135, you can identify the “missing” peaks as Quaternary carbons (e.g., carbonyls or substituted ring carbons).</li>
</ul>
<h5 id="2D-NMR-二维核磁">2D NMR (二维核磁)</h5>
<p>Used when 1D spectra are too crowded or complex.</p>
<ul>
<li><strong>COSY (Correlation Spectroscopy):</strong> Shows which <strong>Protons</strong> are coupling to each other ($H-H$ correlation). Used to trace the carbon skeleton connectivity.</li>
<li><strong>HSQC / HMQC:</strong> Shows which <strong>Proton</strong> is attached to which <strong>Carbon</strong> ($H-C$ correlation).</li>
</ul>
<h4 id="5-Clinical-Relevance-Magnetic-Resonance-Imaging-MRI-核磁共振成像">5. Clinical Relevance: Magnetic Resonance Imaging (MRI) - 核磁共振成像</h4>
<p>MRI is essentially NMR spectroscopy applied to the water content of the human body.</p>
<ul>
<li><strong>Mechanism:</strong>
<ul>
<li>Detects protons in <strong>water ($H_2O$)</strong> and <strong>fat</strong> within tissues.</li>
<li>Uses a massive superconducting magnet (typically 1.5T to 3T).</li>
<li>Non-invasive and uses <strong>non-ionising radiation</strong> (safer than CT/X-rays).</li>
</ul>
</li>
<li><strong>Contrast ($T_1$ and $T_2$ Relaxation):</strong>
<ul>
<li>Different tissues (muscle, fat, cerebrospinal fluid, tumour) contain water in different physical environments.</li>
<li>The <strong>Relaxation Times</strong> ($T_1$ and $T_2$)—the time it takes for spins to return to equilibrium—differ between these tissues, creating image contrast.</li>
</ul>
</li>
<li><strong>Contrast Agents:</strong>
<ul>
<li><strong>Gadolinium ($Gd^{3+}$):</strong> A paramagnetic metal used to alter the relaxation time of water protons nearby, highlighting blood vessels or tumours.</li>
</ul>
</li>
</ul>
<h4 id="6-Exam-Focus-Summary-Checklist">6. Exam Focus / Summary Checklist</h4>
<ul>
<li>[ ] <strong>Calculate $J$:</strong> If peaks are at 3000 Hz and 3007 Hz, $J = 7$ Hz. This value is constant regardless of whether the machine is 300 MHz or 600 MHz.</li>
<li>[ ] <strong>Identify Isomers:</strong> Trans-alkene = Large $J$ (~16Hz); Cis-alkene = Medium $J$ (~10Hz).</li>
<li>[ ] <strong>Labile Protons:</strong> If a peak disappears after adding $D_2O$, it is likely an $-OH$ or $-NH$.</li>
<li>[ ] <strong>DEPT Interpretation:</strong>
<ul>
<li>Peak pointing <strong>DOWN</strong> = $CH_2$.</li>
<li>Peak pointing <strong>UP</strong> = $CH$ or $CH_3$.</li>
<li>Peak <strong>Missing</strong> (vs normal spectrum) = Quaternary $C$.</li>
</ul>
</li>
</ul>
<h3 id="LECTURE24-01-Core-Concept-21-Pharmaceutical-analysis-1">LECTURE24 01 Core Concept 21 Pharmaceutical analysis 1</h3>
<p><strong>Core Concept:</strong> Ensuring medicines are safe, effective, and of high quality through rigorous testing and systems.</p>
<h4 id="1-Quality-Assurance-vs-Quality-Control-QA-与-QC-的区别">1. Quality Assurance vs. Quality Control (QA 与 QC 的区别)</h4>
<p>This is a fundamental concept in the pharmaceutical industry.</p>
<h5 id="Quality-Assurance-QA-质量保证">Quality Assurance (QA - 质量保证)</h5>
<ul>
<li><strong>Definition:</strong> The sum total of the organised arrangements made with the object of ensuring that medicinal products are of the quality required for their intended use.</li>
<li><strong>Focus:</strong> <strong>Prevention (预防)</strong>.</li>
<li><strong>Scope:</strong> It is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It involves the <em>design</em> of the system.</li>
<li><strong>Key Idea:</strong> “Quality is built into the product, not tested into it.” (GMP principles).</li>
</ul>
<h5 id="Quality-Control-QC-质量控制">Quality Control (QC - 质量控制)</h5>
<ul>
<li><strong>Definition:</strong> That part of GMP concerned with sampling, specifications, and testing.</li>
<li><strong>Focus:</strong> <strong>Detection (检测)</strong>.</li>
<li><strong>Scope:</strong> Documentation, sampling, and release procedures. It ensures that materials are not released for use, nor products released for sale, until their quality has been judged to be satisfactory.</li>
<li><strong>Key Idea:</strong> The actual <em>testing</em> of the raw materials and finished products.</li>
</ul>
<h4 id="2-Regulatory-Framework-Standards-法规与标准">2. Regulatory Framework &amp; Standards (法规与标准)</h4>
<h5 id="Pharmacopoeias-药典">Pharmacopoeias (药典)</h5>
<p>Official publications containing quality standards for medicinal products.</p>
<ul>
<li><strong>BP (British Pharmacopoeia):</strong> The standard in the UK.</li>
<li><strong>USP (United States Pharmacopeia):</strong> US standard.</li>
<li><strong>Ph. Eur. (European Pharmacopoeia):</strong> European standard.</li>
<li><strong>JP (Japanese Pharmacopoeia).</strong></li>
</ul>
<h5 id="ICH-Guidelines-国际协调理事会指南">ICH Guidelines (国际协调理事会指南)</h5>
<p>The <strong>International Council for Harmonisation (ICH)</strong> brings together regulatory authorities and pharma industry to discuss scientific and technical aspects of drug registration.</p>
<ul>
<li><strong>Q-Series (Quality Guidelines):</strong> Most relevant to analysis.
<ul>
<li><strong>Q1:</strong> Stability (稳定性).</li>
<li><strong>Q2:</strong> <strong>Analytical Validation (分析方法验证)</strong> - Crucial for ensuring your method works.</li>
<li><strong>Q3:</strong> Impurities (杂质).</li>
<li><strong>Q6:</strong> Specifications (质量标准).</li>
</ul>
</li>
</ul>
<h4 id="3-Types-of-Analysis-分析类型">3. Types of Analysis (分析类型)</h4>
<h5 id="A-Qualitative-Analysis-定性分析">A. Qualitative Analysis (定性分析)</h5>
<ul>
<li><strong>Question:</strong> “What is it?” (Identification).</li>
<li><strong>Methods:</strong> IR Spectroscopy, Melting Point, Colour tests.</li>
</ul>
<h5 id="B-Quantitative-Analysis-定量分析">B. Quantitative Analysis (定量分析)</h5>
<ul>
<li><strong>Question:</strong> “How much is there?” (Assay).</li>
<li><strong>Methods:</strong> Titration, HPLC, UV-Vis.</li>
<li><strong>Limit Tests:</strong> A semi-quantitative test to ensure impurities (e.g., heavy metals, chlorides) are below a certain limit.</li>
</ul>
<h5 id="C-Classical-vs-Instrumental-Methods">C. Classical vs. Instrumental Methods</h5>
<ul>
<li><strong>Classical (Wet Chemistry):</strong> Titrimetry, Gravimetry.
<ul>
<li><em>Pros:</em> Absolute methods (don’t always need a standard), cheap, high precision for macro amounts.</li>
<li><em>Cons:</em> Slow, not sensitive enough for trace analysis.</li>
</ul>
</li>
<li><strong>Instrumental:</strong> Chromatography (HPLC, GC), Spectroscopy (UV, IR, NMR).
<ul>
<li><em>Pros:</em> Sensitive, selective, fast, can measure trace amounts.</li>
<li><em>Cons:</em> Expensive, requires reference standards.</li>
</ul>
</li>
</ul>
<h4 id="4-Titrimetry-Volumetric-Analysis-滴定分析">4. Titrimetry (Volumetric Analysis - 滴定分析)</h4>
<p>Despite being “old-school,” titration is still widely used in pharmacopoeias for <strong>Assay</strong> (content determination) of raw materials because it offers high precision.</p>
<h5 id="Principles">Principles</h5>
<ul>
<li><strong>Stoichiometry:</strong> The reaction between the analyte and titrant must have a known, fixed ratio (e.g., 1:1).</li>
<li><strong>Equivalence Point (化学计量点):</strong> The theoretical point where the reaction is complete.</li>
<li><strong>End Point (终点):</strong> The point where we <em>see</em> a change (e.g., indicator colour change). Ideally, End Point $\approx$ Equivalence Point.</li>
</ul>
<h5 id="Types-of-Titrations">Types of Titrations</h5>
<h6 id="1-Acid-Base-Titration-Aqueous-酸碱滴定（水相）">1. Acid-Base Titration (Aqueous) - 酸碱滴定（水相）</h6>
<ul>
<li><strong>Concept:</strong> Neutralisation reaction ($H^+ + OH^- \rightarrow H_2O$).</li>
<li><strong>Indicators:</strong> Weak acids or bases that change colour depending on pH (Henerson-Hasselbalch equation).
<ul>
<li><em>Phenolphthalein:</em> Colourless (Acid) $\rightarrow$ Pink (Base). Range pH 8-10.</li>
<li><em>Methyl Orange:</em> Red (Acid) $\rightarrow$ Yellow (Base). Range pH 3-4.5.</li>
</ul>
</li>
<li><strong>Application:</strong> Strong acid/base drugs (e.g., Aspirin assay - back titration).</li>
</ul>
<h6 id="2-Non-Aqueous-Titration-Non-Aqueous-非水滴定">2. Non-Aqueous Titration (Non-Aqueous) - 非水滴定</h6>
<ul>
<li><strong>Why use it?</strong> Many drugs are <strong>weak bases</strong> (amines) or <strong>weak acids</strong> that do not dissociate well in water, making the endpoint sharp impossible to see. Water acts as a competing base.</li>
<li><strong>Principle:</strong> Use a solvent that enhances the acidic/basic strength of the analyte.</li>
<li><strong>Solvent:</strong> <strong>Glacial Acetic Acid (冰醋酸)</strong> is commonly used for weak bases. It removes water and acts as a protogenic solvent.</li>
<li><strong>Titrant:</strong> <strong>Perchloric Acid ($HClO_4$)</strong> in acetic acid (Strongest acid in non-aqueous media).</li>
<li><strong>Indicator:</strong> Crystal Violet.</li>
<li><strong>Clinical Example:</strong> Assay of <strong>Adrenaline</strong>, Morphine, Codeine (Weak bases).</li>
</ul>
<h6 id="3-Oxidation-Reduction-Redox-Titration-氧化还原滴定">3. Oxidation-Reduction (Redox) Titration - 氧化还原滴定</h6>
<ul>
<li><strong>Concept:</strong> Electron transfer.</li>
<li><strong>Titrants:</strong> Iodine ($I_2$), Permanganate ($KMnO_4$), Cerium ($Ce^{4+}$).</li>
<li><strong>Iodometry (碘量法):</strong> Indirect titration. Excess iodide ($I^-$) is added to an oxidising agent, releasing Iodine ($I_2$), which is then titrated with Thiosulfate.
<ul>
<li><em>Indicator:</em> Starch (Blue-Black $\rightarrow$ Colourless).</li>
</ul>
</li>
</ul>
<h6 id="4-Complexometric-Titration-配位滴定">4. Complexometric Titration - 配位滴定</h6>
<ul>
<li><strong>Concept:</strong> Metal ion + Ligand $\rightarrow$ Complex.</li>
<li><strong>Reagent:</strong> <strong>EDTA</strong> (Ethylenediaminetetraacetic acid). It forms stable 1:1 complexes with most metal ions.</li>
<li><strong>Application:</strong> Analysis of Calcium, Magnesium, Zinc (e.g., Calcium Carbonate supplements).</li>
<li><strong>Indicator:</strong> Mordant Black 11 (Eriochrome Black T).</li>
</ul>
<h6 id="5-Calculations-Back-Titration-反滴定">5. Calculations: Back Titration (反滴定)</h6>
<p>Used when the reaction is slow, or the sample is insoluble (e.g., Aspirin/Acetylsalicylic Acid).</p>
<p><strong>Steps:</strong></p>
<ol>
<li>Add a <strong>known excess</strong> of reagent (e.g., excess NaOH to Aspirin).</li>
<li>Allow the reaction to complete (hydrolysis of Aspirin).</li>
<li>Titrate the <strong>remaining unreacted</strong> NaOH with acid (HCl).</li>
<li><strong>Calculation:</strong>
<ul>
<li>Total NaOH added - Unreacted NaOH = NaOH reacted with Drug.</li>
<li>Use stoichiometry to find the amount of Drug.</li>
</ul>
</li>
</ol>
<h4 id="Summary-Checklist-复习清单">Summary Checklist (复习清单)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Method</th>
<th style="text-align:left">Key Reagent/Condition</th>
<th style="text-align:left">Target Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Aqueous Acid-Base</strong></td>
<td style="text-align:left">NaOH / HCl</td>
<td style="text-align:left">Strong acids/bases</td>
</tr>
<tr>
<td style="text-align:left"><strong>Non-Aqueous</strong></td>
<td style="text-align:left">$HClO_4$ in Acetic Acid</td>
<td style="text-align:left"><strong>Weak bases</strong> (Adrenaline, Morphine)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Redox</strong></td>
<td style="text-align:left">Iodine / Thiosulfate</td>
<td style="text-align:left">Oxidisable/Reducible drugs</td>
</tr>
<tr>
<td style="text-align:left"><strong>Complexometric</strong></td>
<td style="text-align:left">EDTA</td>
<td style="text-align:left">Metal ions ($Ca^{2+}, Mg^{2+}$)</td>
</tr>
</tbody>
</table>
<ul>
<li>[ ] <strong>Difference between QA and QC:</strong> Prevention vs. Detection.</li>
<li>[ ] <strong>Why Non-Aqueous?</strong> Because water competes with weak bases; removing it sharpens the endpoint.</li>
<li>[ ] <strong>ICH Q2:</strong> Stands for Analytical Validation.</li>
</ul>
<h3 id="LECTURE28-01-Core-Concept-25-Pharmaceutical-analysis-2">LECTURE28 01 Core Concept 25 Pharmaceutical analysis 2</h3>
<p><strong>Core Concept:</strong> The interaction between electromagnetic radiation (light) and matter (drugs) provides information about the drug’s structure and concentration.</p>
<h4 id="1-Introduction-to-Spectroscopy-光谱学简介">1. Introduction to Spectroscopy (光谱学简介)</h4>
<h5 id="The-Electromagnetic-Spectrum">The Electromagnetic Spectrum</h5>
<ul>
<li><strong>Energy Relationship:</strong> Energy is inversely proportional to wavelength ($\lambda$).
<ul>
<li>High Energy = Short Wavelength (e.g., X-rays).</li>
<li>Low Energy = Long Wavelength (e.g., Radio waves).</li>
<li>Formula: $E = h \nu = \frac{hc}{\lambda}$ ($h$=Planck’s constant).</li>
</ul>
</li>
</ul>
<h5 id="Major-Techniques-in-Pharmacy">Major Techniques in Pharmacy</h5>
<ol>
<li><strong>UV-Visible (UV-Vis):</strong> Electronic transitions (valence electrons jump to higher orbitals). Used for <strong>Quantification</strong>.</li>
<li><strong>Infrared (IR):</strong> Molecular vibrations (bond stretching/bending). Used for <strong>Identification</strong> (fingerprinting).</li>
<li><strong>NMR:</strong> Nuclear spin transitions. Used for <strong>Structural Elucidation</strong>.</li>
<li><strong>Mass Spectrometry (MS):</strong> Fragmentation of molecules. Used for Molecular Weight &amp; Structure.</li>
</ol>
<h4 id="2-UV-Visible-Spectroscopy-紫外-可见分光光度法">2. UV-Visible Spectroscopy (紫外-可见分光光度法)</h4>
<h5 id="Principles-原理">Principles (原理)</h5>
<ul>
<li><strong>Range:</strong>
<ul>
<li><strong>UV:</strong> 200 – 400 nm (Deuterium lamp source).</li>
<li><strong>Visible:</strong> 400 – 800 nm (Tungsten lamp source).</li>
</ul>
</li>
<li><strong>Mechanism:</strong> Absorption of light causes electrons to move from a Ground State (Low energy) to an Excited State (High energy).</li>
<li><strong>Chromophore (发色团):</strong> The part of the molecule responsible for light absorption (usually conjugated double bonds, aromatic rings).
<ul>
<li>Examples: Benzene rings, Carbonyl groups ($C=O$), Nitro groups ($NO_2$).</li>
</ul>
</li>
<li><strong>Auxochrome (助色团):</strong> Groups that don’t absorb light themselves but shift the absorption of the chromophore (e.g., $-OH, -NH_2$).
<ul>
<li><strong>Bathochromic Shift (Red Shift):</strong> Shift to longer $\lambda$ (lower energy).</li>
<li><strong>Hypsochromic Shift (Blue Shift):</strong> Shift to shorter $\lambda$.</li>
</ul>
</li>
</ul>
<h5 id="Electronic-Transitions">Electronic Transitions</h5>
<p>Only certain jumps are allowed:</p>
<ol>
<li><strong>$\sigma \to \sigma^*$:</strong> High energy (Vacuum UV &lt;150nm). Not useful for standard analysis (e.g., C-H bonds).</li>
<li><strong>$n \to \pi^*$:</strong> Non-bonding electrons to anti-bonding $\pi$. Lower energy, visible in UV range (e.g., Carbonyls).</li>
<li><strong>$\pi \to \pi^*$:</strong> Bonding $\pi$ to anti-bonding $\pi$. Very useful, strong absorption (e.g., Alkenes, Aromatics).</li>
</ol>
<h4 id="3-The-Beer-Lambert-Law-比尔-朗伯定律">3. The Beer-Lambert Law (比尔-朗伯定律)</h4>
<p>The fundamental law for quantitative analysis. It states that Absorbance is directly proportional to concentration and path length.</p>
<h5 id="The-Equation">The Equation</h5>
<p>$$A = \log_{10} \left( \frac{I_0}{I} \right) = \epsilon \cdot c \cdot l$$</p>
<ul>
<li><strong>$A$:</strong> Absorbance (No units). <em>Note: Formerly called Optical Density (OD).</em></li>
<li><strong>$I_0$:</strong> Intensity of incident light.</li>
<li><strong>$I$:</strong> Intensity of transmitted light.</li>
<li><strong>$l$:</strong> Path length (usually <strong>1 cm</strong>).</li>
<li><strong>$c$:</strong> Concentration (Molar, $mol/L$).</li>
<li><strong>$\epsilon$:</strong> <strong>Molar Absorptivity</strong> (or Molar Extinction Coefficient). Units: $L \cdot mol^{-1} \cdot cm^{-1}$. Constant for a specific drug at a specific $\lambda$.</li>
</ul>
<h5 id="The-“A-one-one”-A-1-1cm">The “A-one-one” $A(1%, 1cm)$</h5>
<p>In the British Pharmacopoeia (BP), concentration is often expressed in <strong>% w/v</strong> (g/100ml) rather than Molar.<br>
$$A = A(1%, 1cm) \times c \times l$$</p>
<ul>
<li><strong>$c$:</strong> Concentration in <strong>% w/v</strong>.</li>
<li><strong>$A(1%, 1cm)$:</strong> Specific Absorbance. The absorbance of a 1% solution in a 1 cm cell.</li>
</ul>
<h5 id="Limitations-of-Beer’s-Law-Deviations">Limitations of Beer’s Law (Deviations)</h5>
<p>The linear relationship ($A \propto c$) breaks down if:</p>
<ol>
<li><strong>Concentration is too high:</strong> Molecules interact with each other (Real limit: $A$ should be &lt; 1.0 or 1.5).</li>
<li><strong>Polychromatic Light:</strong> The law assumes monochromatic light (single wavelength).</li>
<li><strong>Stray Light:</strong> Light bypassing the sample hits the detector.</li>
<li><strong>Chemical changes:</strong> pH shifts, association/dissociation, fluorescence.</li>
</ol>
<h4 id="4-Instrumentation-仪器">4. Instrumentation (仪器)</h4>
<h5 id="Key-Components">Key Components</h5>
<ol>
<li><strong>Light Source:</strong> Deuterium ($D_2$) for UV; Tungsten filament for Visible.</li>
<li><strong>Monochromator:</strong> Prism or Diffraction Grating. Selects the specific wavelength ($\lambda_{max}$).</li>
<li><strong>Sample Cell (Cuvette):</strong>
<ul>
<li><strong>Quartz:</strong> Essential for UV (&lt;350nm) as glass absorbs UV.</li>
<li><strong>Glass/Plastic:</strong> Okay for Visible (&gt;350nm).</li>
</ul>
</li>
<li><strong>Detector:</strong> Photomultiplier Tube (PMT) or Photodiode Array (PDA).</li>
</ol>
<h5 id="Single-Beam-vs-Double-Beam">Single Beam vs. Double Beam</h5>
<ul>
<li><strong>Single Beam:</strong> Must run a “Blank” (solvent only) first to zero the machine, then run sample. Slower.</li>
<li><strong>Double Beam:</strong> Light splits. One beam goes through Reference (Blank), one through Sample. The machine automatically subtracts the blank in real-time. Corrects for light source fluctuations.</li>
</ul>
<h4 id="5-Fluorescence-Spectroscopy-荧光光谱法">5. Fluorescence Spectroscopy (荧光光谱法)</h4>
<p>A more sensitive technique than UV-Vis.</p>
<h5 id="Mechanism-Jablonski-Diagram">Mechanism (Jablonski Diagram)</h5>
<ol>
<li><strong>Excitation:</strong> Molecule absorbs photon, electron jumps to high energy state ($S_0 \to S_1$). (Fast: $10^{-15} s$)</li>
<li><strong>Internal Conversion:</strong> Electron loses some energy as heat (vibrational relaxation) dropping to the lowest level of $S_1$.</li>
<li><strong>Emission (Fluorescence):</strong> Electron falls back to Ground State ($S_0$) emitting a photon.</li>
<li><strong>Stokes Shift:</strong> The emitted light always has a <strong>longer wavelength</strong> (lower energy) than the absorbed light because some energy was lost as heat.
<ul>
<li>$\lambda_{emission} &gt; \lambda_{excitation}$</li>
</ul>
</li>
</ol>
<h5 id="Comparison-UV-vs-Fluorescence">Comparison: UV vs. Fluorescence</h5>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">UV-Vis Absorption</th>
<th style="text-align:left">Fluorescence Emission</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Measurement</strong></td>
<td style="text-align:left">Difference in light intensity ($I_0$ vs $I$)</td>
<td style="text-align:left">Absolute light emitted against dark background</td>
</tr>
<tr>
<td style="text-align:left"><strong>Sensitivity</strong></td>
<td style="text-align:left">Moderate ($10^{-5} M$)</td>
<td style="text-align:left"><strong>High</strong> ($10^{-9} M$ - Nanomolar)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Selectivity</strong></td>
<td style="text-align:left">Low (Many things absorb UV)</td>
<td style="text-align:left">High (Fewer things fluoresce)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Linearity</strong></td>
<td style="text-align:left">Good at moderate conc.</td>
<td style="text-align:left">Only at very low conc.</td>
</tr>
<tr>
<td style="text-align:left"><strong>Structure</strong></td>
<td style="text-align:left">Conjugated systems</td>
<td style="text-align:left">Rigid, planar, conjugated systems</td>
</tr>
</tbody>
</table>
<h5 id="Quenching-猝灭">Quenching (猝灭)</h5>
<p>A reduction in fluorescence intensity.</p>
<ul>
<li><strong>Collisional Quenching:</strong> Excited molecule hits a quencher (e.g., Oxygen, Halides) and loses energy without emitting light.</li>
<li><strong>Concentration Quenching (Self-quenching):</strong> At high concentrations, molecules re-absorb emitted light.</li>
</ul>
<h4 id="6-Applications-应用">6. Applications (应用)</h4>
<ol>
<li><strong>Quantitative Assay:</strong> Determining concentration of drugs in formulations (e.g., Paracetamol tablets).</li>
<li><strong>pKa Determination:</strong> Absorbance often changes with pH (e.g., Phenol shifts $\lambda_{max}$ when ionized).</li>
<li><strong>Dissolution Testing:</strong> Continuous monitoring of drug release from tablets.</li>
<li><strong>Impurity Testing:</strong> Detecting impurities that have different absorption spectra.</li>
</ol>
<h4 id="Summary-Checklist-复习清单-2">Summary Checklist (复习清单)</h4>
<ul>
<li>[ ] <strong>Beer-Lambert Law:</strong> Can you calculate Concentration if given Absorbance and $A(1%, 1cm)$?
<ul>
<li><em>Formula:</em> $c (% w/v) = \frac{Absorbance}{A(1%, 1cm)}$</li>
</ul>
</li>
<li>[ ] <strong>Quartz vs Glass:</strong> Why use Quartz for UV? (Glass absorbs UV light).</li>
<li>[ ] <strong>Stokes Shift:</strong> Why is emission wavelength always longer? (Energy loss due to vibrational relaxation).</li>
<li>[ ] <strong>Bathochromic Shift:</strong> Red shift (to longer wavelength).</li>
</ul>
<h2 id="Core-Concept-Oncology">Core Concept - Oncology</h2>
<h3 id="LECTURE15-01-Core-Concept-13-Cancer-and-immune-disease">LECTURE15 01 Core Concept 13 Cancer and immune disease</h3>
<p><strong>Core Concept:</strong> Cancer is a genetic disease of uncontrolled cell growth. The immune system can recognize and destroy cancer cells, but tumors evolve mechanisms to escape this surveillance. Immunotherapy aims to restore this anti-tumor immunity.</p>
<h4 id="1-What-is-Cancer-什么是癌症">1. What is Cancer? (什么是癌症)</h4>
<ul>
<li><strong>Definition:</strong> A group of diseases characterized by the uncontrolled growth and spread of abnormal cells. It is fundamentally a <strong>genetic disease</strong> caused by mutations in DNA.</li>
<li><strong>Benign vs. Malignant (良性与恶性):</strong>
<ul>
<li><strong>Benign:</strong> Localized, does not invade surrounding tissue or metastasize.</li>
<li><strong>Malignant:</strong> Invades surrounding tissues and can spread (metastasize) to distant organs via blood or lymph.</li>
</ul>
</li>
<li><strong>Carcinogenesis (致癌过程):</strong> A multi-step process involving the accumulation of mutations in:
<ul>
<li><strong>Oncogenes (原癌基因):</strong> “Accelerators” (e.g., <em>RAS</em>, <em>MYC</em>). Mutations lead to gain of function $\rightarrow$ uncontrolled division.</li>
<li><strong>Tumour Suppressor Genes (抑癌基因):</strong> “Brakes” (e.g., <em>p53</em>, <em>RB</em>). Mutations lead to loss of function $\rightarrow$ inability to stop division or repair DNA.</li>
</ul>
</li>
</ul>
<h5 id="The-Hallmarks-of-Cancer-癌症的特征-Hanahan-Weinberg">The Hallmarks of Cancer (癌症的特征 - Hanahan &amp; Weinberg)</h5>
<ol>
<li><strong>Sustaining Proliferative Signaling:</strong> Cells grow without external signals.</li>
<li><strong>Evading Growth Suppressors:</strong> Ignoring “stop” signals (e.g., contact inhibition).</li>
<li><strong>Resisting Cell Death:</strong> Avoiding Apoptosis (programmed cell death).</li>
<li><strong>Enabling Replicative Immortality:</strong> Extending telomeres (Telomerase activation).</li>
<li><strong>Inducing Angiogenesis:</strong> Creating new blood vessels to supply oxygen/nutrients.</li>
<li><strong>Activating Invasion and Metastasis:</strong> Spreading to other parts of the body.
<ul>
<li><em>Emerging Hallmarks:</em> Deregulating cellular energetics (Warburg effect), Avoiding immune destruction.</li>
</ul>
</li>
</ol>
<h4 id="2-Tumour-Immunology-肿瘤免疫学">2. Tumour Immunology (肿瘤免疫学)</h4>
<h5 id="The-Immune-Surveillance-Theory-免疫监视理论">The Immune Surveillance Theory (免疫监视理论)</h5>
<p>The immune system constantly identifies and eliminates pre-cancerous cells. However, cancer cells are “Self” cells, making them harder to target than bacteria.</p>
<h5 id="Tumour-Antigens-肿瘤抗原">Tumour Antigens (肿瘤抗原)</h5>
<p>How does the immune system see cancer?</p>
<ul>
<li><strong>Tumour-Specific Antigens (TSAs):</strong> Unique to cancer cells (e.g., mutated p53 products, viral antigens like HPV). Ideal targets.</li>
<li><strong>Tumour-Associated Antigens (TAAs):</strong> Normal proteins expressed at abnormally high levels or in wrong tissues (e.g., HER2, CEA).</li>
</ul>
<h5 id="Cancer-Immunoediting-The-“3-Es”-癌症免疫编辑">Cancer Immunoediting: The “3 Es” (癌症免疫编辑)</h5>
<p>The dynamic process between the tumour and immune system:</p>
<ol>
<li><strong>Elimination (清除):</strong> Innate and adaptive immunity (NK cells, CD8+ T cells) detect and destroy cancer cells.</li>
<li><strong>Equilibrium (平衡):</strong> Some cancer cells survive but are kept in check. They undergo genetic instability and selection.</li>
<li><strong>Escape (逃逸):</strong> Tumour cells evolve mechanisms to suppress the immune system or hide from it, leading to clinical disease.</li>
</ol>
<h5 id="Mechanisms-of-Immune-Escape-免疫逃逸机制">Mechanisms of Immune Escape (免疫逃逸机制)</h5>
<ul>
<li><strong>Downregulation of MHC Class I:</strong> “Hiding” from CD8+ T cells.</li>
<li><strong>Expression of Inhibitory Ligands:</strong> e.g., <strong>PD-L1</strong> on tumour surface binds to PD-1 on T cells to turn them off.</li>
<li><strong>Recruitment of Suppressive Cells:</strong> Tregs (Regulatory T cells), MDSCs (Myeloid-derived suppressor cells) which secrete immunosuppressive cytokines (IL-10, TGF-$\beta$).</li>
</ul>
<h4 id="3-Cancer-Immunotherapy-癌症免疫疗法">3. Cancer Immunotherapy (癌症免疫疗法)</h4>
<p>Goal: To “release the brakes” on the immune system or engineer it to attack cancer.</p>
<h5 id="A-Immune-Checkpoint-Inhibitors-免疫检查点抑制剂">A. Immune Checkpoint Inhibitors (免疫检查点抑制剂)</h5>
<p>Checkpoints are normal “off switches” to prevent autoimmunity. Cancers hijack them.</p>
<table>
<thead>
<tr>
<th style="text-align:left">Checkpoint</th>
<th style="text-align:left">Mechanism</th>
<th style="text-align:left">Drug Examples (Monoclonal Antibodies)</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>CTLA-4</strong></td>
<td style="text-align:left">Operates in Lymph Nodes. Prevents T-cell <em>activation</em> (priming phase).</td>
<td style="text-align:left"><strong>Ipilimumab</strong> (Yervoy)</td>
</tr>
<tr>
<td style="text-align:left"><strong>PD-1</strong></td>
<td style="text-align:left">Operates in Peripheral Tissue (Tumour). Receptor on T-cells. “Exhaustion” signal.</td>
<td style="text-align:left"><strong>Nivolumab</strong> (Opdivo), <strong>Pembrolizumab</strong> (Keytruda)</td>
</tr>
<tr>
<td style="text-align:left"><strong>PD-L1</strong></td>
<td style="text-align:left">Ligand on Tumour Cells. Binds to PD-1 to shut down T-cell.</td>
<td style="text-align:left"><strong>Atezolizumab</strong> (Tecentriq), Durvalumab</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Clinical Success:</strong> remarkably effective in Melanoma, Lung Cancer (NSCLC), Renal Cancer.</li>
<li><strong>Side Effects:</strong> <strong>Immune-Related Adverse Events (irAEs)</strong>.
<ul>
<li>The immune system attacks normal tissue: Colitis (diarrhoea), Pneumonitis (lung inflammation), Dermatitis (rash), Hepatitis, Thyroiditis.</li>
<li><em>Management:</em> High-dose Corticosteroids (to suppress the overactive immune system).</li>
</ul>
</li>
</ul>
<h5 id="B-CAR-T-Cell-Therapy-嵌合抗原受体T细胞疗法">B. CAR-T Cell Therapy (嵌合抗原受体T细胞疗法)</h5>
<p>“Living Drug” - Engineering the patient’s own cells.</p>
<ol>
<li><strong>Collection:</strong> T cells are harvested from the patient (Leukapheresis).</li>
<li><strong>Engineering:</strong> Genetically modified <em>ex vivo</em> to express a <strong>Chimeric Antigen Receptor (CAR)</strong>.
<ul>
<li><em>The CAR:</em> Fuses an antibody fragment (recognizes cancer directly, independent of MHC) with T-cell signaling domains.</li>
</ul>
</li>
<li><strong>Expansion:</strong> Grown in the lab to billions.</li>
<li><strong>Infusion:</strong> Infused back into the patient.</li>
</ol>
<ul>
<li><strong>Target:</strong> Usually <strong>CD19</strong> (found on B-cell Leukemias and Lymphomas).</li>
<li><strong>Toxicities:</strong>
<ul>
<li><strong>Cytokine Release Syndrome (CRS):</strong> “Cytokine Storm” (Fever, Hypotension). Treated with <strong>Tocilizumab</strong> (Anti-IL-6).</li>
<li><strong>Neurotoxicity (ICANS):</strong> Confusion, seizures.</li>
</ul>
</li>
</ul>
<h5 id="C-Other-Modalities">C. Other Modalities</h5>
<ul>
<li><strong>Cancer Vaccines:</strong> Therapeutic (e.g., Provenge for prostate) or Prophylactic (e.g., HPV vaccine).</li>
<li><strong>Bi-specific T-cell Engagers (BiTEs):</strong> Antibodies with two arms—one grabs the cancer cell, one grabs the T cell, forcing them together (e.g., Blinatumomab).</li>
</ul>
<h4 id="4-Summary-Traditional-vs-Immuno-Oncology">4. Summary: Traditional vs. Immuno-Oncology</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">Chemotherapy</th>
<th style="text-align:left">Targeted Therapy</th>
<th style="text-align:left">Immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Target</strong></td>
<td style="text-align:left">Rapidly dividing cells (DNA/Microtubules)</td>
<td style="text-align:left">Specific Mutations (e.g., EGFR, BRAF)</td>
<td style="text-align:left"><strong>The Patient’s Immune System</strong></td>
</tr>
<tr>
<td style="text-align:left"><strong>Specificity</strong></td>
<td style="text-align:left">Low (Kills hair, gut cells too)</td>
<td style="text-align:left">High</td>
<td style="text-align:left">Variable (Depends on antigen)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Duration</strong></td>
<td style="text-align:left">Effect stops when drug stops</td>
<td style="text-align:left">Resistance often develops quickly</td>
<td style="text-align:left"><strong>Durable Memory</strong> (Potential for long-term cure)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Side Effects</strong></td>
<td style="text-align:left">Nausea, Hair loss, Neutropenia</td>
<td style="text-align:left">Specific to target</td>
<td style="text-align:left"><strong>Autoimmune-like (irAEs)</strong></td>
</tr>
</tbody>
</table>
<h3 id="36">36</h3>
<h3 id="38">38</h3>
<h3 id="39">39</h3>
<h3 id="35">35</h3>
<h2 id="Core-Concept-Professional-Skills-Law">Core Concept - Professional Skills &amp; Law</h2>
<h3 id="LECTURE25-01-Core-Concept-22-Interactive-Lecture-CDs-instalments-and-emergency-supply">LECTURE25 01 Core Concept 22 Interactive Lecture CDs, instalments and emergency supply</h3>
<p><strong>Focus:</strong> Legal requirements for Schedule 2 &amp; 3 CDs, FP10MDA forms, and Emergency Supply regulations.</p>
<h4 id="1-Controlled-Drug-Prescriptions-管制药物处方-Schedule-2-3">1. Controlled Drug Prescriptions (管制药物处方 - Schedule 2 &amp; 3)</h4>
<p>Prescriptions for Schedule 2 (e.g., Morphine, Methadone) and Schedule 3 (e.g., Gabapentin, Tramadol, Midazolam) generally have stricter writing requirements than standard POMs.</p>
<h5 id="A-Legal-Requirements-必须满足的法律要求">A. Legal Requirements (必须满足的法律要求)</h5>
<p>The prescriber <strong>MUST</strong> include the following on the prescription (Rx):</p>
<ol>
<li><strong>Signature:</strong> Usually usually be in ink and handwritten by the prescriber (unless it’s a compliant Electronic Prescription Service - EPS).</li>
<li><strong>Date:</strong> Can be computer-generated.
<ul>
<li><strong>Validity (有效期):</strong>
<ul>
<li><strong>Schedule 2, 3 &amp; 4:</strong> Valid for <strong>28 days</strong> from the date on the Rx (or the start date).</li>
<li><strong>Schedule 5:</strong> Valid for <strong>6 months</strong> (same as standard POM).</li>
</ul>
</li>
</ul>
</li>
<li><strong>Prescriber’s Address:</strong> Must be in the UK.</li>
<li><strong>Patient’s Name &amp; Address:</strong> Must be fixed (No “No Fixed Abode” allowed generally for CDs unless specific arrangements).</li>
<li><strong>Dose (剂量):</strong> Must be clear and specific.
<ul>
<li><em>“One as directed”</em> (遵医嘱) is <strong>NOT</strong> acceptable for Sch 2 &amp; 3. It must say e.g., “One tablet twice daily”.</li>
<li><em>“As required”</em> (PRN) is acceptable <strong>ONLY IF</strong> a maximum frequency/dose is stated (e.g., “One every 4-6 hours when required, max 4 per day”).</li>
</ul>
</li>
<li><strong>Formulation (剂型):</strong> Must be specified (e.g., “Tablets”, “Capsules”).
<ul>
<li>Even if only one form exists, it is good practice (and often legal necessity for clarity) to state it. Abbreviation like “Caps” is usually acceptable.</li>
</ul>
</li>
<li><strong>Strength (规格):</strong> Only required if the drug comes in multiple strengths.</li>
<li><strong>Total Quantity (总量):</strong>
<ul>
<li><strong>MUST be written in both WORDS and FIGURES</strong> (e.g., “10 (Ten)”).</li>
<li>This is to prevent tampering (e.g., adding a zero).</li>
</ul>
</li>
</ol>
<h5 id="B-Pharmacist-Amendments-药师修改权">B. Pharmacist Amendments (药师修改权)</h5>
<p>Pharmacists can amend <strong>minor typographical or spelling errors</strong> on Sch 2 &amp; 3 prescriptions if the prescriber’s intention is clear.</p>
<ul>
<li><strong>Can amend:</strong> Minor typos, spelling mistakes, or if the quantity is missing in <em>either</em> words or figures (but not both) and the intention is obvious.</li>
<li><strong>Cannot amend:</strong> The <strong>Signature</strong> or the <strong>Date</strong>. If these are missing, the Rx must be returned.</li>
<li><strong>Process:</strong> Amend in ink, sign, name, GPhC number, and date the amendment.</li>
</ul>
<h5 id="C-Quantity-Limits-数量限制">C. Quantity Limits (数量限制)</h5>
<ul>
<li><strong>Good Practice:</strong> Department of Health recommends a maximum of <strong>30 days’ supply</strong> for CDs.</li>
<li><strong>Legal Status:</strong> This is <strong>NOT a law</strong>, it is guidance. You <em>can</em> dispense more if clinically justified (e.g., patient going on holiday), but you should document the reason.</li>
</ul>
<h4 id="2-Instalment-Dispensing-分期调配">2. Instalment Dispensing (分期调配)</h4>
<p>Used primarily for the management of substance misuse (e.g., Methadone, Buprenorphine).</p>
<h5 id="The-FP10MDA-Form-Blue-Form">The FP10MDA Form (Blue Form)</h5>
<ul>
<li><strong>Purpose:</strong> Allows a single prescription to be dispensed to the patient in multiple “instalments” over a period (usually 14 days).</li>
<li><strong>Key Requirements:</strong>
<ol>
<li><strong>Amount per Instalment:</strong> Must state exactly how much to give each time (e.g., “60ml”).</li>
<li><strong>Interval:</strong> Must state when to give it (e.g., “Daily”, “Mon/Wed/Fri”).</li>
<li><strong>Supervision:</strong> Often requires “Supervised Consumption” (patient drinks it in front of the pharmacist).</li>
</ol>
</li>
</ul>
<h5 id="The-“Three-Day-Rule”-Missed-Doses">The “Three Day Rule” (Missed Doses)</h5>
<ul>
<li>If a patient on daily supervised maintenance (e.g., Methadone) misses <strong>3 consecutive days</strong> (三天连续漏服):
<ul>
<li><strong>Action:</strong> DO NOT DISPENSE.</li>
<li><strong>Reason:</strong> Their tolerance may have dropped, and the usual dose could now be fatal (Overdose risk).</li>
<li><strong>Procedure:</strong> Refer the patient back to the prescriber for re-titration.</li>
</ul>
</li>
</ul>
<h4 id="3-Emergency-Supply-紧急供应">3. Emergency Supply (紧急供应)</h4>
<p>Under the <strong>Human Medicines Regulations 2012</strong>, pharmacists can supply POMs without a prescription in an emergency.</p>
<h5 id="Route-A-Request-by-Prescriber-医生请求">Route A: Request by Prescriber (医生请求)</h5>
<ul>
<li>The doctor calls and asks you to give medicine to a patient, promising to send the Rx later.</li>
<li><strong>Condition:</strong> You must be satisfied the request is genuine.</li>
<li><strong>Rx Delivery:</strong> The prescriber must furnish the prescription within <strong>72 hours</strong>.</li>
<li><strong>CDs:</strong> You CANNOT supply Sch 1, 2, or 3 CDs on an emergency request <em>from a prescriber</em> (unless Phenobarbital for epilepsy).</li>
</ul>
<h5 id="Route-B-Request-by-Patient-患者请求">Route B: Request by Patient (患者请求)</h5>
<p>More common in community pharmacy (e.g., ran out of meds on weekend).</p>
<p><strong>Conditions (Interview Requirements):</strong></p>
<ol>
<li><strong>Interview:</strong> You must interview the patient (usually).</li>
<li><strong>Immediate Need:</strong> There is an immediate need for the medicine.</li>
<li><strong>Impracticable:</strong> It is impracticable for the patient to obtain a prescription (e.g., GP closed).</li>
<li><strong>Previous Treatment:</strong> The medicine has been prescribed for them before.</li>
<li><strong>Dose:</strong> You know the correct dose.</li>
</ol>
<p><strong>Restrictions on Controlled Drugs (CDs):</strong></p>
<ul>
<li><strong>General Rule:</strong> Emergency supply is <strong>NOT ALLOWED</strong> for <strong>Schedule 1, 2, or 3</strong> drugs.
<ul>
<li><em>Examples of banned supply:</em> Morphine, Oxycodone, Temazepam, Gabapentin, Tramadol.</li>
</ul>
</li>
<li><strong>The Exception:</strong> <strong>Phenobarbital</strong> (Sodium Phenobarbitone) for <strong>Epilepsy</strong> IS permitted.</li>
</ul>
<p><strong>Maximum Quantity Rules (Supply Limits):</strong></p>
<ul>
<li><strong>Schedule 4 &amp; 5 CDs (and Phenobarbital exception):</strong> Max <strong>5 days</strong> supply.</li>
<li><strong>Standard POMs:</strong> Max <strong>30 days</strong> supply.</li>
<li><strong>Exceptions to the 30-day rule:</strong>
<ul>
<li><strong>Insulin / Creams / Inhalers:</strong> Supply the <strong>smallest pack</strong> available (cannot break packs).</li>
<li><strong>Oral Contraceptives:</strong> Supply a <strong>full cycle</strong> (e.g., 21 tablets or 3 months depending on type).</li>
<li><strong>Antibiotics (Oral):</strong> Generally should not be supplied (risk of resistance), but technically allowed if smallest pack for a full course.</li>
</ul>
</li>
</ul>
<h4 id="Summary-Cheat-Sheet-复习速查表">Summary Cheat Sheet (复习速查表)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">Schedule 2 (e.g. Morphine)</th>
<th style="text-align:left">Schedule 3 (e.g. Tramadol)</th>
<th style="text-align:left">Schedule 4/5 (e.g. Diazepam)</th>
<th style="text-align:left">Standard POM</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Rx Validity</strong></td>
<td style="text-align:left">28 Days</td>
<td style="text-align:left">28 Days</td>
<td style="text-align:left">28 Days</td>
<td style="text-align:left">6 Months</td>
</tr>
<tr>
<td style="text-align:left"><strong>Total Quantity</strong></td>
<td style="text-align:left">Words &amp; Figures</td>
<td style="text-align:left">Words &amp; Figures</td>
<td style="text-align:left">Figures only (usually)</td>
<td style="text-align:left">Figures only</td>
</tr>
<tr>
<td style="text-align:left"><strong>Emergency Supply (Patient)</strong></td>
<td style="text-align:left"><strong>NO</strong></td>
<td style="text-align:left"><strong>NO</strong> (except Phenobarb)</td>
<td style="text-align:left"><strong>Yes</strong> (Max 5 days)</td>
<td style="text-align:left"><strong>Yes</strong> (Max 30 days*)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Repeat Rx Allowed?</strong></td>
<td style="text-align:left">No</td>
<td style="text-align:left">No</td>
<td style="text-align:left">Yes</td>
<td style="text-align:left">Yes</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Clinical Note:</strong></p>
<ul>
<li>Always check the <strong>date</strong> on a CD script first. If it’s &gt;28 days, it is legally invalid.</li>
<li>If a doctor forgets to write the quantity in words for Morphine, you (the pharmacist) can amend it <em>if</em> the intention is clear, but you must sign and date the amendment.</li>
</ul>
</blockquote>
<h3 id="LECTURE29-01-Core-Concept-26-Introduction-to-management-planning">LECTURE29 01 Core Concept 26 Introduction to management planning</h3>
<p><strong>Core Concept:</strong> Management is the process of getting things done through others. Planning is the foundational function of management.</p>
<h4 id="1-What-is-Management-什么是管理">1. What is Management? (什么是管理)</h4>
<h5 id="Henri-Fayol’s-5-Functions-of-Management-法约尔的五大管理职能">Henri Fayol’s 5 Functions of Management (法约尔的五大管理职能)</h5>
<p>Henri Fayol (1916) defined management as:</p>
<ol>
<li><strong>Planning (计划):</strong> Predicting the future and drawing up a plan of action. “To foresee and provide means.”</li>
<li><strong>Organising (组织):</strong> Mobilising material and human resources.</li>
<li><strong>Commanding (指挥):</strong> Leading people to achieve goals.</li>
<li><strong>Coordinating (协调):</strong> Unifying and harmonising all activities and efforts.</li>
<li><strong>Controlling (控制):</strong> Seeing that everything occurs in conformity with the established rule and command.</li>
</ol>
<h5 id="Efficiency-vs-Effectiveness-彼得·德鲁克">Efficiency vs. Effectiveness (彼得·德鲁克)</h5>
<ul>
<li><strong>Efficiency (效率):</strong> Doing things right (Process-focused).</li>
<li><strong>Effectiveness (效能):</strong> Doing the right things (Outcome-focused).</li>
<li><em>Goal:</em> Managers usually aim to be efficient, but effectiveness is often more critical for leadership.</li>
</ul>
<h4 id="2-The-Planning-Hierarchy-规划层级">2. The Planning Hierarchy (规划层级)</h4>
<p>Planning is not “one size fits all.” It happens at three distinct levels:</p>
<h5 id="1-Strategic-Planning-战略规划">1. Strategic Planning (战略规划)</h5>
<ul>
<li><strong>Scope:</strong> Long-term (3–5+ years).</li>
<li><strong>Focus:</strong> The “Big Picture.” Defines the organization’s mission, vision, and long-term goals.</li>
<li><strong>Who:</strong> Top Management (Board, CEO).</li>
<li><strong>Example:</strong> “We want to become the leading cancer research hospital in the UK.”</li>
</ul>
<h5 id="2-Tactical-Planning-战术规划">2. Tactical Planning (战术规划)</h5>
<ul>
<li><strong>Scope:</strong> Mid-term (1–3 years).</li>
<li><strong>Focus:</strong> Implementation. Breaking down strategic goals into specific departmental actions.</li>
<li><strong>Who:</strong> Middle Management.</li>
<li><strong>Example:</strong> “The Pharmacy Department will implement a new aseptic compounding unit by next year.”</li>
</ul>
<h5 id="3-Operational-Planning-运营规划">3. Operational Planning (运营规划)</h5>
<ul>
<li><strong>Scope:</strong> Short-term (Daily/Weekly/Monthly).</li>
<li><strong>Focus:</strong> Day-to-day processes and routine tasks.</li>
<li><strong>Who:</strong> Front-line Managers / Supervisors.</li>
<li><strong>Example:</strong> “Staff rostering for next week,” “Ordering stock for the weekend.”</li>
</ul>
<h5 id="3-Mission-vs-Vision-使命与愿景">3. Mission vs. Vision (使命与愿景)</h5>
<ul>
<li><strong>Mission Statement (使命):</strong>
<ul>
<li>Defines the <strong>present</strong> state.</li>
<li>Answers: “What do we do? Who do we serve? How do we serve them?”</li>
<li><em>Example:</em> “To provide high-quality pharmaceutical care to our local community.”</li>
</ul>
</li>
<li><strong>Vision Statement (愿景):</strong>
<ul>
<li>Defines the <strong>future</strong> state.</li>
<li>Answers: “Where do we want to be? What does success look like?”</li>
<li><em>Example:</em> “To be the world’s most trusted healthcare partner.”</li>
</ul>
</li>
</ul>
<h5 id="4-Strategic-Analysis-Tools-战略分析工具">4. Strategic Analysis Tools (战略分析工具)</h5>
<p>Before planning, you must analyse the environment.</p>
<h6 id="A-PESTLE-Analysis-External-Environment">A. PESTLE Analysis (External Environment)</h6>
<p>Used to scan the <strong>macro-environment</strong> (external factors you cannot control but must adapt to).</p>
<table>
<thead>
<tr>
<th style="text-align:left">Letter</th>
<th style="text-align:left">Factor</th>
<th style="text-align:left">Examples in Pharmacy</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>P</strong></td>
<td style="text-align:left"><strong>Political</strong></td>
<td style="text-align:left">NHS funding changes, Brexit implications, Trade tariffs.</td>
</tr>
<tr>
<td style="text-align:left"><strong>E</strong></td>
<td style="text-align:left"><strong>Economic</strong></td>
<td style="text-align:left">Inflation rates, drug pricing, exchange rates (importing drugs).</td>
</tr>
<tr>
<td style="text-align:left"><strong>S</strong></td>
<td style="text-align:left"><strong>Social</strong></td>
<td style="text-align:left">Ageing population, increasing demand for home-care, public health trends.</td>
</tr>
<tr>
<td style="text-align:left"><strong>T</strong></td>
<td style="text-align:left"><strong>Technological</strong></td>
<td style="text-align:left">Electronic prescribing (EPS), robotic dispensing, AI diagnosis.</td>
</tr>
<tr>
<td style="text-align:left"><strong>L</strong></td>
<td style="text-align:left"><strong>Legal</strong></td>
<td style="text-align:left">Medicines Act, GPhC regulations, Health &amp; Safety laws.</td>
</tr>
<tr>
<td style="text-align:left"><strong>E</strong></td>
<td style="text-align:left"><strong>Environmental</strong></td>
<td style="text-align:left">Carbon footprint of inhalers, waste disposal regulations.</td>
</tr>
</tbody>
</table>
<h6 id="B-SWOT-Analysis-Internal-External">B. SWOT Analysis (Internal &amp; External)</h6>
<p>Used to analyse the specific organization.</p>
<ul>
<li><strong>Internal Factors (You can control):</strong>
<ul>
<li><strong>Strengths (S):</strong> What do you do well? (e.g., “Highly trained staff,” “Good location”).</li>
<li><strong>Weaknesses (W):</strong> Where are you lacking? (e.g., “Outdated IT system,” “Staff shortages”).</li>
</ul>
</li>
<li><strong>External Factors (You cannot control):</strong>
<ul>
<li><strong>Opportunities (O):</strong> What market trends can you exploit? (e.g., “New Pharmacy First service launched”).</li>
<li><strong>Threats (T):</strong> What external forces could harm you? (e.g., “Competitor opening next door,” “Drug shortages”).</li>
</ul>
</li>
</ul>
<h5 id="5-Setting-Objectives-SMART-Goals-设定目标">5. Setting Objectives: SMART Goals (设定目标)</h5>
<p>Once the analysis is done, you set objectives. Vague goals like “Improve service” fail. Goals must be <strong>SMART</strong>:</p>
<ul>
<li><strong>S - Specific (具体):</strong> Clear and unambiguous.
<ul>
<li><em>Bad:</em> “Improve dispensing.”</li>
<li><em>Good:</em> “Reduce dispensing errors.”</li>
</ul>
</li>
<li><strong>M - Measurable (可衡量):</strong> Must have a metric.
<ul>
<li><em>Good:</em> “Reduce dispensing errors by <strong>50%</strong>.”</li>
</ul>
</li>
<li><strong>A - Achievable (可实现):</strong> Realistic given resources.</li>
<li><strong>R - Relevant (相关):</strong> Aligns with the broader mission.</li>
<li><strong>T - Time-bound (有时限):</strong> Has a deadline.
<ul>
<li><em>Final Goal:</em> “Reduce dispensing errors by 50% <strong>within the next 6 months</strong>.”</li>
</ul>
</li>
</ul>
<h4 id="Summary-Checklist-复习清单-3">Summary Checklist (复习清单)</h4>
<ul>
<li>[ ] <strong>Management Functions:</strong> Planning, Organising, Commanding, Coordinating, Controlling (Henri Fayol).</li>
<li>[ ] <strong>Planning Levels:</strong> Strategic (Long) $\rightarrow$ Tactical (Medium) $\rightarrow$ Operational (Short).</li>
<li>[ ] <strong>PESTLE:</strong> Used for External Macro-environmental analysis.</li>
<li>[ ] <strong>SWOT:</strong> Internal (Strengths/Weaknesses) + External (Opportunities/Threats).</li>
<li>[ ] <strong>SMART:</strong> Specific, Measurable, Achievable, Relevant, Time-bound.</li>
</ul>
<h3 id="LECTURE30-01-Audit-Evaluation-and-Research">LECTURE30 01 Audit, Evaluation and Research</h3>
<p><strong>Lecturer:</strong> [Name not explicitly stated in text, likely Course Lead]</p>
<h4 id="1-Context-Clinical-Governance-临床治理">1. Context: Clinical Governance (临床治理)</h4>
<ul>
<li><strong>Definition:</strong> A framework through which NHS organisations are accountable for continually improving the quality of their services and safeguarding high standards of care.</li>
<li><strong>Key Pillars:</strong> Education, Clinical Audit, Clinical Effectiveness, Risk Management, Research and Development.</li>
<li><strong>Relevance:</strong> Pharmacists use AER (Audit, Evaluation, Research) tools to measure and improve patient outcomes within this framework.</li>
</ul>
<h4 id="2-The-“AER”-Distinction-核心区别">2. The “AER” Distinction (核心区别)</h4>
<p>It is critical to distinguish between these three because they have different <strong>ethical requirements</strong> and <strong>regulatory frameworks</strong> (e.g., NHS REC approval).</p>
<h5 id="A-Research-研究">A. Research (研究)</h5>
<ul>
<li><strong>Goal:</strong> To generate <strong>new knowledge</strong> or test a hypothesis.</li>
<li><strong>Key Question:</strong> “What is the right thing to do?” (finding out something unknown).</li>
<li><strong>Characteristics:</strong>
<ul>
<li>Often involves <strong>randomisation</strong> (allocating patients to different treatments).</li>
<li>Results are intended to be <strong>generalisable</strong> (applicable to other hospitals/populations).</li>
<li>Requires strict <strong>Research Ethics Committee (REC)</strong> approval.</li>
</ul>
</li>
</ul>
<h5 id="B-Clinical-Audit-临床审计">B. Clinical Audit (临床审计)</h5>
<ul>
<li><strong>Goal:</strong> To measure practice against a <strong>pre-existing standard</strong>.</li>
<li><strong>Key Question:</strong> “Are we doing the right thing?” (Checking compliance with guidelines).</li>
<li><strong>Characteristics:</strong>
<ul>
<li>Does <strong>not</strong> involve randomisation or changing treatment; it observes current practice.</li>
<li>Aims to inform <strong>local</strong> decision-making and quality improvement, not necessarily generalisable.</li>
<li>Usually does <strong>not</strong> require Research Ethics approval (institutional approval is sufficient).</li>
</ul>
</li>
</ul>
<h5 id="C-Service-Evaluation-服务评估">C. Service Evaluation (服务评估)</h5>
<ul>
<li><strong>Goal:</strong> To judge a <strong>current service</strong> to aid local decision-making.</li>
<li><strong>Key Question:</strong> “What standard does this service achieve?”.</li>
<li><strong>Characteristics:</strong>
<ul>
<li>Measures current care without reference to a strict external standard (unlike Audit).</li>
<li>No randomisation.</li>
<li>Results are specific to the local setting.</li>
</ul>
</li>
</ul>
<h4 id="3-Comparison-Table-Determining-the-Project-Type">3. Comparison Table: Determining the Project Type</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Feature</th>
<th style="text-align:left">Research (研究)</th>
<th style="text-align:left">Clinical Audit (临床审计)</th>
<th style="text-align:left">Service Evaluation (服务评估)</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Intent</strong></td>
<td style="text-align:left">Generate <strong>new</strong> knowledge</td>
<td style="text-align:left">Improve quality of care against a <strong>standard</strong></td>
<td style="text-align:left">Judge current service</td>
</tr>
<tr>
<td style="text-align:left"><strong>Treatment</strong></td>
<td style="text-align:left">May involve experimental protocol/placebo</td>
<td style="text-align:left">Routine clinical care (no change)</td>
<td style="text-align:left">Routine clinical care</td>
</tr>
<tr>
<td style="text-align:left"><strong>Allocation</strong></td>
<td style="text-align:left">Randomisation possible</td>
<td style="text-align:left">No randomisation</td>
<td style="text-align:left">No randomisation</td>
</tr>
<tr>
<td style="text-align:left"><strong>Analysis</strong></td>
<td style="text-align:left">Statistical testing to prove hypothesis</td>
<td style="text-align:left">Comparison against target (e.g., “90% compliance”)</td>
<td style="text-align:left">Descriptive analysis</td>
</tr>
<tr>
<td style="text-align:left"><strong>Generalisability</strong></td>
<td style="text-align:left"><strong>Yes</strong> (Universal application)</td>
<td style="text-align:left"><strong>No</strong> (Local application)</td>
<td style="text-align:left"><strong>No</strong> (Local application)</td>
</tr>
<tr>
<td style="text-align:left"><strong>Ethics Approval</strong></td>
<td style="text-align:left"><strong>Required</strong> (NHS REC)</td>
<td style="text-align:left">Not usually required (Hospital governance)</td>
<td style="text-align:left">Not usually required</td>
</tr>
</tbody>
</table>
<h4 id="4-The-Clinical-Audit-Cycle-临床审计循环">4. The Clinical Audit Cycle (临床审计循环)</h4>
<p>Audit is not just data collection; it is a cyclical process of improvement.</p>
<ol>
<li><strong>Select Topic:</strong> Choose a high-risk, high-volume, or high-cost area (e.g., Antibiotic prescribing).</li>
<li><strong>Agree Standards:</strong> Define criteria based on guidelines (e.g., NICE guidelines).
<ul>
<li><em>Example:</em> “100% of patients with community-acquired pneumonia should receive antibiotics within 4 hours.”</li>
</ul>
</li>
<li><strong>Collect Data:</strong> Retrospective (looking back) or Prospective (going forward).</li>
<li><strong>Analyse Results:</strong> Compare actual practice vs. the standard.</li>
<li><strong>Implement Change:</strong> Crucial step. Education, new protocols, system changes.</li>
<li><strong>Re-audit:</strong> Repeat the cycle to confirm improvement.</li>
</ol>
<blockquote>
<p><strong>Donabedian’s Model:</strong> Audit can look at <strong>Structure</strong> (resources), <strong>Process</strong> (what we do), or <strong>Outcome</strong> (impact on health).</p>
</blockquote>
<h4 id="5-Governance-and-Ethics-治理与伦理">5. Governance and Ethics (治理与伦理)</h4>
<h5 id="HRA-Decision-Tool-HRA-决策工具">HRA Decision Tool (HRA 决策工具)</h5>
<ul>
<li>The <strong>Health Research Authority (HRA)</strong> provides an online decision tool to help you determine if your project is “Research”.</li>
<li><strong>Key Criterion:</strong> If you are randomising patients or using a protocol that changes their care, it is likely Research.</li>
</ul>
<h5 id="Ethics-Committees">Ethics Committees</h5>
<ul>
<li><strong>NHS REC (Research Ethics Committee):</strong> Required if your research involves NHS patients, tissue, or data.</li>
<li><strong>UREC (University Research Ethics Committee):</strong> Required for university research involving healthy volunteers or students.</li>
<li><strong>Governance:</strong> Even Audits need “Governance approval” from the hospital (e.g., Caldicott Guardian for data protection), even if they don’t need ethical approval.</li>
</ul>
<h4 id="6-Summary-Checklist-复习清单">6. Summary Checklist (复习清单)</h4>
<table>
<thead>
<tr>
<th style="text-align:left">Concept</th>
<th style="text-align:left">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left"><strong>Is it Research?</strong></td>
<td style="text-align:left">Check: Is there randomisation? Is it generalisable? Is it creating <em>new</em> knowledge?</td>
</tr>
<tr>
<td style="text-align:left"><strong>Is it Audit?</strong></td>
<td style="text-align:left">Check: Are you comparing against a <em>known standard</em> (e.g., NICE)?</td>
</tr>
<tr>
<td style="text-align:left"><strong>Is it Evaluation?</strong></td>
<td style="text-align:left">Check: Are you just asking “how is this service running?” without a standard?</td>
</tr>
<tr>
<td style="text-align:left"><strong>HRA Tool</strong></td>
<td style="text-align:left">The definitive online tool to check if you need NHS ethics approval.</td>
</tr>
</tbody>
</table>
<h3 id="33">33</h3>
<h3 id="34">34</h3>
<h3 id="37">37</h3>

                
            </div>
            <hr/>

            

    <div class="reprint" id="reprint-statement">
        
            <div class="reprint__author">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-user">
                        Author:
                    </i>
                </span>
                <span class="reprint-info">
                    <a href="https://thyzzs.top" rel="external nofollow noreferrer">thyzzs</a>
                </span>
            </div>
            <div class="reprint__type">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-link">
                        Link:
                    </i>
                </span>
                <span class="reprint-info">
                    <a href="https://thyzzs.top/2025/11/29/immunity-infection-and-respiratory-system/">https://thyzzs.top/2025/11/29/immunity-infection-and-respiratory-system/</a>
                </span>
            </div>
            <div class="reprint__notice">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-copyright">
                        Reprint policy:
                    </i>
                </span>
                <span class="reprint-info">
                    All articles in this blog are used except for special statements
                    <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/deed.zh" rel="external nofollow noreferrer" target="_blank">CC BY-NC-SA 4.0</a>
                    reprint policy. If reproduced, please indicate source
                    <a href="https://thyzzs.top" target="_blank">thyzzs</a>
                    !
                </span>
            </div>
        
    </div>

    <script async defer>
      document.addEventListener("copy", function (e) {
        let toastHTML = '<span>Copied successfully, please follow the reprint policy of this article</span><button class="btn-flat toast-action" onclick="navToReprintStatement()" style="font-size: smaller">more</a>';
        M.toast({html: toastHTML})
      });

      function navToReprintStatement() {
        $("html, body").animate({scrollTop: $("#reprint-statement").offset().top - 80}, 800);
      }
    </script>



            <div class="tag_share" style="display: block;">
                <div class="post-meta__tag-list" style="display: inline-block;">
                    
                        <div class="article-tag">
                            
                                <a href="/tags/Biology/">
                                    <span class="chip bg-color">Biology</span>
                                </a>
                            
                        </div>
                    
                </div>
                <div class="post_share" style="zoom: 80%; width: fit-content; display: inline-block; float: right; margin: -0.15rem 0;">
                    <link rel="stylesheet" type="text/css" href="/libs/share/css/share.min.css">
<div id="article-share">

    
    <div class="social-share" data-sites="twitter,facebook,google,qq,qzone,wechat,weibo,douban,linkedin" data-wechat-qrcode-helper="<p>微信扫一扫即可分享！</p>"></div>
    <script src="/libs/share/js/social-share.min.js"></script>
    

    

</div>

                </div>
            </div>
            
        </div>
    </div>

    

    

    

    

    
        <style>
    .valine-card {
        margin: 1.5rem auto;
    }

    .valine-card .card-content {
        padding: 20px 20px 5px 20px;
    }

    #vcomments textarea {
        box-sizing: border-box;
        background: url("/medias/comment_bg.png") 100% 100% no-repeat;
    }

    #vcomments p {
        margin: 2px 2px 10px;
        font-size: 1.05rem;
        line-height: 1.78rem;
    }

    #vcomments blockquote p {
        text-indent: 0.2rem;
    }

    #vcomments a {
        padding: 0 2px;
        color: #4cbf30;
        font-weight: 500;
        text-decoration: none;
    }

    #vcomments img {
        max-width: 100%;
        height: auto;
        cursor: pointer;
    }

    #vcomments ol li {
        list-style-type: decimal;
    }

    #vcomments ol,
    ul {
        display: block;
        padding-left: 2em;
        word-spacing: 0.05rem;
    }

    #vcomments ul li,
    ol li {
        display: list-item;
        line-height: 1.8rem;
        font-size: 1rem;
    }

    #vcomments ul li {
        list-style-type: disc;
    }

    #vcomments ul ul li {
        list-style-type: circle;
    }

    #vcomments table, th, td {
        padding: 12px 13px;
        border: 1px solid #dfe2e5;
    }

    #vcomments table, th, td {
        border: 0;
    }

    table tr:nth-child(2n), thead {
        background-color: #fafafa;
    }

    #vcomments table th {
        background-color: #f2f2f2;
        min-width: 80px;
    }

    #vcomments table td {
        min-width: 80px;
    }

    #vcomments h1 {
        font-size: 1.85rem;
        font-weight: bold;
        line-height: 2.2rem;
    }

    #vcomments h2 {
        font-size: 1.65rem;
        font-weight: bold;
        line-height: 1.9rem;
    }

    #vcomments h3 {
        font-size: 1.45rem;
        font-weight: bold;
        line-height: 1.7rem;
    }

    #vcomments h4 {
        font-size: 1.25rem;
        font-weight: bold;
        line-height: 1.5rem;
    }

    #vcomments h5 {
        font-size: 1.1rem;
        font-weight: bold;
        line-height: 1.4rem;
    }

    #vcomments h6 {
        font-size: 1rem;
        line-height: 1.3rem;
    }

    #vcomments p {
        font-size: 1rem;
        line-height: 1.5rem;
    }

    #vcomments hr {
        margin: 12px 0;
        border: 0;
        border-top: 1px solid #ccc;
    }

    #vcomments blockquote {
        margin: 15px 0;
        border-left: 5px solid #42b983;
        padding: 1rem 0.8rem 0.3rem 0.8rem;
        color: #666;
        background-color: rgba(66, 185, 131, .1);
    }

    #vcomments pre {
        font-family: monospace, monospace;
        padding: 1.2em;
        margin: .5em 0;
        background: #272822;
        overflow: auto;
        border-radius: 0.3em;
        tab-size: 4;
    }

    #vcomments code {
        font-family: monospace, monospace;
        padding: 1px 3px;
        font-size: 0.92rem;
        color: #e96900;
        background-color: #f8f8f8;
        border-radius: 2px;
    }

    #vcomments pre code {
        font-family: monospace, monospace;
        padding: 0;
        color: #e8eaf6;
        background-color: #272822;
    }

    #vcomments pre[class*="language-"] {
        padding: 1.2em;
        margin: .5em 0;
    }

    #vcomments code[class*="language-"],
    pre[class*="language-"] {
        color: #e8eaf6;
    }

    #vcomments [type="checkbox"]:not(:checked), [type="checkbox"]:checked {
        position: inherit;
        margin-left: -1.3rem;
        margin-right: 0.4rem;
        margin-top: -1px;
        vertical-align: middle;
        left: unset;
        visibility: visible;
    }

    #vcomments b,
    strong {
        font-weight: bold;
    }

    #vcomments dfn {
        font-style: italic;
    }

    #vcomments small {
        font-size: 85%;
    }

    #vcomments cite {
        font-style: normal;
    }

    #vcomments mark {
        background-color: #fcf8e3;
        padding: .2em;
    }

    #vcomments table, th, td {
        padding: 12px 13px;
        border: 1px solid #dfe2e5;
    }

    table tr:nth-child(2n), thead {
        background-color: #fafafa;
    }

    #vcomments table th {
        background-color: #f2f2f2;
        min-width: 80px;
    }

    #vcomments table td {
        min-width: 80px;
    }

    #vcomments [type="checkbox"]:not(:checked), [type="checkbox"]:checked {
        position: inherit;
        margin-left: -1.3rem;
        margin-right: 0.4rem;
        margin-top: -1px;
        vertical-align: middle;
        left: unset;
        visibility: visible;
    }
</style>

<div class="card valine-card" data-aos="fade-up">
    <div class="comment_headling" style="font-size: 20px; font-weight: 700; position: relative; padding-left: 20px; top: 15px; padding-bottom: 5px;">
        <i class="fas fa-comments fa-fw" aria-hidden="true"></i>
        <span>评论</span>
    </div>
    <div id="vcomments" class="card-content" style="display: grid">
    </div>
</div>

<script src="/libs/valine/av-min.js"></script>
<script src="https://unpkg.com/valine/dist/Valine.min.js"></script>
<script>
    new Valine({
        el: '#vcomments',
        appId: '102OcU05Y8Tw9VQ0bl9I0Msv-gzGzoHsz',
        appKey: 's2tfPOVV1WnY0EMDuI9HKqEA',
        serverURLs: '',
        notify: 'false' === 'true',
        verify: 'false' === 'true',
        visitor: 'true' === 'true',
        avatar: 'mm',
        pageSize: '10',
        lang: 'en',
        placeholder: 'just go go'
    });
</script>

<!--酷Q推送-->


    

    

    

    

    

<article id="prenext-posts" class="prev-next articles">
    <div class="row article-row">
        
        <div class="article col s12 m6" data-aos="fade-up" data-aos="fade-up">
            <div class="article-badge left-badge text-color">
                <i class="far fa-dot-circle"></i>&nbsp;Current
            </div>
            <div class="card">
                <a href="/2025/11/29/immunity-infection-and-respiratory-system/">
                    <div class="card-image">
                        
                        
                        <img src="/medias/featureimages/13.jpg" class="responsive-img" alt="Immunity, Infection and Respiratory System">
                        
                        <span class="card-title">Immunity, Infection and Respiratory System</span>
                    </div>
                </a>
                <div class="card-content article-content">
                    <div class="summary block-with-text">
                        
                            
                        
                    </div>
                    <div class="publish-info">
                            <span class="publish-date">
                                <i class="far fa-clock fa-fw icon-date"></i>2025-11-29
                            </span>
                        <span class="publish-author">
                            
                            <i class="fas fa-bookmark fa-fw icon-category"></i>
                            
                            <a href="/categories/Course-Notes/" class="post-category">
                                    Course Notes
                                </a>
                            
                            
                        </span>
                    </div>
                </div>

                
                <div class="card-action article-tags">
                    
                    <a href="/tags/Biology/">
                        <span class="chip bg-color">Biology</span>
                    </a>
                    
                </div>
                
            </div>
        </div>
        
        
        <div class="article col s12 m6" data-aos="fade-up">
            <div class="article-badge right-badge text-color">
                Next&nbsp;<i class="fas fa-chevron-right"></i>
            </div>
            <div class="card">
                <a href="/2025/08/12/future/">
                    <div class="card-image">
                        
                        
                        <img src="/medias/featureimages/6.jpg" class="responsive-img" alt="关于未来">
                        
                        <span class="card-title">关于未来</span>
                    </div>
                </a>
                <div class="card-content article-content">
                    <div class="summary block-with-text">
                        
                            然后，向着明天——
                        
                    </div>
                    <div class="publish-info">
                            <span class="publish-date">
                                <i class="far fa-clock fa-fw icon-date"></i>2025-08-13
                            </span>
                        <span class="publish-author">
                            
                            <i class="fas fa-bookmark fa-fw icon-category"></i>
                            
                            <a href="/categories/Stack/" class="post-category">
                                    Stack
                                </a>
                            
                            
                        </span>
                    </div>
                </div>
                
                <div class="card-action article-tags">
                    
                    <a href="/tags/Stack/">
                        <span class="chip bg-color">Stack</span>
                    </a>
                    
                </div>
                
            </div>
        </div>
        
    </div>
</article>

</div>


<script>
    $('#articleContent').on('copy', function (e) {
        // IE8 or earlier browser is 'undefined'
        if (typeof window.getSelection === 'undefined') return;

        var selection = window.getSelection();
        // if the selection is short let's not annoy our users.
        if (('' + selection).length < Number.parseInt('120')) {
            return;
        }

        // create a div outside of the visible area and fill it with the selected text.
        var bodyElement = document.getElementsByTagName('body')[0];
        var newdiv = document.createElement('div');
        newdiv.style.position = 'absolute';
        newdiv.style.left = '-99999px';
        bodyElement.appendChild(newdiv);
        newdiv.appendChild(selection.getRangeAt(0).cloneContents());

        // we need a <pre> tag workaround.
        // otherwise the text inside "pre" loses all the line breaks!
        if (selection.getRangeAt(0).commonAncestorContainer.nodeName === 'PRE' || selection.getRangeAt(0).commonAncestorContainer.nodeName === 'CODE') {
            newdiv.innerHTML = "<pre>" + newdiv.innerHTML + "</pre>";
        }

        var url = document.location.href;
        newdiv.innerHTML += '<br />'
            + 'From: 天何言哉<br />'
            + 'Author: thyzzs<br />'
            + 'Link: <a href="' + url + '">' + url + '</a><br />'
            + '本文章著作权归作者所有，任何形式的转载都请注明出处。';

        selection.selectAllChildren(newdiv);
        window.setTimeout(function () {bodyElement.removeChild(newdiv);}, 200);
    });
</script>


<!-- 代码块功能依赖 -->
<script type="text/javascript" src="/libs/codeBlock/codeBlockFuction.js"></script>


  <!-- 是否加载使用自带的 prismjs. -->
  <script type="text/javascript" src="/libs/prism/prism.min.js"></script>


<!-- 代码语言 -->

<script type="text/javascript" src="/libs/codeBlock/codeLang.js"></script>


<!-- 代码块复制 -->

<script type="text/javascript" src="/libs/codeBlock/codeCopy.js"></script>


<!-- 代码块收缩 -->

<script type="text/javascript" src="/libs/codeBlock/codeShrink.js"></script>



    </div>
    <div id="toc-aside" class="expanded col l3 hide-on-med-and-down">
        <div class="toc-widget card" style="background-color: white;">
            <div class="toc-title"><i class="far fa-list-alt"></i>&nbsp;&nbsp;TOC</div>
            <div id="toc-content"></div>
        </div>
    </div>
</div>

<!-- TOC 悬浮按钮. -->

<div id="floating-toc-btn" class="hide-on-med-and-down">
    <a class="btn-floating btn-large bg-color">
        <i class="fas fa-list-ul"></i>
    </a>
</div>


<script src="/libs/tocbot/tocbot.min.js"></script>
<script>
    $(function () {
        tocbot.init({
            tocSelector: '#toc-content',
            contentSelector: '#articleContent',
            headingsOffset: -($(window).height() * 0.4 - 45),
            collapseDepth: Number('0'),
            headingSelector: 'h2, h3, h4'
        });

        // Set scroll toc fixed.
        let tocHeight = parseInt($(window).height() * 0.4 - 64);
        let $tocWidget = $('.toc-widget');
        $(window).scroll(function () {
            let scroll = $(window).scrollTop();
            /* add post toc fixed. */
            if (scroll > tocHeight) {
                $tocWidget.addClass('toc-fixed');
            } else {
                $tocWidget.removeClass('toc-fixed');
            }
        });

        
        /* 修复文章卡片 div 的宽度. */
        let fixPostCardWidth = function (srcId, targetId) {
            let srcDiv = $('#' + srcId);
            if (srcDiv.length === 0) {
                return;
            }

            let w = srcDiv.width();
            if (w >= 450) {
                w = w + 21;
            } else if (w >= 350 && w < 450) {
                w = w + 18;
            } else if (w >= 300 && w < 350) {
                w = w + 16;
            } else {
                w = w + 14;
            }
            $('#' + targetId).width(w);
        };

        // 切换TOC目录展开收缩的相关操作.
        const expandedClass = 'expanded';
        let $tocAside = $('#toc-aside');
        let $mainContent = $('#main-content');
        $('#floating-toc-btn .btn-floating').click(function () {
            if ($tocAside.hasClass(expandedClass)) {
                $tocAside.removeClass(expandedClass).hide();
                $mainContent.removeClass('l9');
            } else {
                $tocAside.addClass(expandedClass).show();
                $mainContent.addClass('l9');
            }
            fixPostCardWidth('artDetail', 'prenext-posts');
        });
        
    });
</script>

    

</main>


<script src="https://cdn.bootcss.com/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
<script>
    MathJax.Hub.Config({
        tex2jax: {inlineMath: [['$', '$'], ['\\(', '\\)']]}
    });
</script>



    <footer class="page-footer bg-color">
    
        <link rel="stylesheet" href="/libs/aplayer/APlayer.min.css">
<style>
    .aplayer .aplayer-lrc p {
        
        display: none;
        
        font-size: 12px;
        font-weight: 700;
        line-height: 16px !important;
    }

    .aplayer .aplayer-lrc p.aplayer-lrc-current {
        
        display: none;
        
        font-size: 15px;
        color: #42b983;
    }

    
    .aplayer.aplayer-fixed.aplayer-narrow .aplayer-body {
        left: -66px !important;
    }

    .aplayer.aplayer-fixed.aplayer-narrow .aplayer-body:hover {
        left: 0px !important;
    }

    
</style>
<div class="">
    
    <div class="row">
        <meting-js class="col l8 offset-l2 m10 offset-m1 s12"
                   server="netease"
                   type="playlist"
                   id="911214248"
                   fixed='true'
                   autoplay='false'
                   theme='#42b983'
                   loop='all'
                   order='random'
                   preload='auto'
                   volume='0.7'
                   list-folded='true'
        >
        </meting-js>
    </div>
</div>

<script src="/libs/aplayer/APlayer.min.js"></script>
<script src="/libs/aplayer/Meting.min.js"></script>

    

    <div class="container row center-align"
         style="margin-bottom: 15px !important;">
        <div class="col s12 m8 l8 copy-right">
            Copyright&nbsp;&copy;
            
                <span id="year">2019-2025</span>
            
            <a href="/about" target="_blank">thyzzs</a>
            |&nbsp;Powered by&nbsp;<a href="https://hexo.io/" target="_blank">Hexo</a>
            |&nbsp;Theme&nbsp;<a href="https://github.com/blinkfox/hexo-theme-matery" target="_blank">Matery</a>
            
                <span id="translate">|&nbsp;繁/简：</span><a id="translateLink" href="javascript:translatePage();">繁</a>
            
            <br>
            
                &nbsp;<i class="fas fa-chart-area"></i>&nbsp;Total Words:&nbsp;<span
                        class="white-color">228.4k</span>
            
            
            
                
            
            
                <span id="busuanzi_container_site_pv">
                &nbsp;|&nbsp;<i class="far fa-eye"></i>&nbsp;Total visits:&nbsp;
                    <span id="busuanzi_value_site_pv" class="white-color"></span>
            </span>
            
            
                <span id="busuanzi_container_site_uv">
                &nbsp;|&nbsp;<i class="fas fa-users"></i>&nbsp;Total visitors:&nbsp;
                    <span id="busuanzi_value_site_uv" class="white-color"></span>
            </span>
            
            <br>

            <!-- 运行天数提醒. -->
            
                <span id="sitetime"> Loading ...</span>
                <script>
                    var calcSiteTime = function () {
                        var seconds = 1000;
                        var minutes = seconds * 60;
                        var hours = minutes * 60;
                        var days = hours * 24;
                        var years = days * 365;
                        var today = new Date();
                        var startYear = "2019";
                        var startMonth = "6";
                        var startDate = "28";
                        var startHour = "0";
                        var startMinute = "0";
                        var startSecond = "0";
                        var todayYear = today.getFullYear();
                        var todayMonth = today.getMonth() + 1;
                        var todayDate = today.getDate();
                        var todayHour = today.getHours();
                        var todayMinute = today.getMinutes();
                        var todaySecond = today.getSeconds();
                        var t1 = Date.UTC(startYear, startMonth, startDate, startHour, startMinute, startSecond);
                        var t2 = Date.UTC(todayYear, todayMonth, todayDate, todayHour, todayMinute, todaySecond);
                        var diff = t2 - t1;
                        var diffYears = Math.floor(diff / years);
                        var diffDays = Math.floor((diff / days) - diffYears * 365);

                        // 区分是否有年份.
                        var language = 'en-uk';
                        if (startYear === String(todayYear)) {
                            document.getElementById("year").innerHTML = todayYear;
                            var daysTip = 'This site has been running for ' + diffDays + ' days';
                            if (language === 'zh-CN') {
                                daysTip = '本站已运行 ' + diffDays + ' 天';
                            } else if (language === 'zh-HK') {
                                daysTip = '本站已運行 ' + diffDays + ' 天';
                            }
                            document.getElementById("sitetime").innerHTML = daysTip;
                        } else {
                            document.getElementById("year").innerHTML = startYear + " - " + todayYear;
                            var yearsAndDaysTip = 'This site has been running for ' + diffYears + ' years and '
                                + diffDays + ' days';
                            if (language === 'zh-CN') {
                                yearsAndDaysTip = '本站已运行 ' + diffYears + ' 年 ' + diffDays + ' 天';
                            } else if (language === 'zh-HK') {
                                yearsAndDaysTip = '本站已運行 ' + diffYears + ' 年 ' + diffDays + ' 天';
                            }
                            document.getElementById("sitetime").innerHTML = yearsAndDaysTip;
                        }
                    }

                    calcSiteTime();
                </script>
            
            <br>
            
        </div>
        <div class="col s12 m4 l4 social-link social-statis">
    <a href="https://github.com/thyzzs" class="tooltipped" target="_blank" data-tooltip="访问我的GitHub" data-position="top" data-delay="50">
        <i class="fab fa-github"></i>
    </a>



    <a href="mailto:thyzzs@163.com" class="tooltipped" target="_blank" data-tooltip="邮件联系我" data-position="top" data-delay="50">
        <i class="fas fa-envelope-open"></i>
    </a>





    <a href="https://twitter.com/thyzzs" class="tooltipped" target="_blank" data-tooltip="关注我的Twitter: https://twitter.com/thyzzs" data-position="top" data-delay="50">
        <i class="fab fa-twitter"></i>
    </a>



    <a href="tencent://AddContact/?fromId=50&fromSubId=1&subcmd=all&uin=1458077873" class="tooltipped" target="_blank" data-tooltip="QQ联系我: 1458077873" data-position="top" data-delay="50">
        <i class="fab fa-qq"></i>
    </a>





    <a href="https://www.zhihu.com/people/thyzzs" class="tooltipped" target="_blank" data-tooltip="关注我的知乎: https://www.zhihu.com/people/thyzzs" data-position="top" data-delay="50">
        <i class="fab fa-zhihu1">知</i>
    </a>



    <a href="/atom.xml" class="tooltipped" target="_blank" data-tooltip="RSS 订阅" data-position="top" data-delay="50">
        <i class="fas fa-rss"></i>
    </a>

</div>
    </div>
</footer>

<div class="progress-bar"></div>


    <!-- 搜索遮罩框 -->
<div id="searchModal" class="modal">
    <div class="modal-content">
        <div class="search-header">
            <span class="title"><i class="fas fa-search"></i>&nbsp;&nbsp;Search</span>
            <input type="search" id="searchInput" name="s" placeholder="Please enter a search keyword"
                   class="search-input">
        </div>
        <div id="searchResult"></div>
    </div>
</div>

<script type="text/javascript">
$(function () {
    var searchFunc = function (path, search_id, content_id) {
        'use strict';
        $.ajax({
            url: path,
            dataType: "xml",
            success: function (xmlResponse) {
                // get the contents from search data
                var datas = $("entry", xmlResponse).map(function () {
                    return {
                        title: $("title", this).text(),
                        content: $("content", this).text(),
                        url: $("url", this).text()
                    };
                }).get();
                var $input = document.getElementById(search_id);
                var $resultContent = document.getElementById(content_id);
                $input.addEventListener('input', function () {
                    var str = '<ul class=\"search-result-list\">';
                    var keywords = this.value.trim().toLowerCase().split(/[\s\-]+/);
                    $resultContent.innerHTML = "";
                    if (this.value.trim().length <= 0) {
                        return;
                    }
                    // perform local searching
                    datas.forEach(function (data) {
                        var isMatch = true;
                        var data_title = data.title.trim().toLowerCase();
                        var data_content = data.content.trim().replace(/<[^>]+>/g, "").toLowerCase();
                        var data_url = data.url;
                        data_url = data_url.indexOf('/') === 0 ? data.url : '/' + data_url;
                        var index_title = -1;
                        var index_content = -1;
                        var first_occur = -1;
                        // only match artiles with not empty titles and contents
                        if (data_title !== '' && data_content !== '') {
                            keywords.forEach(function (keyword, i) {
                                index_title = data_title.indexOf(keyword);
                                index_content = data_content.indexOf(keyword);
                                if (index_title < 0 && index_content < 0) {
                                    isMatch = false;
                                } else {
                                    if (index_content < 0) {
                                        index_content = 0;
                                    }
                                    if (i === 0) {
                                        first_occur = index_content;
                                    }
                                }
                            });
                        }
                        // show search results
                        if (isMatch) {
                            str += "<li><a href='" + data_url + "' class='search-result-title'>" + data_title + "</a>";
                            var content = data.content.trim().replace(/<[^>]+>/g, "");
                            if (first_occur >= 0) {
                                // cut out 100 characters
                                var start = first_occur - 20;
                                var end = first_occur + 80;
                                if (start < 0) {
                                    start = 0;
                                }
                                if (start === 0) {
                                    end = 100;
                                }
                                if (end > content.length) {
                                    end = content.length;
                                }
                                var match_content = content.substr(start, end);
                                // highlight all keywords
                                keywords.forEach(function (keyword) {
                                    var regS = new RegExp(keyword, "gi");
                                    match_content = match_content.replace(regS, "<em class=\"search-keyword\">" + keyword + "</em>");
                                });

                                str += "<p class=\"search-result\">" + match_content + "...</p>"
                            }
                            str += "</li>";
                        }
                    });
                    str += "</ul>";
                    $resultContent.innerHTML = str;
                });
            }
        });
    };

    searchFunc('/search.xml', 'searchInput', 'searchResult');
});
</script>

    <!-- 白天和黑夜主题 -->
<div class="stars-con">
    <div id="stars"></div>
    <div id="stars2"></div>
    <div id="stars3"></div>  
</div>

<script>
    function switchNightMode() {
        $('<div class="Cuteen_DarkSky"><div class="Cuteen_DarkPlanet"></div></div>').appendTo($('body')),
        setTimeout(function () {
            $('body').hasClass('DarkMode') 
            ? ($('body').removeClass('DarkMode'), localStorage.setItem('isDark', '0'), $('#sum-moon-icon').removeClass("fa-sun").addClass('fa-moon')) 
            : ($('body').addClass('DarkMode'), localStorage.setItem('isDark', '1'), $('#sum-moon-icon').addClass("fa-sun").removeClass('fa-moon')),
            
            setTimeout(function () {
            $('.Cuteen_DarkSky').fadeOut(1e3, function () {
                $(this).remove()
            })
            }, 2e3)
        })
    }
</script>

    <!-- 回到顶部按钮 -->
<div id="backTop" class="top-scroll">
    <a class="btn-floating btn-large waves-effect waves-light" href="#!">
        <i class="fas fa-arrow-up"></i>
    </a>
</div>


    <script src="/libs/materialize/materialize.min.js"></script>
    <script src="/libs/masonry/masonry.pkgd.min.js"></script>
    <script src="/libs/aos/aos.js"></script>
    <script src="/libs/scrollprogress/scrollProgress.min.js"></script>
    <script src="/libs/lightGallery/js/lightgallery-all.min.js"></script>
    <script src="/js/matery.js"></script>

    

    
        <script type="text/javascript" src="/js/tw_cn.js"></script>
        <script type="text/javascript">
          var defaultEncoding = 2; //网站编写字体是否繁体，1-繁体，2-简体
          var translateDelay = 0; //延迟时间,若不在前, 要设定延迟翻译时间, 如100表示100ms,默认为0
          var cookieDomain = "https://thyzzs.top"; //Cookie地址, 一定要设定, 通常为你的网址
          var msgToTraditionalChinese = "繁"; //此处可以更改为你想要显示的文字
          var msgToSimplifiedChinese = "简"; //同上，但两处均不建议更改
          var translateButtonId = "translateLink"; //默认互换id
          translateInitilization();
        </script>
    
    
    

    <!-- 雪花特效 -->
    

    <!-- 鼠标星星特效 -->
    

    

    <!-- Baidu Analytics -->

    <!-- Baidu Push -->

<script>
    (function () {
        var bp = document.createElement('script');
        var curProtocol = window.location.protocol.split(':')[0];
        if (curProtocol === 'https') {
            bp.src = 'https://zz.bdstatic.com/linksubmit/push.js';
        } else {
            bp.src = 'http://push.zhanzhang.baidu.com/push.js';
        }
        var s = document.getElementsByTagName("script")[0];
        s.parentNode.insertBefore(bp, s);
    })();
</script>

    
    <script src="/libs/others/clicklove.js" async="async"></script>
    
    
    <script async src="/libs/others/busuanzi.pure.mini.js"></script>
    

    

    

    <!--腾讯兔小巢-->
    
    
    <script type="text/javascript" color="0,0,255"
        pointColor="0,0,255" opacity='0.7'
        zIndex="-1" count="99"
        src="/libs/background/canvas-nest.js"></script>
    

    

    
    <script type="text/javascript" src="/libs/background/ribbon-dynamic.js" async="async"></script>
    

    
    <script src="/libs/instantpage/instantpage.js" type="module"></script>
    

</body>

</html>
